var title_f42_32_43520="Hepatitis B surface antigen seroclearance";
var content_f42_32_43520=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 660px\">",
"   <div class=\"ttl\">",
"    Hepatitis B surface antigen seroclearance following liver transplantation in patients receiving entecavir",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 640px; height: 627px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Cumulative rate of HBsAg seroclearance.",
"    <br>",
"     (B) Cumulative rate of HBsAg seroclearance in patients with and without HBV DNA level &lt;5 log copies/mL and HBsAg level &lt;3 log IU/mL.",
"     <br>",
"      (C) Cumulative rate of HBsAg seroclearance in patients with and without detectable anti-HBs after liver transplant.",
"      <br>",
"       (D) Cumulative rate of HBsAg relapse after initial seroclearance.",
"       <div class=\"footnotes\">",
"        %: percent.",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced from: Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141:1212. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_32_43520=[""].join("\n");
var outline_f42_32_43520=null;
var title_f42_32_43521="Bookwalter retractor A";
var content_f42_32_43521=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Bookwalter retractor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 262px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEGAd8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopk0qQQvLM4SNFLMzHAAHJJoAfRWRoHiXRPEXn/wBharZ6h5G3zfs8ofZuzjOOmdp/KtegAoqrBqFtcX93ZROxubUIZVKMAu8ErgkYPQ9Ccd6Hv7ZNSjsGdhdSRmVV2NgqCATuxgdRxnNAFqiiigAooooAKKKq6rqFrpWnXN/qEwhtLaMyyyEEhFAyTxzQBaoqO3mjubeKeBt8Uqh0YdwRkGo7O+tL4TGyuYLgQytBKYpA/lyLwyNjow7g8igCxRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUgZSSAwJHUA9KwPiBemw8Fa1cKzK4tXRWVtpDMNowexyRzXK2+iWWk/F7QrbRols4YdDuXnjhGPOHmxKhkP8ZGWOTk5zzzQB6VRRRQAUUUUAFFFFABTJmZIXdIzI6qSEUgFj6DPH50+sDwtr0mvXOtskKJYWd61lbygkmYooEjemA5ZRj+6aAPKdJ8JeKZ9AfTrvRbyxWbxWmpzbb6JS1nI5Mg3RyZBUAZAOTkbc44kTwN4gsiLd9MutQ8OWuuXky6QNQUNNavFGIGDM+NquJDsZgec17jRQB4lf8AhDxLcWXiaGHT9StLW8h0xbS2h1GOR0ESP5qZdwGAJUEEru9TUXh/wd43hjCeVHpbtpF/bxvDcYWKZ3Xyiyh22tgE5Qsq9jmvcqKAPBU8EeK20PUYLLTrrS4Jhp6fYv7SVnkkjkBnnDh8KCvuGbGcA16H8OfDt34b1TxRbmKWHR5b1JdOR7jzRsMa7yMsWHzZ64rt6KAPDJfBfiltF1i0XTLj/hJZmnY6/wD2oFS5jaXcIwgbcu6P5ACoC9c1Ybwb4jm0TULe00+603T7rWbOa30sX4MltboFE58xXwAxydqtn8a9rooA8N0nwHrmi6za30FtdxQWuraiAWvy6ppzI3kgKXPBY5xjdnk1zvhPwx4i8QeCRd6bYXMUd14dntZZZ75XOpzOf3eFLnaFweW29cdK+lKKAPCtf8D+LJ/EsF0Ir6a3S3shZyWl1EjWLxookU73GAWBJKhsg4qGf4e+I7bSvEllpWnTQmbXjfblvl239iWYiEAvwwyCd+3djGTXvdFAHHfCvSL7RPC7Weox3kJFzI8UN3LHI8cZwQoKMwCg5wNxxXY0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVzPxL8Qz+FPAet65aRxS3FjbmWNJc7GbgDOMHGTXN2v8Awtl0E32jwRJHKodVaK6UpkdOCc0AelUV5s6fF3ztyTeBdhXGwx3XB9c5p2Pi3gc+BT68XfNLXsB6PRXngPxXK5I8DhvTN2aUn4rKQNvgdx67rpf6GgEehUVwLP8AFEN8sXgtgcn/AFl0uPb7pz9ePpR5vxQIX/RfBanv/pF0fy+SmB31FcEJ/ibsZjYeDy2flUXdz09z5f40rzfE4KCll4OLdwbq54/8h0Ad5RXnZuvit20zwZ/4GXPP/kOorjUvitHNEIvD/hSVHBLFdRmAjI9coCc+w+tAHpNBOBk9K86+3/FTP/IC8IkY/wCgjP8A/Gq4bxt4q8bahpWraBrDeFdCSZhZS3iXtxIwLKHdEVY85EZG4nAAcc56AHXeP/G/hnV7OPw3p+s2d5qF9qFrZtFA3m7MzKW3bc8bVYVrPIx+OMUexmVfDrHcBwublep99vH0Ncv8K/DMfiGx1S98XDStTeC8+x2cWnk/Y7aGJRsEPTONzDdjPvV/4meF9I8MeDda8SeHrAWmu2Nv5sFzDJIHyrA7ThuVP908HPSkM9Tory/TvEHxL1HTrK/sdB8K3FpdwJPG66nMOGUMM5j96sjU/iof+Zc8Kj66pL/8bpiPR6K83/tL4rHfjw94UG3pnUpju+n7v+dMOpfFkx7h4e8JqcfdbUZif/QMU7Ael0V5rFf/ABZcrv0TwfHnruv5zt+uEpTe/Fkcf2N4ObnGRfTjj1+5RYDq/HWtv4e8J6jqVvEZruOPZbRAZMk7kJGv4uyipfBuip4d8L6bpSnc1vCBI+c75D8zsfcsWP415ZrF18SNZ8W6Lol3pvhYSWYGsSql3OYyFJSNXOzOd53DAOTH2xXWG5+KO9wNM8HbR90m+uOf/IdKzFc9AorgDcfFDaMad4N3d/8ATbnA/wDIVTLL8Svl3WnhDnqBc3PHv/q+fpxRqM7miuGaT4lZO228HkE4Gbi549/uc/SmGT4nYfFt4NP93/SLnj6/JSDQ7yiuADfFItyngpR/v3R/oKcf+FoA8HwWRnpi6Gf8KYHe0Vwu74mf88/B3/fy5/8AiaieX4oq4C2ngt1z1+0XQJ/8coA7+ivO57r4qrGPJ0vwa7g8k3txgj2Hl8Uxb34sFRnRvBoOOf8AT7jr/wB+6APR6K85Nz8WSw26b4KVe4N5cn/2Ska5+LOfl07wSOQObu5PHr9ygD0eivOUb4tFiXj8CqMdA12f6U7zPixnH2fwP06+bdc/+O0AeiUV52ZfiuCSLXwQQO3n3XP47eKQ3PxX4xp3grr3vLngf9+6LAei0V52s/xXx81j4Iz6i7uv/jdDT/FcICLLwSW9PtN1/wDEUAeiUV5Tp/xF1XRfHM/h74gjQ7IDThfQz2EkriQmXYECsMs3U4UHp+UXiz4kXjRSR6Uq6bF5qRedMvmXDqyiTdGgygJTG0MSSZEBUbhSA9boritJnuPD/iuz0a81S7vrbVbeSe1W9ZGmgkj2l0LKBuUh8jOcFSM4IrtaYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwfx3QSfB7xaCM4sHb8uf6V2Oktv0qybruhQ/+OiuU+NqGT4ReL1XqNNmb8lJ/pXT6Ac6FpxOf+PaPr/uigC/RRRQAUUUUAFFFFABRRRQAUVUutSs7V9k9zGsnaMHLn6KOTVpGDorrnDDIyCD+R6UAZHirxDY+GNJfUdTMgt1JB2Lk8KzH8lVj+FeVeEPD2o+KdTuJ7/UNQ0ci2N276dcJvd7yRpCjMUI+WKO3XjBHY13Pxc0KbX/BtxbW0ElxIjFjDFje6MjRvtyRlgkjEDPJGO9eM+DfAvieHw/rGp3TG0gt4kcR6rHdLJcNFAquyqlwu1DsGN3PHAUYFJjR3vwv8S6NoPhy40nTLDVLo22oXamGw06WRYV+0SBQWA2ngDkE1d8ceLrPUdNsrC40vWLaC41G0WZryxeKPyxMrMGJ+6CFxziua+HUFn4tv9H0nXNOs44tP0Yy3GnW+8QpcG5eIHGecLG2Mk43tjrXJ65o1rNP8YNE0NorMwSWUEMKx/8APYQAAMTkKHQ8D+99KBHf/AvxRdzvD4auzam1g0yC8tGVGR1EhLeScsd5SNoiSAMbunSvYEbdu+Vlwcc9/cV8saFZzW/xr0ePUNItkMXiGeGC+gWRQEjtNoiBJClRtQgYyMehr6ppgFFFFABRRXK/E6/uLLwddw6bII9T1Bk06zJPPmzMEBH+6CW+imgCn8NkbUp9e8USkn+1rspbegtYCY4sf7xDv/wOu2qnounQaRpFjptmu22s4Et4x/sqoUfoKuUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFMnljgheWeRI4kBZ3dgAoHUknoKAH0V53r3xMtobJ7nQbeO9tFBxqFxN5NtIwz8kJwXnfg4WNSD03ZrzXxB8dfE9rdLpsXhjyWun8q11RMtG+eAfLYDad3HzN8vUqcYoA+gNY1aw0Wya71W7itbdeN8jYyewA6k+w5NeT678XLjUbuax8JWvlCGGWaa9vFwsaxkB+OQuNy9ctlgNnNeR32oXutRz6rrt/LIkW1A8kpIcGXaFL4BKO5QFEVBt8z5SVr03wT4R1e+01rWx0z+xLBZk8q/vFxI8UTl0VLcY+V3LSneV+ZwNpCikOxj6fcXn9i3kerxafJrGqApJf3hO8CM4mjEjf7bRxKFx8xcgAKK7TQ/Bt9c3FmwtfsqW6KXvb5QWM4kLtJBAMBcttw0mcLHGAuBVPwZ4cj8N/G86UlzeXtpb+Go5Ld72XzWRvtBViueFyMfdA/nXstAjD8P+GNP0R5J4RNdahLnzb67k82eT2LHoP9lcKOwrcoopgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHF/GkZ+Eni8YB/4ldwef9w1v+FHMnhbR3Y5ZrOEk/wDABWT8WF3fC7xcOedJuug/6ZNWh4Gk83wT4fkwRv0+3bB7ZjWgDbooooAKKK5rVdR06wab+3fEsFt5a+Y0KzJBheucZ3/kaAN+6ure0j33U8UKesjBR+tUv7ZilcpYwXF24Gf3abV+u5sDH0zXE2dx4h1bSWvdA8M2NjHfQMLW51C7ZbuLd92WRPLJHB3bd+enTtqWfw30ODT7SNlul1CNAs2oW91LDcXBwAxeRW3MDjOCSB2xQBDfeOkguXjuA1jaR3H2aa9NtLLBC4OCHlwqLg/KTkgE81nr4iutUvLqXStNvfEOiWdwLee8gvVQSHaCxhiUBZVXcAfm5IOMkV3Wnabp2iaNHYWsUdvp8KkBJHLDBJJyWJJJJJJJ5zXJa38WfAHhtGhuvEWnKYfl8i1PnFccYxGDj6UrgQRah4zjvJ7zQvC2lx6BG21LKeQ29/cgDl16xpz0V8EgckZqAN8TtV1VtTtl0rQtOhwsej3u24kusZ3M80efLznA27sY5Hrzd7+0l4T8tm0bTtb1UqefJtwg/Dc2T+VZl18f9flhMml/DjUxGSAs17P5KZPTqmP1oA9DnsfiJq+ptdJq+l+HLKNVWOxS3F+ZWByWeQ7NoPTC9vepdYj8balol/a3Meg6chs5UeWNpbppmKkfKpEYQd+S3p714LrH7TvivT7swS+FtKhk27thuGlIHuVPHSr+m/tA/EG/iVo/h/8AaI5fljaG3uSHPoCAck5H501r0DY9I+DVgkXjPxXf288n2e7s9MmWLhkBeAuzA9RlmY4/2s9xXj/jzVL6H42Q6XpJCpqeqJDqJWMMzoLxCm5sZG3yxg9QM44Neu/sv3N5qPgG51DU4XguWu/soiIICpBGkSjB5yNpBz3BryOD4tap4L8b+Pho2kx3kN5rMsn2q/kZY1MZ2FFCjk/jwMZxyaQ9C7451PUdK+L0o0Sxub3VT4iSSzto/kiuD5Ee9ZGwBkK55JbaCeFHX3eLXfGGmXONe8NxX1vLDvjk0SbzDHKP+WbiUrwezjj1x1rw3wV8QrCx8cax428X6TDHdXbLbWosZ4SIcoBKfnZWZsRpk9FBxxnFeg2v7SPgi5aNVi1gO/3VFujHGMk/K54x/I0AdsninxBZ3UZ1zwjdQ2EqblmsJxeSRN/cljVQQT6puHqaLvxvdae8c+reFtZs9Id9hvsRy+WOzyRRs0iqfXHGecVz8nx38FQbxeTanauu3KS2Eob5hleAD1FW4vjh8PJHCHxFHE5x8stvMh/VPagCS7+I159o+16Z4U1S98MxOBc6vkR7Ux8zxwEebIqnqQvIBIziuX1nx9a+KPiR4ej8I6fd+J7PTIZbmQ2YCwxXMg2RGV3wF2p5nvlhXZr8W/ARDE+KNOQrnKyMUbjrwQDxisH4XeNvCTaZc6jdeItHh1TXLt76W3ku41kjDYWKMjOcrGqDB75piN6D4l6TdW9nDYxS3evTymB9Ehkj+128iglxIrMAoXacsSAeME5Fadh440G48N/21cX0Vlbxt5NxHcMFkt5s4MLr13g8YGc9sgir6at4fS+mKahpS3hAEpE0Yk6ZG7nPTHWhLDQLvUV1NLXS577gi6EcbScdDv60AR6J4s0LW7a8uNM1OCWGy/4+WbMfk/LuywYDAxzk1a0bXtI1vzv7G1Sx1DySBJ9lnWXZnpnaTjoaqav4T0DWb9LzVNKtLq6QKN7pksFOVDf3gD0BzUWueCvD+tSK99p4EgTyy9vK9uzpnOxjGyllz2OR1pAb0U8UxYRSo5U4bawOD70/IJIBGRXKTeA9Hjkgm0MS6BdRRmIT6VsiLp/ddSpV/UbgSD0Iyaib4daEtrF9jSe01OIl11WGTF2ZCcs7OQd5bnIYEHPSmB2NFcQ/w7tZ45ZbzXfEVxqjsHXUP7QaN4iOm2NNsQAx0KEHnOann8Ma5qWwav4svUjjBCrpUK2ZY9mdiXJI9BgZ7UgOworiV0TxiyRaa/iWBNPjbnUI7cG/kQZwrbgYg3TLheQOgJpTaePIN9hbaho09vu/d6rdRsZ1TjhoECozjn5gyg8fL6sDtaK4yGbxlo+oSJew23iLT3hzFJaRpazxzA9HDybShHccj0NQSeOLzRbu3XxroyaNZXCMY7yK6N1Ejrg+XIQg2EgnB5BwR1oA7qiuPs/iJoVzJFuXUrW1nlEUF7dWE0NvKT0IkZQoB7E4z2ryj4p/FjTJtcnsLe7uL3Q7S3SR7eymEJv5GLgqHwWdF2rwgAYk7mwMUXA9W1fx1Zot5F4fSPVbm1JW4l80RWlqR1M05+Vcd1G5vavKfE/ii5vri2muo5/ESTr50cXkFLJYwcZgtC3mXJByRJL8nHGOK4/x74xOoeIbOKaz+y6GsDW8WlTIRb2F3HzID5P3mAaNlYj5dx+6RW54X0bWtbsStnaJqhCZmvInWNWbIJCkZiD8jqrN6gUhlW7MGtolxqdumszCXypbjUbby5RHn/Vui7o4UAPAV4gc5OTWfdeANDfK6Pa3Vm1yrLDa2l4rQ3MmMp8k7eW7BsEeVM/PbtXo48MaDpsIuPFniKTSstgWKXqO4IIxtcDdggdEC9awfEvxKj0pZPD/AIRs00WwWN7k6lqYIuJ8FctDHJ8zSYJ2tJn7vIxg0Ad38KPCfh6w8K6J4jvW+2apNaRztfai4LQMwLssY4WMBnf7oB5OSa9F0/VNP1JWOnX1rdheGMEyyY+uDXz7peveEovBl1f+DPDEWpT6ZGbu9g8Qxn7TPb5YPPGxDg4bcWAHqMA4ot/D3xH8Z61o2p2WieHvBOmQyx3cdxbbJLiRcAjJTllIONh2j16UXEemyK4+PsL/AMDeGXA+oulz/MV6DXBTJt+O1m4BJbw5MpOeBi5jx/M13tPqHQKKKKACiiigAooooAKKKKACiiigAooooAKK4Hxx4xl0PxLa6ZBdxwSzWjXKxzWRlRwHCk+YJVIILKMbTnIxmuPsPjpp07TNDqehagqx+YIkF1ayBR1JMkRUAepIA70rge3UVwml/EeyvLdJXtOGiWf/AEa9tpx5ZOBJxIG2k8Zx1rRbx3o0QBuV1KBSCQzafOyn6MqlffrRcCx8R1D/AA98TqzBVOl3QJIzj901RfC+Yz/DbwrKxBLaVak4BH/LJfWsvxZ4y8N33gnXha67pjSNY3CLG86BixjbA2MQc+xFc/8AC/4j+ErD4f8AhfTr/wAQWSX8Gk2xmjLlvL/dj7xAwD7E0XHY9brO1jXNJ0RI31nU7GwSQkI11OkQbAycbiM1yOq/EKyuvEujeHfCepaTe6nqAkmeUyedHBEi5yQjDLMSABkdzWrpHhNBqmoat4ia11PU71I4T/o+IYYk5VI1YsQNxLEk8nHoKYjNsNU8ReL4rnUPDOo6dpulJO8FrJcWbXX2tVODMCJEAUnO3Gc4znnFbXh/wzpXhvQ7aCRLeV7VfMlvZ41DySdWlZj0JOT14rnfiR8UdP8AB93Doum2Vxrfii5UG30mzUlsHozkA7V/XHOMc155f+CPF/ja1u9Z+MuunQvDdsDOdF0+UBBGvzZkYEg8Z/vH0xQgZ1niz49+ENGulsdIe58R6mxKrb6UnmDd6F+n/fO6uX1rxX8WNXsJr25j0H4eaHkJ9q1WYNOM+mcjPsVFYnwul8T6xZbvhz4c8O+EdEdnMd68Yl1C5gVsblEhO7sMt8ue9ex6R8MtGgu49Q1+a98S6rG5kS51eXzhEf8AYi4jTHbC0bj2PBU8IWXiSQ3Go3Pjv4jXLfKstuhs7HcOwklI4zjleK7zw38Hb63EBt9K8J+HIhyWitm1O7AwMAyT/Ju5IJCnpxnNe80UbbCPNtV+HOjjTbiTxP4k1ybTVUeakl8LO2VR6rCEX86x7Lwb8JrPRTqNtpdjrMCT+Ssi7792lb7sYGWJPI46d69S1LVdMsFYalf2dsoG4i4mVOPXk157rHx2+HGjnYdfhuGz92zheUfmo2/rRYLklvPa+HtNlvrX4af2fpltbvI7r9jilWMD5soH9ByC3NW9FvvF/i22kvbTy/Cmm5C2sN1Zi4uZUwCJG+cIgIPCjd3ye1ee+JvjNonjuytPD2haTrc0Gp6hZ2k13NbBIFVp0LIzZP3lBGO+ar+I/wBpe2i1y50vwzokcy2rMklzqN0LdG2tg7FAJOe3Q+1AHoXgPWbPw14T1SbxFqkbXA1m/SR2jEbyyee2AsY6sRggD1rhPhz8OLjxP4auNbTxFrOjNqeoXlw9raygIP3zqPunDHCjJ5z64xXKv8TdQ8Qm5Enhzwiwu3Mlwg1xrUXW0bTvO5VcbSAQ2eOor1/wn8SIY9Bgl1fw1c6NpsCCI3Ng8V9ZRbRjAa3LFVHuoAHWgDlbq7034T3kWi+ILDQ9Ug1JmuE1S5IgkaTjcs+8ONx4KtkAgEYGOelk0jwBexh/EvgrTdKDlQlxcWcPkSbuQVnjyuD7lT7V43+1vrOlXnivwmkhM+ky2ZunnswpeRWfAZH6NgKcZyBuPrX0h4W8WeGda0ezTTdb066RoFHlG5jaTG0DDKDwfUYpDMJPhD8N75DLD4c06VGO7fDI2M/VWqpL8Bvh61x50Oiy20uQQ0F7Mm0jpj5uK6ybwN4cdzJbaXFYzE583T2a0c/8CiKk1parp15dENY6tdWDrE0ahI45F3EghyHUkkYI645PtTEeJeN/g14T05tPsdJXVRqeuXSWIP2122wA75mOf4RGh47kitqT9nrwwbkSx6prqJtaNozPG4ZWABHzRk8gAE9SBjpWlokPibU/ildXc91pl/p2hIuniV4XgbzJQskzIAWBcL5a9hyRxzn1SgDwtv2bPDfyAa3rjxrJ5vlzPDIpPbIMfI68d6ybn9mCweWeSLxRd75VZS01lE5XcckjBUBuvPbPFfRVFAHzo37Ot/aS27ab4mtmWNQhM1nIrHAJDErL8xLYz0446cFlt8EPGtjLcGz8UWixuVKILq8QjA6Eq/TPXHJ6ZWvo6igD5om+FnxniTMHj5ZCvRRqVyu7n3U9uK1IPDfxhsnh26pdSIBHuY6pFJ8w5c4eHox+UDnaOTuNfQdQXUs0fleRb+dukVX+cLsU9W5649KVkFz58upf2gLRF8qC3nJc5w9pJhc/ROcEfkfXArQ+KvjvBKGudADxeX2sY3O/0wsoO3pk/XA6V7hqet61aXs0Nr4Vvb2BeI54ru3UPx6M4I9KrHxPqUdo/wDaPhjWLO4bKp9nWO7X2PyN+hAoGeSf8LE+LsDM8vhESRohYqdJnDOeAFGyRgMnJz2A7k4qGT42ePdPWX+1PAoXy8MCYbqHzOQAADG3J55J6DnHSu8PxTTSNetNH160uHuLoJ5RjtWgmbLbMmBySRu7qzHvjHNaet/E/RrbTrq40V01Q2xKzyeaILa3IJUiWZ/lU5H3Rlz2U0IDzaz/AGm7G1uXt/E3hbU7FozhpIGDqecZAkCNj9a6bV/j94Xt/CsesaZb6jemYMsMTQGEGQZ+Qu3GeP4d1eU/EP4j3/ia6jtluLC8tGSOWGKW2ZbXfuJL+U+HkVVUtukwp4wnIrE8Nade+NdSa40S1utX1DykjjbesawQbyNzv9yJjhnCKPlHlqFI3U7iNbxH438R+N7f7TrTrb6EHlZLGIFTMqgBMoQeQ6v8zE/6tiFUqMz6PpbaXZ2Sw2E+uW+k3g+03rc28+oMUjjLOxy0aO6INu4hY34+eux134D63qejKtp4mt9Ku2R43tLW3YQeUxGITJu3soVVXJGCB05OeX8V6j8W/BXhG70/xBp8Gq6RbPC0F1DF5hRIpA4bfGBtA2D76/jSGS2WiS+Kvh14lmvriwsfEGkXYENja3QSVHtQyyszHkPLukySMEBe1ZGqzXVlDY6Gkt7NbrpVrfvOzfaE8yZNzYtgyRhV+c52s3HXmnCD4a/EW9vL62Ntpevaw32iSw1t5IQZCTloLleBk9iGBP8ACK6DWrSHwz4gt9D1K7+zSNoFhH5ct2x8wxNKjAMAVfgDrEwP+zQwOaXQrHVkZrLWLpLZP9IVISv2eEjquxUQOpI5Eix7emT1qi/hm7jSwCywNbzgiJVG3KjJCh0HzcMQMbsZPNdVfaaXs7e/06G/iDTMUfyA0SzA4+dWIjX3YSIRnhVxwC/bT5zZ+IJvDVqlyyr50errN5jnnDKuZTzgYkEyj6c0r2Cxynhhk8FX2uzXNvMtnqejXenRiORQsdw5U/vGdhGo9MHJA5FfRPwp8d6Xq9np3h4Jc2+p2tjGFEyqUuFjVVZ45EZkbBIyM5GRxXiHjDwvrWn32q6jLcPNcSgQwvAMwMI+sDMrBdxIKgKAck/IuSK0fhRfal/wtbwjb363EMCQXkUcazCWFd0SttAUkRkbOV2qeB1pge2XX/JbtNGP+ZfueQOv+kQ9a7muDvzj446MBjJ0C73fTz4MV3lABRRRTEFFFFABRRRQAUUUUAFFFFABRRRQB514s+FVn4o1yDVtR13V/tdsHW1wICsCucsoBj5Hb5snFeaz/s0PaW8kWi+Kfke3ktNt7ZBysTnJAKsOcknJFfR9FFgufLEfwI8X6VqdleQLoGom1tDbJsnkhYkRsqM4ZWVhlgSvfYORznntX+EXxAsNJ0eCx0qaOSyspYnOn3MeJp2ZtrZ3hvulck8ZHAGa+yKKAPh/UdO8RaMQ+q6V4gtfsulwCQSJO4kuPOBklDAFRtj3jJ9O9dL4MbQNCs7281LVNGW91Nobq6i1jR5pI7UyAvHGs8ZGCUIJBFfQ3xN8QaHB4X1/Sr7UbVbybT51FqZlEjbo2wMZ4J7Z61454d+FEXj3wfZXtlqzLptvcSQ2dvfWxmilt422IQ4ZZNpwSOeM4GBxSYDrvTdGuTD/AGfqPhlbbe7zjR76V7kMykgx20smw5OCeCfQGsrQtO0SwTUrjxD4x8YeGjA5a3uLe68pLyI4x+6QOFkDHGwHJ4IHJxe1n9n7ULiS3iktre506M/LFbamyyQ+vlmWJiF77CxGa7bwzpviDwnbTNa+FtZvbdx5czXN5ZPcwqMYaHau6XkZCu49uaBnG+ENEi0LVZta8FRePzNfj97e3GlQTLcqSCCTOyv6nIxn9K0PF2utr8ekaV4v123utMbUVS+0f7CdLvZMRu6iTzZsbMqPu4DcYbPFeb3Pwy1XW9aSCbxGl/LNK6z3F/dDK9SDNDI6zRSDAyAp68NXbeK/h0t8nh7wZpWvQa9qEBF4jXVz+9s44wRKokUMyRsWjCqQfmGemaLgem2Xi3wb9l8ifTL5LZkaEGfT3nVYncExhkDAR5xxnaMD0rmtSsPh3rt3daNpmu6n4YvkRZEuLXUJLZJF9gzbD7qQG7+9cT4y+EPi2/1TVtRTw7pcgluLRrYW06ebFDEoV1ydgLMFXtySa43xbonjux16/vbbwvqtjp7Xbz28EfmFDFuYiNvKYhcLgcH6GnZibNLxR8O/EuiyPHa+Ndc12e7k/wCJeumXLSm5VVLOkih90Z4GHAZfXHFYF94X8UyW4Gqv4ysGkdvl1O7kESIF6s5Tbz0/A8VQfWLuySR7w3cTQAsY9QtlLlcHcoZk+8Plx2bvitz4eeJfFes6nJD4euNZW3hmXzDpk6GULycrbyShW6Lngjrz0oEjnNP0bRRpdxFLcX95dyKiTSrPZvbu/I2xzSjKsMk4HOCDTY9EB1bTbu61NNPsrxjZmGadJ7qFYynyksMDcjArt4OMda9/+IfhzVda+G1p4lufCcaeKYIna7WFEE7KrABjEQyNuRSSOWTI25xivnVzoF74p0Z9Rs2tNHMQ8wXWpPKCGO0ncOVKEhig/u8gUDPRbi00rwJepZ/8JFPJeWGtWt1PZtImwGG8ZM7MF/8AVOjgFu5OTgYyNV021s/E/iVSlxaCDU7yJZbVkhm2NISQ7MpB4xjHQdOaTxNr3hi18JSaZ4cs0mu9Sto5HFjE7Mpa2TeGcj5ts8CtjJxuPfIrs9Wv9Rsdfnl0zxBf6Taara2mrRG2RSgSWJVOSFJzujf8PSi4NEXhPTdQ1i3mtdKe+aWVxEjS3cbsjEAFise35cA8nPNe9/C7whfeEdMvIdS1Z9SmupvOOYFiVCBjgAnJIAyST0rifhZqkmq63BDceJ5daCMZFyIMqwznO5d2MD+DGK9rpJDPl79rCwltfEHh19KsFuUmsbiGazjBAeJHViAq/wDXQnIGRjIrhzD4H13RbaTTPCmuaVqkaQrZ3kFu88bzBSX81nyr/OuwfL788ges/tVLNFP4Ru4EkLB7uLMSqzAmNGztPDjCHKd+3NcFoVl4pn+HF/HpOgw6lor7NSke4mMW+PzN7GMmQkHdFJxgEbj6imxJFTxRpjaHqIstP1oW0tw8EdrIUuLUTKzRuh8yFwm50lO4Y4EZwF4NTWHiTxtaWzyRSapYxwWgnCf280hcGN3GxZkkBO2JwQe4xkVgQ2NzoEGp+H/+FeS3Wr2s6NcXyy/aowDnCqzDCrtliAwc55PXi9qPgj/QIdduvD5GlTJM17bR3Km5tkiuhkRrtUIQsgDKGwRzxikPU7vwB4h8d6T4YtEZv3lxdStcS3K2zsk7+Y7eaDLGVyyPgkjsKgv/AI++JdNnsIBa2F7NcBZNk2mXFs0kLHCzKyySAqfUA+2a5vSU0u90m9vrPwzeDVFsTNbXE1qrIJo1jmEg818OBtnyOQyjjNS3EnixIH0s2dr9usNPZ0v3hETWxtJPO325V2MkgWc/LhRg915oQjt9P+P3iS4wU+Ht3fxsBslspZdpJDED54hnIVun901pL+0D5Cp/bHhG+0kyxiaFr67jhSZD0MbOF3fgK4G10XxXcwWk9t4s1K0s7VndRLaIkjCGVcOVUgp+5uWkxk/Lnp2xvEEvibSdSsNG8U+KFuF0+W5fTJjDB+7a23fu33DcrPsj254IYYJ5FFwsexD4+WAWNpdKhRHbHmf2xahMeoLOM00ftB6QY939jzghSzA6lZdB6fvuT7VxGj+K9RuvG+m6J4hu9M8VC5vJUtHaaNTGqrJAQVwV3tmOTcO2TUWjaRe+GbOS9t/D8S6RDF9r1O2huC8pSJZbW6EKbVUE5DkE57g9AAD1B/jdpcQgEnh7XpJJnMaLZi3utzbC+B5cpz8oJ/Cqz/tA+FYZRFcafrsEv2ZbzZJbxqRCRuD48zuCDjrjtXGPqXgvxAltd6vai2nlsrGch7KUSQNE7RzhZNmR8jryO4HtWHpcPhTwotlLJd6/DMYLiO7X7DvZpLeUGMHzICjnar57jvjHAB7RafGPw3Na2t1Pa6/a2lyu6G4l0qZo3+jIGBpF8VJ4wiEtnrUeg+GZgRDePIIbu+AOC0Qkx5cecjfgse23gnwO+1XRLLSvEtjb2+sTQW87XYnhsJLfq0yOW4UBtk8YJOB8oHpnN8QWA1u08Pxpp0NxbTaLYSqrzOrZWFkJCqDlQyOP948kdwD6c8UeFjB8OdcsfASJa6tc2rLBcpKTLI3vMSWLEZAYnjPUV4xcfDzxf411Sytrazl0Tw1pYW3soL9DHHABGu6Xygd0sjOXO44H+1XE+CvEesfDfULm9sp9RhhQeZPo0yia2uUyM7HU7UYJyCNxBGDxXt0vizxB8Ub+90HwhPD4d0xbeGefULh9168MuSPLhU/JuABySCAw6E0wPNfGHhFdP1+Ow8Mx3ev+ZcoLpb2RY7fUblZCWt4giggRqH3BSFUcMTjB9++GfiHRdd0qGPT9Mi0i8tU+fT/KCGEE7SUwBlcqVJAGCpBAIxV/wf4I0nwtmSzWSe9ZBEbq4IZ1jHSNAAAiA87VAHc5PNc74w0YaTrY1cSSwWE0wmF3CmW0y5K7TKR/FBIAokU8AjcepKoPI9JqvqFnBqFhc2d2gktriJoZUJxuVhgjj2NQaJNeT6bE+pJbrc4+ZrZ98Ug7OpPOD1wenv1q/TA8A+JfwXTUbGTy0kugsW1L21iQXa7QdgmjGEuFHTI2yf79eafDRNI0eZvC/wAVdMZ9OluES21D7RMFDZJRJBuBWMkkqcLggg9Dj7B1Kyh1GxmtLnzPKlGGMUjRsO+QykEH3Brzb4v/AAxtfFPgX7Paq9zrGmQyNYzXjtM8ncxuxO5t2Bgk5BAPrkA6PSfht4P0tVFpoVq6AYVbgtcKo/2RIWA/CvJPjT8N/B3hie18UR2MVuLrUIreZAWCwGRwTPFGnLOu0nZyCCcAYrrP2ZvFM+veBP7PvZjPdaTsgaQ5BCsuRG2edycp9FB716R4sZ4/DepTQaXHq08MDyRWUmMTuFJCcg9enShAfNehSeK/F19qWseBIri7hmuJFa6mCw27/NnGXx5q+oaM7T2716X4A+H2vWfi+z1/xBHo1kLVZ9tvpzysZDIAoLhvkUhQfuAA56Ctv4AX0l98LNKNxaiynheeB7UIU+z7ZnAj2nkYGBzzXolJDZwOsRsvxt8Myg8No1+hGfSS3P8AWu+rh9d4+L/hPk86bqA47/Nb13FMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeVfGnx8ngrUdDi1SfU7HQ75ZRNeafAkkgkXbtQluFBBY5ALccd64KT4mfCO4hmvH1LxLc3USb9r392kjEc/LmULn2FfRV9ZWuoW5gv7aC5gJyY5ow6k/Q8Vlt4Q8NMQW8PaOSBgZsojgf980AfJGr/AB8tLbw9caT4N8MtYWs87Sy3N7dtczSMcZZtwIZjx98sOgweK5z4Z6pqEWgS/wBl6tdtqMskvlafBdzRiJV2EssSSIG3BnJ27m+XhDya9a+MGu/ZfiFcaLpEGnWR01bUxie2iW1+bEnVlI804IUHC4XjJOK4PVtLvpdQurvUyhjvCP3+MxiVGY7ZYwse042jKBHTA6gklWuO5eTxBczLCDfXUD3Acxy/brqSGZAcHaz3H3x3U429wBkrbubG8Zo/tN5PFkYaTc7KWGAxO6QnAJyQSDhsnHy7obS0l1W2uLTXLK5E0KCWe6MJZ9gIG92UDz1G0gSqBNHgghwDVwWZ8M3UVnea/o89u6qxZNTQva5HysMlWdBx8hwy5yrYLLSsFzlryx1aBZxa6TpWo3DgvGRZ27SPyMMC8LPJghgV3bjnGAQRXrX7O97o+qfEDVdR03TINIludEts2cZjA3pI6SsAmP4lTOQDk8jpXP28emR6lawzataXS3TAzTaVBJdBCCDuRFjJVjjgfdOegA21JpthqvhzxofGen+HtclS1aKzaaCxkH9pQlm895InAlUhGjKsQQTEQWJ5p3FY+pKKoaPrOm61arcaVfW93CwzuicNj2I6g+x5q/TArahYWmpWrW2o2sF3bN96KeMSIfqCMV4p4++EPhmOb7XcafcW2mIA0eo6YStzphHT5QD5kXvgsn+7933SigDw9fCHxR02xgm8F/Ee11qwaMNEuqW6sWXtiUBi31yK87+IvgL4i69a3Vzf+ENIk1OeILPeaakaSOoYFhtMpDngHO0N2B7V9IP4dl069a78Mzx2RlfdPZyKWtpsnlgo5jfGfmXg9wak1XxFJpF5MNQ0jUPsCkeXeWsf2hSMZO5Ey6YOedpHHWgD4fm11PD6yaNrWpa0EEmBBpsaWcsUcj75Uk3puVtyqQoG35jg4Jz2Og63beK4/D1j4f1q403V9Lt30t1l/wCXmxDZhkPBTeu7DIQTycA4r6jv9G8G/EHTzJc2mla1Awx5yhWdPTDj5lPXuDXkfiH9mfT0DS+D9YmsZ93mp9sUyNFIOVaOVCrrjjru/PmkB03wl8aaJY+FmSW5vryYTMJJrXTp5YpWGBvUpCBzxnjr7YrsH+JXhmLP2m5vrXA3f6RptzHx6/NGOK8Jbw18fvDVuEs9TbVFiOVaG4gl47/65QxbHfnrWV4j+JfxY0ezlGradrVpbxSblnnsUAIHKZdUQE7sZxgEZ4p2C56H+0t4g0y8+HkGo6dqNrMbDUBG0bJuZmeFlIAJGSFlDEc+/SvCLTx7qvh/w5a2fhXx+lxZzgrLpNxYCN4lYDcC7oyEnLZO7HfPNZ/jzxf4j8XW73GvyapJpchUwPeDdBE3UuojRQCRtA4bGSM96oaRqugm2jhltNPjFug82cxoWuSM5Vdy/Kn3Tkqz5BGccUgNTSL/AMc20QWw1fTLgau7W8cE9/ayzMZPLGT82VP7mIZOMFRW34s+Ifjy3ivLLVY9BtY55HW6+zMswf7RGFkJKO4AIGcjoenPFce66FcTbrmwscLuQCwWcAcghmJIBIAPQ4I/OvRf2avA/h3xnrmtDU9On1DSrGONEJcQpvcsSX2kOw+QYBLY59qAOS0bx9b2lrbLAdesEjdY0aO8jmjgQNJhEEqYA8qWRACeepzW/pPi/wAJaq2jQeKrvXtXmmuYJp7eTy1hB8t4X2iIrzsEI5PIByPX174yfBnwLp3w213UdO0ptOurG2e5ikgmkOXUcBlZiCD09s14TJ4bV/gTD4zF5eC+Fx/ZBh8uNo/I9vk3ZzjnPrTA2JNQ+H+l6S0VvD4jjjjhieSO11LyQxJeKZgrScsy7PlAPGRwKi0zx18OdP02wvrPR7v+3YriMyyXuZ5X+VN0nmHPyq0YwAc4Y8VgeHtBuv7Z1C5ubm6u0tNGi1m4kEiK4haJGYYkR1Y/MoAOOlX9J8N38Fnf3cHiWXSUvk8+5U6e8saRGQopZ4lKj5/lyFXntQBaOt+B7+VLDSvsOiRW6DOt+W8c7yqG2bEXB2sYoyWPKlzxk5r0WfWfD+ppqwk+IXiO5CRsltDpsHnG6ikgjZ14iY8ybgdzdsE9TXj9t8OvGMumLq1x4RGp6XPHshl89oycEHzlXeGywXuMEE8DtKLXVPCWnwzNEstrcw+XNp9tql1G9ux53SKhHy9R3HPJNIPI7nwZZ2+k+B9PbWfHFvp0k0U9kts91HcG1tJkLKChYhMyIoOArKa7jTYfEvivwxqFta6rod4Z3h1ARRxGOR/tVuRIqN5oAOWl4JGSDyAcD540nw0viPQdY1PSPDerzPpymW4uba8Bhj/3ldN5IALHaxOOuKoWif2RqCvHo9nqZaLy3KXbToGZciRDEQyuuCc5OO4oHqetah4b8S6krwXZsoIZ9PzNqmt3vnspaIK7qoZkQlrVgrcEd+1Q33hu+k+HHh2OaPT59V0PU5tFk89iymGQmSPLIQRhgVBDDG7rg15TDdWMl0LfXX1fT9MyFMDM07dSdwB2AhSfunH3mIOa9A+E2o6VJcat4Si1Oa9fW0Y2vmRhYzdQuHtdhc5XeAyENjBI5OaLAeieB/D2t6g+qPcWc8MENnM0E9vdrPG0nlEIySZ3nDAqVO7k+nNcmg8SaD8Tre78Pzulw9tZvbK4BgkLWMZaFmPTf5YA4GSvHKivWPhTd6a/iK1n0+aP980sPkPG9s+QSHwshcSbWUglJOMfdryn4i2V4X0K/OnG8s/7HQXcImMfmfZLp0Kkj5scoM9FyCcUCPpr4b+PdJ8eaO13pkgju4CI7yzZgXt5O4OOCOuGHBx9QOtdVdWV1DKwwQRkEV8cSy+JvCep2Ou2N/bnybK0J1FTGI/MkjG+GYRqTMMQONxIGVzkN1+j/h58RLLxXBa215byaVrctsl19inIIljYZEkL9JE9xyOhANCGai6FL4fsbo+EIolZ3V1sLmZxbDBO4R4z5Wc9gVBA+XrWjoGrnVYZvOsbuwurd/LnguExtbAPysPldefvKSPoeK1Kq6pDdz2Esen3S2l2R+7meLzFU57rkZHbqPrTEWqK5zQtdu21EaP4htorTV9hkiaFi0F2gIBaMnkEZGUPIyOSOaqeKtXub27bw14dbdqkyj7Xcr93ToG6ux/56EZ2J1J+Y8A0Ac78DNGgsl8XaraYFvqet3TQ7Rw0ccrqGz3y278AK9E1q7lsNHvry3tpLqa3geVIIxlpWVSQo9zjFN0PSrPQ9Is9M02IRWdrGIok64A9T3J6k9yTXHfGLxnqvgzQre50XTI7qWaQo91c7vs1ooA+aXZ83JOBjqe/QEQMz/2frvWdU8Japq/iGzis73UdWuLgwR5GzG1CCDkghkYYJzxXp9edfAay1208CGXxRDLBqF7e3F6YJBhoxI+7GOq5YswB5AYA16LQBw2vvj4weEV3HJ03UDjHbdb13NcF4iKj4yeDefmOnajxntmCu9oYkFFFFAwooooAKKKKACiiigAooooAKKKKACiiigAooooA+S/jZ4N1DW/ijr97Y6PcXdvK9ra+bG42tL5S/uyOCCQykHkZA9aueGfC+vWlgbHVNPaK1JFuZtQWOICM8qGDN84ByccYJBUoc17/AOI/Anh7xBeve6nYySXLBd5iupYRIUB2lgjAMRkgE+teP/BD4YeEfFfw/wBM1zWdOnl1ZmngmlN5MNxSZ1HG7HAA/KkB514t8N6L4l1e3t7vUtfkW0SOCK3tLRZRDvdt2Gd1yu7p8o5P4nc0i+1LwcmmeG7TQNWl0qITSRz2bLp15d7myomz1K4kPytyCuQOlT/ED4Z6x4T1AuttrPiHwmY5Ei+x3sy3FmTkqWjXh9vY8BuM4PWx4f13wLougSXl5YeE9dtrZQjfaNO+w6idvVTHIrJLIB/dZcke9DuM634a/FNHvtUOoR65FoFrawzSSX0kV01m7M+S7xnf5eFH3gdpBztFeh+Gvif4N8Ta0mk6HrsF5furMkSI43hRlsMVAOBzwaW58BeDte0mDf4etILaaMMFgiNo5RgCUby9pweMqePUVh658LNGsJNM1Lwfotvaalp85kVYLl7YsrIysFYZXdyD8wIOCD1oEdjrvhHQddbzNT0y3ln7XCgxzL9JFww/A1njwnLp7B9K1/xDEThAklyLpFHqRMGOPXBzXj1z4e+L2hfYPEut+NoDHDdRfabEljEsTyAN5hVNuFB5IXgZOeK3b39oG2tdZis/+EX1O5tmvBZfbrWQTQySbgv7oqD5nXI6E9AM02CPQRF46sJsJc6DrNsOczJJZzH1GV3r+OBS3XizVNPZRqPg/WmUj/Wae0V0o9eA4b/x2qt74uufED3Ol+AhHPfopWfULqJ1trF/7rggFpf+mY6fxY6HnIvh5r7skmuSaNr1xj95cXE95BIxxyRtdlXPoqgDtSH6nT3nxL8O2NhdXN+2o2b20LTvb3VhNDIQoztXeoBY9gDXk1p+0NaaxPIw1nTPDSo37u3vtPmvDIvYtJEwVSRjgA4yea9Q1XwlDpiI2hadq8x2ksltrcsYB4GNsj7DwT19PevnX4jaZ8J47zUYJtP8TQ69alYbiC3khWOBscF5AGQAdCeT7UxHsuhfEr7S0txY6l4Av5Jmwzxak9lNLgcbkeNiDz3JrqX8fS2cD3Op+HrxbFE8yS8srq3uYUX1bDhsf8Br5s+EHgTQfF6S6J4hvlstSEamyDpETewHccxkqrnbtweT0zwK9Ns/2dxpWq2t9peuWcnkTmcQX2nebHu2gKSBIC20jcASRmgD2jw14l0nxNaSXGi3fnpG22RWjaN0JGRuRwGGRyMjkdK2K89tvB/irTtav9WsfFtrPd3scSTpeaUpRvLDBceW6kfePrWrGvjqKfMsnhm6hx91UngbP1y/8qQFm98D+GtQM51LRbC+M0plY3MCSEE44BIyBx0rkdZ+BPw41JwJNAitJXJKm1neEk+yhsfpXVz6j4sgQEeHtNuW7+TqhH/oUQquniLxIOZ/BF6DjP7rULZ+fTl1pgeV61+y74duiw0rXtYsYn5eKRlnVj2PY/mTWt8PPhZ4l+F82pHwlf6LqVtqBjMsF/HLAVKbsbXUv13HORXejxu0YP2vwv4ntyrbTixE3pyPLZsjntTofH+jsMz2+tWo6ZuNIukH5+XigDjPiJZ/FHxJ4P1XQodH8Owm+h8lriDUnYhSRuG14h1GR14zXmeseCfHI+Ctn4Gfwlcm5t9QF01zazwSRGLLE4G8MWy3TFfQzePvCyFhPrdpbleD9oYw4/77Aqzb+MvDFygaDxFo8ingFb2M8/8AfVGjA+W7W3n8MweMZvFWk6xp8F14aXQ7BrmxkIllWMKF3JlRkoMZPvWV/bWiWvgzVdNsddsru9Oi2JRVJjDzLemVohkcsFxnFfUHxB1iwsbzwfLdXttFbSasCZHlVV2iCb5snsCVyfcVDoPgDwnaas+v+EitjJPIHuH0+ZWhuACSVYHcApzyFx2o2A+fPHOr6f4y+C/hTwx4eb7drGlvDPfW0alfJQI6MNzYBOSOASa4ODw14s0zTkurK11SG+tWEsTWcFwrOrJ/sqANrLyQep7jmvqn4ijSIfiP4UuNWsI76AWOoFYltzcPKx8gBFjAOc5PsOeRzXjPjrxp4Zt9TkGk6NotndRAkQac/lFGHIWe4h4Y5OTHFnuDIOlID3L4KSJefC6wv9WVG1O4gZdUlkQLK7oWU+dxksFAHPOK+fvBHwbv/Fukz6noeuWtrDZ3DWot5bbyQ6+XHJuZ0zk/OBkrnCjPpUvwnS41fxebXS/E2p6dF4mE0d/zHM8uyIsQm9TtODgHlgAevb33Q/h/rfh6GWHQvGEkUE0pmkjuNMgkDHYqD7u0/dRfypoGj5+8feC/HfhrQ47t9VWXQ+IGkiuxeQpnOC6mIE5JA3AHHevKZJtIuF8v+y4YLuMZS5sZ5IGRkUn5twZG5wcrtPHavtHT/h5rEc5YeIo9GQHJGgWQtfPP951kaRPXhVH1rL8UfA628Wtbf8JP4o1XUPs7FkY21rHJz2Z1iBYex4oTFY8S8A/GG/0DWotW8S6aNYj8lIZNQ066MbsgBAMsQbZI4JIywDe9T+NviJ4I8Q+F723W7u7e4t9UludOV7Mu7W1xtM6jnarBmkK5YcovPNeqaZ+zJ4GsmR5ZtXunXOTLOmDkY6BBXYab8GvAdjJDKdAhu5oiCsl7I9wePZyR2Hakij5N03xze22m/ZNJuryeOQbksksVkRnSTeqoch41/eSg/e74yGwOh8NJ481J9PWy8AahdaXaK6lLsvC6FtjHyJG2mHY6lk8sDG4g5r6+tdO0Tw/BJNa2enaZCB88kcSQrj3IArFuviFoZJi0Z7jX7rtDpMRuPzcfIoz3ZgKNgOb+Gmr/ABGS9Ww8YeHjLpzcQ6kJ4lljXB4lTdlz0G5QD6ivRNY1fT9GtvP1S7htozwu9uXPoo6sfYAmufYeMNaVcGz8N2rD5ul3djnt/wAskOP9+r+i+EdJ0q/bUVhe71Zxh9QvHM05HoGP3R/sqAPagW5j39pq/jC6sZokn0HTLZmkS4fAvZCyMh2IQRECrHlst/sqea6bw/oen+H9PFnpVuIYcl3JJZ5HPV3c5LMe7Ek1fmfy4nfaz7VJ2qMk+w968+X4z+BjLBC2rTLdTSGFIDYzmQyg4MYATlwSBgZ5NMD0NjhSfQZr5c8L2PxK+KGtyTeKrdU8K3pL28zSqIrZFkGTFGp+eQqGUM443Fs9Kmt/C/xC8f8AiZvFw1KK48PDVZEg0W6vZIVa3jlKFXRQVx8vzDknB9cV794A8PN4V8H6Zosk6TyWsZDyImxSzMWO1ey5YgD0xQC0OgooooA4HxJtHxk8FHA3Gw1EZ9v3Fd9Xn/ihmHxm8CjnabLUu/fENegU2JBRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXlf7M5/wCLUWq/3b28H/kd69Uryz9mtSnwzCHqupXo/wDI7UAep1mXPh/Rrq8F3c6Rp810G3iaS2Rn3eu4jOa06KACiuf17xbpukTi0XztQ1R+I9PsVEs7HryMgIP9pyo96o/8JZe6fKknifRH0nT5SFW8Fys6REnAE20Dy88fN8y+pHcA64gMCCMg9jXCa00XjOWfw5pUajSbaUC/1BVwI3UgiK3Yf8tQerj/AFf+90x/H3jmxPib/hGJ72903TViV7/Uba3kk3lxlbZHRW2MyncW6hcY5OR2HhbVvCsenWmneHL7S47aJAkNrBKqlB6bM5B57jOTSuBsaVptnpNhFZadbpb2sQwqL+pJ6kk8knknk1bPAyaRmCqWYgKBkk8YrwP4h+PpvFt/Jofh4OuhRnFxdOuxb8j+BWZlHk+rbvnwQARnLAg+LvxagujNo+hahHb6cjlbm7DOJLvbjMUOwhgh6GQHkgqvc15xa6WU8FX+v6TYx6TZ6bPDI1zc2jTIVkn2M6RSqxbbkk5b0wa67So9antEttJ0a0tWU5UC/YoBkKCI7OMe3BY4rd1nS/O+G+qeFr02Nnr2rZmu2jgWJbS0jkDG4mydwXCkLuOSWGBwcIDjLfxd4V0Ke6XXfFzTXKpFIuqaLEZNQ1DzF3FjNIG8hV6eUhXH6V6R4B+JtxL8P9Y1exsdY8RaVpck3lX1zLbxTtEiK+JQWBLDLDIXkAdTXD/DD4U+GNRg8Oafrlra351Dw5NdGeLKN5huVIYEYJZVkCgn09K4fxn8Ir74e6zLHpt6usW80sbx21tG8935IySJbZcK0ZO1SSwB/GiwM7nwN+0hr+ueOLGw1Dw5AmlXjYVLSKaW5VOTvUDPmYxyAvQGuv8AHH7RuheGdfTTItI1K62xCSd5o3tWTPIUJIm4nHPOByOaf8G9MHjq113xB4mgtVne6htbWLTpnCWYgjyDDIrZU5mcHaQByvTivT9E8G6JpEN4kNp9pkvDm5nvXa5ln424d5CWIA4AJwBTAq23xC8LXHg//hJ11m0XRwgd5WcZjJGdjKOQ/bb1zVX4ffE3wv4/nvYfDV7JPLaBWkWSFoztJIDDcORkVVu/hXod/pWnaPqMt3d6Fp8yzwac/lrFlVKqGKqGZQCcAt9c1LF4AtdB1pdW8D2+l6Tcm2a1lga2YwyIXVshUZdrZXrznPPSgDodY8VaBot5DaavrWm2N1N/q4ri5SNm+gJzWznIyOleCaj+zfo+rRapqGrate3HiW8lkuBchv3Mbkkqux9xZRwPmJOPStrx94c8d+LPCem+GdJMfh+JCkd7ffbd/mxKm3aoUBjk8kHGcdeaAPXVeG4VgrRyqDggENg+hqld6FpF4ALzS7CcDoJbdH/mK8X+Hvw81T4O+I3ubZ7rXtDvrQxXAsrYiZJ1YMjshcgjBcbhz2I71Tv0+K9vdf8ACY3+oLDZvdwiDw8rlZfLaUIse0fIXKkZDMeSTlcUgRf+Lfh/TtKtPGMuj2Nlpyp4aEZeCMRbTJOwP3R0ITnH6189/CX4j+ItF8PX/gnw7ZWM76vK+yadsFGdAhxn5cYXuK+gfiJNean4F1vUL2eCPWPEJh0Gy0/54BEhm+ZcyhfMkwzkthV4445Oh4Z+F+paZpB07S9O8L6Np+ADHeWX9qXFyc/emkJRfooyB60wdzwT4RPNH8LfiyDIYdRtrGFEl3fvI497741OchTtAOOOlVNF0mXTri33SiC33q43S26tGvBw2Ywc9eeBX0zeeCPB2h+H55fHFroDTSBleSwsjYiZO0flo5Lkfj9K85+Hmh+Cb/x54j0u30e6hsbd7J10Sa6BWUkMfNk3vh1Tev7sFhxkBjjA7CIPh54e1zXNQ0fXfAUcFtBDJM0msagmYQWXY0cMIw79T852gnjtk+5Np3jmCNBb+ItEuWx8xudKdcn22TCvJ9T/AGgNTtdeurLw94BvrzR9PYxzuhPmRKrFWyiKyx42tgMegzwK9H8U/Fnw/wCHPAdn4pvY7/7Le7BbW5gKyyMybwuDwPl5znHHBNAy+8XxCWP5LvwpI/T5ra4QfX/WH8qekfj9m+e58LIuOgt7hjn67xWJ8M/jF4f8c6TqN7zpJsWbzY7yVAdgXcXGD90DOfTFYfh/9ojwjrfi+DRLeG/hindo4r64VUiYgHBxu3AHGBkd+1AHcRWHjeZAt3r2iW/q1rpkjN+G+YgfkaH8IajdMW1Dxhr8mRjZbGG2Tp/sR7v/AB6uN+KvxxsPBetNoekaTc6/rUaeZPDA21IF6/MwDHOMHGOhHNJD8bYrn4b3XiOHw5rAvYleMQfZnaDzg2wL52ACCxA9e2M0AdvZfD7w1bSiaXTjfzD/AJaajPJdn6/vWYD8K6iCGOCJYoI0iiUYVEUKAPYCvAfhl8VPG8viO80n4jaNaaUTb/aYZ7n/AEJUAIB++fn6jgHIwfw5XS9L+N/iKwtPG1v4haOOeUTx6XDIVJhzjKwkBGBAyFLZI75NAH0T4n8b+GvC11bW3iLWrPTp7kFoknfaWA4z7D3NZ3jD4h6HoPgm88Q22o2F9GsLPapFco32mToqKQecnA4rg5/hVafEnXbvV/HtrqgMFtBZWjOVtXl27mkl8tC20FnAAJ7HitLwp8CtE8N/bLa01PUJNJubiK4a1dYtzGMhgrShdxTcoO0Yz3zQB554V+MPxD1DxLBpvirTotDtr6JpIWXRbiWYgDgRpn5ix4ycgV0XgL9n7SItG0bU9TuNb0/XlLXEyQ3KKEL5ym0KQvykA7efevfqKFoB59c/C3S7Zo5PCWoal4Vmjj8rGlygRSDjG+JwyE8dQATk5JrPuj8V/D0mLX+wvF1ggzmXNjdv7cfu8++B9K9Roo3A+fvF37RTeHLZYNS8JappuuxzJ5tlegCN4j94xyjqemDtxXqfw6+IXh/x/pX2zw/eB5E/11rJ8s0J/wBpfT3HB9axvi78LYfiYthDqOt39lZWmXFtbqhV3P8AGcjOQOB6c+tcBpX7MljouqQ6hofjDWrG8hYNHNGiblP1GOPai3mFz0fxS5Hxg8Brn5WtdS4z32w139ebalBd2fxI+HcOqXov7wW2pRvc+UIvMOyI52jgcDtXpNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeWfs3Z/4V1MpXbt1W9G3uP3zcGvU68q/Zzi8jwfrUOCDHr18m09sSYxQB6rXmP7QXijVfC3g2xk0Od7a6v9RhsGnjRXeNHDZKBiF3ccZ4+nWvTq84/aC0l9U+F2pS28Pn3OmvFqMUe3O4xOGYf98bh+NAHmnw2+IS+Cb6XS9Wnhv/AA9JNiPXBYtbSSuUVmMjciR1DAsSckZYFsYr6N/cXtp/yyuLadPZkkRh+RBBr5XvntLrTpYZYodR0XWZ1kyY2jMrMhdIyoB2Py7IRkem75lPafA/xBqHhW5tvBviFppdKmdk0W/nGx1IG4Wsqn7r7TuXswPy5GKQyz4usNc+E0c83gOysLjw/q10izW97M6rp0rDbvVy4CxEADBI2nABwQA2y1RrTSbWbx7ouj31nHHsO2GX7RDbrwbkpMWZo17yHa3GRu4z7XfWlvf2c1reRLNbzKUdGGQwNeKW/wDYWia3r2m+N7k3UMDLxcH5rwMMxyMnLzNjeCzEIu35VHWgCx8b9LmtPBWj6N4e1C8tdH1O/wDJufKn8xmhMLvsR5GGEJTn5gMH04rnPBz+FfCum+dJfW+bWVFiZpBcbSVyImZI3YKEGcBzg8d6tavq8d98GvBN1aTNcwWmsLYiRDhnjTz4FJyj9VCkgqev41HoaXerHydCupwYWy2PkAz/ABYE0a/+OigR1umrcavqd9KtlqF9FKsltJsR44kD4/57XGBgYOAg4IFZesfB+/1h9avLvVriCOW0hFnplr5aI08MQVDOQoV13KCE4UZNXtA0HU7/AFFZdYlU6bazC5lna8hmIdQCDt2uQDg/xDA5FRan4in13WL3TvCFvquqX7Ospa9maO2tkLZ+ZRt2DgbdwLEHIUjmgZJLZ+ILfT9N8QePvFFt4YhsLZ7eR4li86TzSpYM+DGpyi7Qik+5NN8KXOp67ZzW3w40pvD+jSSET+IdVjMlzd46vFGx3O3X55Dgdgeg6Lw38N4U1VfEHjS7HiLxJwUmmjAgtP8AZgi6KB/eOSevHNeg00Iw/BXhjTvB/h220bSBJ9mhyxklbdJK7HLO57sSc1uUUUAFFFFABRRRQAVyXxEz9n0AjOP7bs84/wCun/6q62sLxlpVzq2iiPTmhW/t7iG7t/OJEZkikVwrEcgHbjI6Zzg0Acf8cNEXWrLSYnCgk3SRSMAQkv2aSSMkHgjdEMg/SvHfhPZa54ruodOs/EGo2cJtVnuHgnci3ygwu1JFVcnoMDoa9j8VzeMtVsYIH8IQmSGdJt9tqsbgjlXADqh+6zD8a8x8HyL8K9Ys9S8bWdzYwLbm1WaPTncMSqDG9GKj7meRn9aTA5b4s+H5tM8UTaQmo3BjXSoJ5DK0QnuXdpAwdnJJX5fu7tuetR+D/h/da48FjZ+beXFy3nXE1w0UhVCMBpZNhIT5cABgzYO3HJHceLfD9p8VviUZtIuLqKQ6fCshuLSW3+zwbpMS5LL5m5mwqgEHackDg+8eGPD9l4c0tLOxEjnhpZ5mLyzvgDe7HknAH0AAGAAKLAVPAnhHTfBnhe20TS4kEMYJlfYFMzn7zt7n9BgdqrQeAPDsVzZStZzTpYtvtbe4upZoIGwVykbsVGASBxx2xXV0UwOV1rwRp2qfb0W61Cxt9QXZeW9lMIo7jK7SWGCQSoAJBBIApknw78L/AGbT4rLSbfT5NPcPaXFkgilhIBGQ45OQTkHIPfNdbRQFjB8O+FNM0G8v761WWfUr9la6vbl/Mml2gBQW7KAAABgVV/4QHwv/AGl9vGkQi4+0C7wHcR+cDnf5edm7IBzjrzXUUUAVr2ws79UW+tbe5VG3KJow4U+oz0NWFUKoVQABwAO1LRQAUUUUAFFFFABRRRQAUUUUAcN4pTd8VvAjZPyw6jx/2zirua4nxTGG+JvgZySCiX/AGc5iT8q7akMKKKKYgooooAKKKKACiiigAooooAKKKKACiiigAoqlq2qWulWrT3khAAyqIpd36cKoyWPI6CsI3/izUIUm03StP06NjkLqc7NKV7EpGCFPtuP4UAdVXhvw28a6F4L8L+J5fEN6ttMfEWoslooL3D/vM4EY+bt1IA9xWt8Q7z4o2unxCxOkWtk8m25v9Mt5bq5t4/7wgYfN/wAB3H2715FpmqeGdCb/AIpWzn1bUzK0z6zqKi5maVxkMEHyB8gYDZZe4U0gPpjw54x0TxCyx6fdOlyyhxbXUL28xBGchJACRjuMj3pnjLxVY+H9PnUp/aGpsmINLtyGnuWPAUKMnB7sRgDmuK8I+DtR8S6PDd+Mr7UyrZe3geQpPC+QRKHByhyMgLg4OCSOKseELrR/BFhq1ne2JbxJYqHumtoTLeapFn5LhRy8mcnPJ2sGHAxQM8msdHvLN7CHbp3hvTIFkjvZSk08tu+S8MUsRCleAoDAkOUBUhsAx+ObzVdU16ex1CaW91AXFv8AZriyZRbyMrCSHDMw2fMCNpO4ZcAkgl+l+Ifi9r7XDd3sEGlWraVd27W8jiW/WUIJYvMSMsqESKhVSd+d2QBmvNvC91a6vd3mtzKTDqxUmF3Ek0XlLt3b9vLM2WIwVyeRkAqWEfW2jajNr+h2GqaXcxRwXYWfbLCWKoUwY+GGGDdT7EY715d8evh1pk3h061o2kWf9qQTHzCSyCQSkoXYgjlXdXz/ALJ9q1f2ftQiGk6voKSs7afcLOgZ2bEc6+YPvfMPn8w4JbqMMwwT3/jPTF1nwjrWmtj/AEuzmhBIzgshAP4HBpgeST/DXUPDHwOsvDsc8V7qsOp290GjUiMO1wuQM84wSM981yttZ2FhaK/iHQtTbUJLlkswkkSPMMDjaoZyR0GATkncFAzXqfhLwZY6r4Q0TULbVfEmnyXVrBcuLfV5yNzRqSMOzDGe2K6rw74P0bQLuW9s7eSbUpV2S311K007jOcb2JwM87VwPagDktO8La1rlpaQ3zyeH9FgAaKC3ZRfv8mw7pFG2LIznaXb5j8y9K7/AEPR9P0HTYrDR7SK0tI/uxxrgZPUnuSe5PJq/RQAUUUUAFFFFABRRRQAUUUUAFFFFABVTVtOtNX0250/UrdLmyuUMU0T9HU9Qat0UAfKWt/B7xf4M8aLqvgtJb2xtpBJpsds6I8RP/LOUuclB3HQjP3TX1NYG5Njbm+EQuzGvnCLOwPgbtuecZzip6KACiiigAooooAKKKKACiiigCK6l8i1mlAz5aF8euBmvOtC+JU2p2vgSVtMjj/4SV7hXAmJ8jygTxx82ce1ekuqujI4DKwwQe4rh/D/AMM9H0TUtNuoLvU7iHSzKdPs7iZWhtDJ97YAoY9SBuZsUAZyfGXw3Jam4itNckiNq14jLp74khQ4d1PTavcnA9zRe/FK107xDqcd5bTy6HbWdpeJeWsDOUSbPzyc8KPl6DPJ4OKt2nwr0S10yCxjutSMMOlXOkKWkTcYZ2LOx+T74J4PT1Bpt98KdIvJH8zUtYS2ltLayubaOaNY7iKAYRXOzdz32sM+1AEVx4/nXxDbWFqLS4il10aU7BHUxp5PmZznDN05HGD0qfSfiRZTaLpE0kdxqOo6ibhorbTbVixSKVkZ9rH5QMAZJ5PSrq/DzSE1caik16so1T+1ggdAgl8ry9uNv3NvbOc96rW3wy0uysdKh03UtXsbnTROkN7BLGJik0hkdGyhVl3Hj5cjA780AXU+IOiNaTXBN2iRX0OnOrwFWWaUKVBB5H3xn0p3hzx5pPiLWrjTtKjvZfIeSNrjycRbkOGGc5HPHIGe1ZU/wp0ibUGujquuBXuoL2SD7Upjkni24kYFSSx2jPPPtxV7Rfh3pOleLW8RC5vrrUdsio05jwgc5bJRFZ/Qby2O1ADfFIX/AIWV4HJAztv8Z/65L0rta4zxRx8SPBBxni+XPp+6U/0rs6SAKKKKYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFC+0bTNQuorm+0+1ubiJDHHLLErsinqASOAasiBUaaSHCyykFmOSCQAOmfQVNRQAV4Z8ZvCEegvN4n0mOKHTJ226tAItyx7jj7So+vDr905DEHBNeyaxqcOlW8M9yrmKSeK3LKM7DI4RSfbcw/OpNXsYtT0q8sLhQ0N1C8LhuhDKQf50AeO+CfixYaTFYaH4hmvLi/mx9mMNu0r7CPlQqoJJwCeNw6fMau6k+p+JPHvhWbU9Mu9CtbtLy1Ma3IW7uIAok/ebOYkyi5Ctuy2DiuX8KufBvwm0fWNF0y3t9WvGlh1fWrhlmmhaN2Rm+dhvZmTCqWCjjOe9jwvpPjfXNeTxN4cVdMiSF4EvPEjy3E96jlWyIhtWFQV4ChQc/xDmkM9y0fSdP0bT47HSrOC1tIx8scSAD6n1PqTya+ffH3gFPBmqXc9lDcTeFr4sy26Pt+zTOcFEYcpktlCeOqnsD6KLH4ths/214OIxwDYz8n/AL7qC50r4r3kEtve3/gW4tZlKSwy2NwyEHqMb+R9aHqLQ5PwXe2fhbx62ovcXMuhSaVNELl/mx5bRyY2LkZG6QHB4OcqvVt208Y+KfibbT23g7Sbnw/oU/A8Q34G94ujGCHHLHkBicDr1rmNO+EHju0vDLPqXhS/tldpIbG8huJLeJmPJCbhuJ6ZctwBXcCw+L6bVj1XwSsY4CizuAAO2BuoA7/w5pFvoGgafpFkXNtYwJbxmQ5YqoABJ9eK0a8rktfjPj5NR8Dcd/IuRn9aY1v8ahIoF94FKADJ8q55NMdj1eivKo7T40FiX1LwOME4HkXByPWrNpH8YIkxcT+Brgn+LZdJj8utAj0yivOHHxcyCh8Cj2Iu6a4+L2PlbwJnPpd9KAPSaK87kHxZaL5G8DJJ6kXRH+elVxB8YeQb7wL9fs11/wDFUAemUV50W+LIAAj8DE9yXuv8Kcf+Frk8DwOBjr/pZ59KAPQ6K85K/FsniTwKB/u3f+NCp8WvMBaXwNs5yoS6yfxzQB6NRXnbJ8V9gxN4I3dzsuvz6014viyZQUuvBCx/3TDdEn8d1K77D07no1FeaywfF4vmK98Dquehguun/fVLJb/FwgFNQ8EqR2+zXOD753Ua9vyFp3PSaK8z+zfF8LxqXggtnva3PH/j9I9p8Xyq41TwSpzyBaXP/wAXT1A9NorzZrH4tFTjWvBwOOMWFx1/7+VGLD4u551vwb06fYZ//i6QHptFeZix+Lmfm1rwdj2sZ/8A4uo2sfjAsnyax4LZM5+azuBn/wAe/rTA9QorzT7L8Xtv/IT8EFv+vS5/+LpBZfF44zq/gsY9LK45/wDH6APTKK8zNj8XT/zGvBg/7crj/wCLo/s74tnrr/hEfTT5v/i6APTKK81j0b4qnLSeLPDinsi6S5H5+YDSHRviqHYDxb4cK8YJ0lwfy8ygD0uivNv7F+KWP+Rv8PZ/7BDf/HKRdF+KZBL+L/DynnAGkMQfT/lpQB6VRXmK6J8VyRu8X+HQO+NKY/8As9PbQ/insVl8ZaAXIwynRyAvuD5mT2p2A9LorzVdD+KQCA+MtBbP386Ofl+n7zn9Kc+h/E/zPk8Z6EU99GIzx/10pAaXixj/AMLJ8CKHAy18SvqPIH9SK7avNdN8FeLpfF2h654j8XWl6NLEwS3t9LEIfzAA2W3k8gfhge9elUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzPxItp73wde2losjXFw8MUexSSpMqDdx0A657YzV7xRq0Oh6TPfyjzZgNltAOWmmOQkaDqWYnH69AaztV1JdU1GO20SKHUbiwlEkh85kihk5UbmAIJALEp14XjnI0YNChbUYtS1Mi91GEv5ErrhbcN1Ea9AccbvvEcE0Acr4D+GOl6FY2E2rK+patE73Ra4kZ4beeRi7mGInYnzEgMBnHevQqKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkZQylWGQRg0tFAFewsrXTrSO1sLeK2toxhIokCqPwFWKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bookwalter retractor and accessory retractors in place.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_32_43521=[""].join("\n");
var outline_f42_32_43521=null;
var title_f42_32_43522="Nerves of the lower extremity";
var content_f42_32_43522=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F72523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F72523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nerves of the lower extremity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 659px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_32_43522=[""].join("\n");
var outline_f42_32_43522=null;
var title_f42_32_43523="Glutamine: Patient drug information";
var content_f42_32_43523=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Glutamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/3/19507?source=see_link\">",
"     see \"Glutamine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Enterex&reg; Glutapak-10&reg; [OTC];",
"     </li>",
"     <li>",
"      NutreStore&trade;;",
"     </li>",
"     <li>",
"      Resource&reg; GlutaSolve&reg; [OTC];",
"     </li>",
"     <li>",
"      Sympt-X G.I. [OTC];",
"     </li>",
"     <li>",
"      Sympt-X [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       NutreStore&trade; is used to treat short bowel syndrome.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to glutamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11959 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_32_43523=[""].join("\n");
var outline_f42_32_43523=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176566\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026159\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026158\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026163\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026164\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026166\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026161\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026162\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026167\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026168\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/3/19507?source=related_link\">",
"      Glutamine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_32_43524="Nelfinavir: Patient drug information";
var content_f42_32_43524=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nelfinavir: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     see \"Nelfinavir: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/31/23033?source=see_link\">",
"     see \"Nelfinavir: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Viracept&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Viracept&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nelfinavir or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy in HIV disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696918",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use a hormone-related kind of birth control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695351",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may crush the tablet, melt it in water, and mix it with chocolate milk, milk, or pudding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695418",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix the oral powder with a little bit of water, ice cream, pudding, milk, formula, or soy milk and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694550",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid mixing with acidic foods such as apple juice, applesauce, or orange juice.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699437",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (solution) in a refrigerator. Throw away any part not used after 6 hours.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10896 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-115.25.216.6-BA4666D7DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_32_43524=[""].join("\n");
var outline_f42_32_43524=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200394\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200395\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020451\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020453\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020452\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020457\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020458\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020460\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020455\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020456\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020461\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020462\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=related_link\">",
"      Nelfinavir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/31/23033?source=related_link\">",
"      Nelfinavir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_32_43525="Mod diff squamous CA Light";
var content_f42_32_43525=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Moderately differentiated squamous cell carcinoma of the head and neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph of a moderately differentiated squamous carcinoma. Note keratinization at the center of the tumor nests (black arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth Haines, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_32_43525=[""].join("\n");
var outline_f42_32_43525=null;
var title_f42_32_43526="Ursodeoxycholic acid in the treatment of primary biliary cirrhosis";
var content_f42_32_43526=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ursodeoxycholic acid in the treatment of primary biliary cirrhosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/32/43526/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43526/contributors\">",
"     Steven Flamm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43526/contributors\">",
"     Raoul Poupon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/32/43526/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43526/contributors\">",
"     Paul Angulo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/32/43526/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43526/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/32/43526/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     Ursodeoxycholic acid",
"    </a>",
"    (UDCA;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"     ursodiol",
"    </a>",
"    ) is a naturally occurring dihydroxy bile acid with known choleretic properties. Because UDCA was found to lower serum levels of the aminotransferases (ALT and AST) in patients with chronic viral hepatitis and since it was well-tolerated, investigators examined its efficacy in primary biliary cirrhosis (PBC) in the 1980s. In the initial trial, UDCA significantly lowered serum levels of alkaline phosphatase, ALT, and AST, and improved itching [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/1\">",
"     1",
"    </a>",
"    ]. This led to its use in several placebo-controlled trials in PBC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THERAPEUTIC TRIALS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Placebo-controlled trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several large randomized, placebo-controlled, double-blind trials have been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/2\">",
"     2",
"    </a>",
"    ]. Five of the largest trials will be reviewed briefly to illustrate the findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Each of these administered UDCA from two to up to six years in a dose of 13 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. UDCA was well-tolerated and very few patients had to discontinue therapy because of side effects. In three of these trials patients who were initially given placebo were placed on UDCA after two years because of the significant improvement in liver function tests in those patients who were treated with UDCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/4,6,8,9\">",
"     4,6,8,9",
"    </a>",
"    ]. In one of the studies, patients in the control group remained on placebo for four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of 180 patients at one medical center, UDCA led to a significant decrease in the plasma levels of aminotransferases, alkaline phosphatase, and bilirubin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/3\">",
"       3",
"      </a>",
"      ]. Although there were also fewer deaths in the treatment arm, there was no improvement in fatigue, pruritus, liver histology, or referral for liver transplantation. In a follow-up report in which treatment had been continued for a total of three years, UDCA was associated with a significant reduction in the risk of death and need for transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar findings were noted in a multicenter Canadian study of 222 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/4\">",
"       4",
"      </a>",
"      ]. The active therapy group had lower plasma levels of the aminotransferases, alkaline phosphatase, bilirubin, IgM, and cholesterol. Fatigue, pruritus, and the rates of liver transplantation and death were unchanged. There was, however, a beneficial effect on liver histology as manifested by decreased progression of periportal hepatocellular ballooning and bile duct loss.",
"     </li>",
"     <li>",
"      Results were similar in a multicenter trial of 151 patients in the United States. Patients were stratified into four groups at the start of the study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/9\">",
"       9",
"      </a>",
"      ]. Stratification was based upon the initial serum bilirubin level (2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      was the cutoff level) and on the histological stage, early (stages I and II) and late (stages II and IV). Only patients in one stratum benefited from UDCA: those with serum bilirubin levels less than 2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      <strong>",
"       and",
"      </strong>",
"      stage I and II disease. A follow-up report of these patients (during which all received open-label UDCA for an additional two years) found no significant impact on rates of liver transplantation or death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/5\">",
"       5",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      This study had three important limitations: (1) the dose of UDCA was probably too low (10 to 12",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day compared with the standard dose of 13 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day); (2) the study was underpowered to detect differences in survival; (3) milligram per milligram, the bioavailability of Actigall preparation that was used in the study is about two-thirds that of the URSO 250 tablet available in the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/11\">",
"       11",
"      </a>",
"      ]; the latter is the formulation that was used in the Mayo study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/3\">",
"       3",
"      </a>",
"      ] and comparable to that used in the French [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/6\">",
"       6",
"      </a>",
"      ] and Canadian [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/4\">",
"       4",
"      </a>",
"      ] studies.",
"     </li>",
"     <li>",
"      In the fourth trial performed primarily in Europe, 145 patients were randomized to UDCA or placebo for two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/6\">",
"       6",
"      </a>",
"      ] and then all patients received UDCA for two additional years in open trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/8\">",
"       8",
"      </a>",
"      ]. The progression of PBC, as defined by the onset of hyperbilirubinemia or the development of variceal bleeding, ascites, or encephalopathy, was delayed in the patients receiving UDCA throughout the study (",
"      <a class=\"graphic graphic_figure graphicRef59511 \" href=\"mobipreview.htm?20/9/20637\">",
"       figure 1",
"      </a>",
"      ). The probability of liver transplantation or death was also decreased by UDCA (",
"      <a class=\"graphic graphic_figure graphicRef82631 \" href=\"mobipreview.htm?21/4/21581\">",
"       figure 2",
"      </a>",
"      ). This effect, however, was not seen until the second two years of the study.",
"     </li>",
"     <li>",
"      A fifth trial included 192 consecutive patients who were randomly assigned to UDCA (14 to 16",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/7\">",
"       7",
"      </a>",
"      ]. Patients were followed for a median of 3.4 years (range 0.3 to 6.1 years). UDCA treatment was associated with significant decreases in serum alkaline phosphatase, gammaglutamyl transferase, alanine aminotransferase and cholesterol levels. Treatment failure (death or liver transplantation) was observed in 17 patients receiving UDCA and 11 receiving placebo. Times to death or liver transplantation were not significantly different. However, histologic improvement (and a delay in stage progression) occurred more often in the treatment group.",
"      <br/>",
"      <br/>",
"      In a follow-up report, the authors described the clinical course of patients who achieved a biochemical response to UDCA (defined as a decrease in alkaline phosphatase to &lt;40 percent of pretreatment levels at one year) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/12\">",
"       12",
"      </a>",
"      ]. Using this definition, 117 patients (60 percent) were considered responders. Survival free of liver transplantation was significantly higher than predicted by the Mayo model and was similar to that of the general population during a mean follow-up of seven years. By contrast, survival free of liver transplantation among nonresponders was significantly worse than the general population (although better than predicted by the Mayo).",
"     </li>",
"     <li>",
"      Similar findings were reported in a later study, which found significantly better 10-year transplant-free survival (90 versus 51 percent) in patients who achieved an alkaline phosphatase &lt;3 times the upper limit and a total bilirubin &le;1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      and a serum AST &lt;2 times the upper limit of normal within one year of beginning UDCA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/13\">",
"       13",
"      </a>",
"      ]. Two other reports also confirmed a better prognosis in patients who achieved a biochemical response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Effect on liver histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the individual trials suggested that UDCA is associated with a beneficial effect on liver histology. One of the largest studies to focus on this issue included a total of 367 patients (200 who had received UDCA and 167 placebo) who had participated in four clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/16\">",
"     16",
"    </a>",
"    ]. Paired liver biopsy specimens were compared after approximately 36 months of treatment. No overall benefit was seen when the whole group was analyzed together. However, a significant benefit was observed in patients with stage I or II disease including a reduction in the degree of ductular proliferation and in the progression of periportal necroinflammatory lesions. Similar benefits have been described in other reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Esophageal varices and portal hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether UDCA prevents the development of esophageal varices is uncertain. A placebo-controlled trial that directly addressed this issue found a significantly lower rate of development of new esophageal varices compared with placebo after four years follow-up (16 versus 58 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/18\">",
"     18",
"    </a>",
"    ]. In another report, the portohepatic gradient (PHG) and liver enzymes were measured before and at two years of treatment with UDCA in 132 patients with PBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/14\">",
"     14",
"    </a>",
"    ]. After two years of treatment, a decreased or stable PHG and normalization of AST levels were predictive of improved survival. Patients with stable or improved PHG and normalized AST level at two years had a 15-year survival similar to that of a control population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Meta-analyses and population-based studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the number of patients randomized in almost all individual trials was too small to detect a difference in survival in the short term, a combined analysis of three randomized trials (with a total of 548 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/3,4,6\">",
"     3,4,6",
"    </a>",
"    ] was subsequently performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/19\">",
"     19",
"    </a>",
"    ]. UDCA was associated with a significant reduction in the likelihood of liver transplantation or death (47 versus 66 patients at four years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/19\">",
"     19",
"    </a>",
"    ]. This benefit was seen in patients with moderate and severe disease but not in those with mild disease (serum bilirubin concentration &lt;1.4",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    stage I or II histologic change) in whom progression to end-stage disease did not occur in this short time interval. In two separate reports, the benefit of UDCA appeared to persist for up to 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other meta-analyses have been reported, which have reached variable conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/2,22,23\">",
"     2,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two meta-analyses of 16 randomized trials (with a total of 1447 patients) found that UDCA had no effect on overall or transplant-free mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/2,24\">",
"       2,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another meta-analysis of 17 randomized trials found no differences between UDCA and placebo in the incidence of death, liver-related death, liver transplantation, or the development of complications of liver disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/22\">",
"       22",
"      </a>",
"      ]. The authors concluded that the available evidence does not demonstrate a benefit for UDCA, and its use as standard therapy needs to be reexamined. However, most of the studies included in the meta-analysis were of two years duration, which may have been too short to determine the efficacy of any medical therapy.",
"     </li>",
"     <li>",
"      A fourth meta-analysis that included seven randomized trials concluded that long-term UDCA significantly improved transplant-free survival and delayed histologic progression in early-stage patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/23\">",
"       23",
"      </a>",
"      ]. Unlike the two other meta-analyses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/2,22\">",
"       2,22",
"      </a>",
"      ], the authors excluded studies of short duration (&lt;24 months) and those that used a low dose of UDCA (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day or less), which may explain why a beneficial effect on survival was detected in this meta-analysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    How should the findings of these meta-analyses be reconciled with the results of the individual trials, uncontrolled studies, and clinical experience? Discrepancies between meta-analyses and large clinical trials (and among meta-analysis) are common. They are often due to different baseline risks in the study populations, variable protocols and study quality, different assumptions when combining data, and publication bias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A decision analysis considering these factors concluded that treatment with UDCA in early stages (stages 1 or 2) was associated with survival similar to an age-matched control population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/26\">",
"     26",
"    </a>",
"    ]. By contrast, survival was significantly worse in patients beginning treatment at later stages.",
"   </p>",
"   <p>",
"    A population-based study looked at the influence of patient characteristics on response rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/27\">",
"     27",
"    </a>",
"    ]. It found that men were less likely than women to respond to UDCA (72 versus 80 percent). In addition, younger age at the time of diagnosis was associated with a poor response (&lt;50 percent for patients diagnosed younger than age 30 years and 90 percent for patients diagnosed after the age of 70 years).",
"   </p>",
"   <p>",
"    The controversy surrounding the effect of UDCA on mortality continues. A population-based study from the United Kingdom found that patients treated with UDCA had slightly reduced mortality but the effect did not reach statistical significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    UDCA should still be considered first line therapy considering the results of the individual trials and the alternative treatments for patients with PBC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/19/34105?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the treatment of primary biliary cirrhosis\", section on 'Treatment of the underlying disease process'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Side-effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;UDCA is generally well-tolerated. Side effects may include headache, weight gain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/29\">",
"     29",
"    </a>",
"    ], constipation, and diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In aggregate, the data suggest that UDCA is associated with improvement in liver biochemical tests, a reduction in disease progression, and possibly transplant-free survival. However, they do not confirm initial reports that suggested relief of the troublesome systemic symptoms of fatigue and pruritus. Several additional conclusions can be made from these data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      UDCA appears to be more effective in patients with early disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/9,16,26,30\">",
"       9,16,26,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with advanced PBC and complications of portal hypertension (eg, ascites or variceal bleeding) do not benefit from UDCA. Such patients should be considered for liver transplantation.",
"     </li>",
"     <li>",
"      Additional therapy is probably needed in patients with florid bile duct lesions and severe lymphocytic piecemeal necrosis and lobular inflammation since these patients appear to be at increased risk for disease progression despite UDCA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/19/34105?source=see_link\">",
"       \"Overview of the treatment of primary biliary cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of benefit of UDCA in PBC is incompletely understood. It appears to act by increasing the secretion of bile acids, decreasing the toxicity of bile, and inhibiting hepatocyte apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the setting of cholestasis, transporter proteins on the basolateral membranes of hepatocytes are upregulated to export bile acids and other cholephiles into the systemic circulation, decreasing the accumulation of toxic compounds in hepatocytes. The expression of one of these transporters, MRP4, is upregulated by UDCA in noncholestatic subjects.",
"     </li>",
"     <li>",
"      UDCA may decrease the toxicity of bile by changing its composition. UDCA administration results in bile that is enriched with UDCA. The endogenous bile acids have greater detergent activity and are therefore more hepatocyte toxic than UDCA. UDCA also stimulates the secretion of phospholipids, which form mixed micelles with bile acids, mitigating their toxic effects. Finally, UDCA stimulates cholangiocytes to secrete bicarbonate, leading to dilution of the bile within the canaliculi.",
"     </li>",
"     <li>",
"      Hydrophobic bile induces hepatocyte apoptosis, in part by causing mitochondrial membrane permeability. UDCA is thought to stabilize the mitochondrial membrane, preventing apoptosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other ways in which UDCA may be of benefit in PBC include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      UDCA (or one of its metabolic conjugates) may decrease immune-mediated destruction of hepatocytes. As an example, UDCA decreases the expression of HLA class I and II antigens on hepatocytes, which may diminish recognition by the immune system, thereby decreasing autoimmune destruction of the hepatocyte [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/34\">",
"       34",
"      </a>",
"      ]. Other reports have confirmed that UDCA may act as an immune modulator either directly, or more likely, indirectly by lessening the severity of cholestasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      UDCA inhibits eosinophil activation and degranulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/36\">",
"       36",
"      </a>",
"      ]. Increased numbers of eosinophils have been demonstrated in the blood and liver of patients with PBC, particularly in its early stages, suggesting that they may have a pathogenic role [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      UDCA does not appear to influence the prevalence of florid bile duct lesions, suggesting that it exerts its beneficial effects by protecting against the consequence of bile duct destruction rather than preventing it [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43526/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      UDCA is associated with improvement in liver biochemical tests, a reduction in disease progression, and possibly transplant-free survival. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Summary'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      UDCA appears to be more effective in patients with early disease.",
"     </li>",
"     <li>",
"      Recommendations for treatment of PBC are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/19/34105?source=see_link\">",
"       \"Overview of the treatment of primary biliary cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23379669\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's past work as an author for this topic, as well as his work as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/1\">",
"      Poupon R, Chr&eacute;tien Y, Poupon RE, et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/2\">",
"      Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 2007; 102:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/3\">",
"      Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/4\">",
"      Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/5\">",
"      Combes B, Luketic VA, Peters MG, et al. Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am J Gastroenterol 2004; 99:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/6\">",
"      Poupon RE, Balkau B, Eschw&egrave;ge E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991; 324:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/7\">",
"      Par&eacute;s A, Caballer&iacute;a L, Rod&eacute;s J, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000; 32:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/8\">",
"      Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 1994; 330:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/9\">",
"      Combes B, Carithers RL Jr, Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/10\">",
"      Lindor KD, Therneau TM, Jorgensen RA, et al. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996; 110:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/11\">",
"      Williams CN, Al-Knawy B, Blanchard W. Bioavailability of four ursodeoxycholic acid preparations. Aliment Pharmacol Ther 2000; 14:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/12\">",
"      Par&eacute;s A, Caballer&iacute;a L, Rod&eacute;s J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006; 130:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/13\">",
"      Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/14\">",
"      Huet PM, Vincent C, Deslaurier J, et al. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Gastroenterology 2008; 135:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/15\">",
"      Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/16\">",
"      Poupon RE, Lindor KD, Par&eacute;s A, et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003; 39:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/17\">",
"      Degott C, Zafrani ES, Callard P, et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 1999; 29:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/18\">",
"      Lindor KD, Jorgensen RA, Therneau TM, et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997; 72:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/19\">",
"      Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/20\">",
"      Angulo P, Batts KP, Therneau TM, et al. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999; 29:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/21\">",
"      Poupon RE, Bonnand AM, Chr&eacute;tien Y, Poupon R. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology 1999; 29:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/22\">",
"      Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/23\">",
"      Shi J, Wu C, Lin Y, et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/24\">",
"      Rudic JS, Poropat G, Krstic MN, et al. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2012; 12:CD000551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/25\">",
"      Ioannidis JP, Cappelleri JC, Lau J. Issues in comparisons between meta-analyses and large trials. JAMA 1998; 279:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/26\">",
"      Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/27\">",
"      Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 2013; 144:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/28\">",
"      Jackson H, Solaymani-Dodaran M, Card TR, et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology 2007; 46:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/29\">",
"      Siegel JL, Jorgensen R, Angulo P, Lindor KD. Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. J Clin Gastroenterol 2003; 37:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/30\">",
"      Jorgensen RA, Dickson ER, Hofmann AF, et al. Characterisation of patients with a complete biochemical response to ursodeoxycholic acid. Gut 1995; 36:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/31\">",
"      Paumgartner G. Biliary physiology and disease: reflections of a physician-scientist. Hepatology 2010; 51:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/32\">",
"      Paumgartner G, Pusl T. Medical treatment of cholestatic liver disease. Clin Liver Dis 2008; 12:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/33\">",
"      Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol 2001; 35:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/34\">",
"      Hillaire S, Boucher E, Calmus Y, et al. Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterology 1994; 107:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/35\">",
"      Z&uuml;chner D, Sternsdorf T, Szostecki C, et al. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology 1997; 26:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/36\">",
"      Yamazaki K, Suzuki K, Nakamura A, et al. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Hepatology 1999; 30:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/37\">",
"      Yamazaki K, Nakadate I, Suzuki K, et al. Eosinophilia in primary biliary cirrhosis. Am J Gastroenterol 1996; 91:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/38\">",
"      Terasaki S, Nakanuma Y, Yamazaki M, Unoura M. Eosinophilic infiltration of the liver in primary biliary cirrhosis: a morphological study. Hepatology 1993; 17:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43526/abstract/39\">",
"      Combes B, Markin RS, Wheeler DE, et al. The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. Hepatology 1999; 30:602.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3605 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B64CF0B05F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_32_43526=[""].join("\n");
var outline_f42_32_43526=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THERAPEUTIC TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Placebo-controlled trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Effect on liver histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Esophageal varices and portal hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Meta-analyses and population-based studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Side-effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23379669\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3605\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3605|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/9/20637\" title=\"figure 1\">",
"      UDCA response in PBC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/4/21581\" title=\"figure 2\">",
"      UDCA and survival in PBC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/19/34105?source=related_link\">",
"      Overview of the treatment of primary biliary cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_32_43527="Bad breath";
var content_f42_32_43527=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bad breath",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/32/43527/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43527/contributors\">",
"     Mel Rosenberg, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/32/43527/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43527/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/32/43527/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43527/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/32/43527/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bad breath (sometimes referred to as halitosis, oral malodor, fetor oris, or fetor ex ore) is defined as any detectable offensive smell carried on the breath. Gases that might appear in the breath in abnormal concentrations, yet are not detected by the nose, would not fall under this definition.",
"   </p>",
"   <p>",
"    This topic will cover the etiology, pathogenesis, diagnosis, and treatment of bad breath. Other related topics such as gingivitis, periodontitis, and odontogenic infections are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18777?source=see_link\">",
"     \"Gingivitis and periodontitis in adults: Classification and dental treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16873?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/53/20313?source=see_link\">",
"     \"Complications, diagnosis, and treatment of odontogenic infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BRIEF HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bad breath has been with us for thousands of years. The problem is discussed at length in the Jewish Talmud, as well as by Greek and Roman writers. Islam also stresses fresh breath in the context of good oral hygiene.",
"   </p>",
"   <p>",
"    Ancient folk remedies abound that are still in use. The book of Genesis (Chapter 37) mentions ladanum (mastic), which may be the mastic gum derived from the Pistacia lentiscus tree, which has been used in Mediterranean countries for breath freshening for thousands of years. Other folk cures include mint, anise, parsley (Italy), cloves (Iraq), guava peels (Thailand), and eggshells (China).",
"   </p>",
"   <p>",
"    Modern literature on bad breath dates back to a monograph published by Howe in the nineteenth century. Experimental research on the subject dates back over 70 years.",
"   </p>",
"   <p>",
"    Few people die from bad breath. However, for a large number of individuals, it is a health-associated problem that incurs a great amount of suffering and affects personal relations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/1\">",
"     1",
"    </a>",
"    ]. It can also, in certain cases, be indicative of gingival inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact incidence of bad breath is not known. The maximal prevalence should be found by testing people getting out of bed in the morning, since bad breath is worst upon awakening. The prevalence of daytime bad breath ranges from 15 to 30 percent in studies performed in several countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ironically, many of the people who worry about bad breath do not suffer from it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/2\">",
"     2",
"    </a>",
"    ]. Because of the difficulties inherent in rating our own malodor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/6\">",
"     6",
"    </a>",
"    ], millions of people with bad breath don't know that they have it while millions of others harbor exaggerated concerns that they have terrible bad breath when little or none is detected by professionals (the so-called \"halitophobics\"). Approximately 25 percent of individuals seeking professional counsel for complaints of bad breath are halitophobics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bad breath can be observed starting in very young children, as young as two to three years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/2,4,8\">",
"     2,4,8",
"    </a>",
"    ]. Bad breath may increase slightly with age. In one study, women scored themselves as having higher levels of bad breath than men, although the men actually were deemed to have worse breath [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Oral cavity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bad breath originates in the mouth itself in 80 to 90 percent of ambulatory patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. This is largely the result of bacterial breakdown of certain amino acids derived from proteins and glycoproteins present in stagnant saliva, food debris, desquamating epithelial cells, blood, and postnasal drip in the oral cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. Volatile sulfur compounds (VSCs), primarily hydrogen sulfide and methylmercaptan, are partly responsible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/13-15\">",
"     13-15",
"    </a>",
"    ] and often used as indicators for oral malodor. VSCs arise presumably via microbial degradation of methionine and cysteine&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/14,16-18\">",
"     14,16-18",
"    </a>",
"    ]. Other gases that are by-products of amino acid degradation and may be implicated in the pathogenesis of bad breath include indole and skatole (via breakdown of tryptophan) and cadaverine (via breakdown of lysine). Probably dozens of other gases contribute to bad breath [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bad breath from the mouth comes primarily from bacterial accumulation between the teeth, and from the posterior part of the tongue dorsum (perhaps due to accumulation and subsequent putrefaction of postnasal drip on the back of the tongue) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/20\">",
"     20",
"    </a>",
"    ]. Faulty dental restorations, dental abscesses, and unclean partial or complete dentures may also cause foul odor. Bad breath is usually worse when an individual's mouth is dry, presumably because gases are increasingly volatized in these conditions and cleansing by saliva is minimal.",
"   </p>",
"   <p>",
"    Gram negative anaerobic proteolytic bacteria are the primary microbes implicated in producing VSCs and therefore causing bad breath. Pathogens involved include Porphyromonas gingivalis, Fusobacterium nucleatum, Prevotella intermedia, and spirochetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to Gram negative bacteria, Gram positive microorganisms may also be involved in the initial stages of malodor production by deglycosylating the glycoproteins that are subsequently broken down by the proteolytic enzymes secreted by the Gram negative bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Solobacteriium moorei has also been found to be associated with oral malodor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral environments that promote the formation of VSCs include those low in carbohydrates, with a neutral or alkaline pH, and that are anaerobic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/24\">",
"     24",
"    </a>",
"    ]. Oral pathology such as gingival inflammation and periodontitis may also contribute to bad breath, although individuals without such disorders may also experience oral malodor. Some studies have found a significant correlation between bad breath parameters and gingivitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/25\">",
"     25",
"    </a>",
"    ], especially when the indicators involve active inflammation, while others have not found an important relationship (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18777?source=see_link\">",
"     \"Gingivitis and periodontitis in adults: Classification and dental treatment\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/26\">",
"     26",
"    </a>",
"    ]. Other dental problems associated with bad breath include peri-implant disease, deep carious lesions, exposed necrotic tooth pulp, pericoronitis, wounds, imperfect dental restorations, and unclean dentures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/27\">",
"     27",
"    </a>",
"    ]. Oral malodor is directly linked with interdental hygiene and subsequent development of periodontal problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/3,28\">",
"     3,28",
"    </a>",
"    ]; flossing and dental hygiene reduce the incidence of malodor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nasal passages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second most common origin of bad breath is the nasal passages (about 5 to 8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. Typical nasal malodor usually has a slightly cheesy character and differs appreciably from other types of bad breath [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nasal odor may be indicative of a frank nasal infection (such as sinusitis), or a problem affecting airflow or mucous secretions (eg, polyps). In some cases, craniofacial anomalies, such as cleft palate, may be involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/30\">",
"     30",
"    </a>",
"    ]. It is not uncommon for patients with no obvious pathology to suffer from nasal malodor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39688?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rhinoplasty and extensive use of nasal spray in the past might also be linked to individual cases of nasal malodor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tendency of very young children to insert foreign bodies into their nostrils is a common cause of offensive odor that comes from the nose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/32\">",
"     32",
"    </a>",
"    ]. Children may spread the purulent exudate all over their body, making it seem that the odor envelops their entire body and thereby confusing the proper diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Tonsils",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tonsils may be involved in the pathogenesis of bad breath in a small percentage of cases (perhaps 3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/10\">",
"     10",
"    </a>",
"    ]. Tonsillectomy based solely upon a complaint of bad breath should be avoided.",
"   </p>",
"   <p>",
"    Some patients complain of small stones on their tongue or tonsils when they cough that have a foul odor (and often lead patients to assume that they must have terrible breath). These stones are \"tonsilloliths\" that form in crypts of the tonsils.",
"   </p>",
"   <p>",
"    There is little literature available on tonsilloliths. They are relatively common, occurring in perhaps 7 percent of the population at one time or another. Tonsilloliths contain anaerobic bacteria, including Eubacterium, Fusobacterium, Porphyromonas, and Prevotella, which produce volatile sulfides and are the same bacteria implicated in periodontal diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/33\">",
"     33",
"    </a>",
"    ]. Although the stones have a foul smell, they do not always cause bad breath. However, they do lead patients who have them to infer that their breath is extremely fetid. It is also possible that the exposure of the tonsilloliths prior to their expulsion from the crypts causes transient odor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/22/35176?source=see_link\">",
"     \"Tonsillectomy in adults: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tonsilloliths can be prevented by lasing the crypts in which they form (laser cryptolysis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/20,30\">",
"     20,30",
"    </a>",
"    ]. Since the stones themselves are usually unassociated with any pathology, it is questionable whether this procedure is called for unless great physical discomfort or emotional distress is involved. One study did find reduction in self-reported halitosis following this procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many other diseases may cause bad breath, including bronchial and lung infections, kidney failure, liver failure, various carcinomas, metabolic dysfunction, and biochemical disorders, but these are very rare in the ambulatory population and are usually accompanied by more obvious symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. As an example, whereas reviews on bad breath often cite ketone (acetone) odor as a sign of diabetes, ketone odor is rare among well-maintained diabetics in modern societies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/38\">",
"     38",
"    </a>",
"    ]. In less developed countries, among indigent populations, or in diabetic young adults away from home, ketone odor might still constitute a telltale sign for uncontrolled diabetes. Volatile sulfur compounds may be implicated in bad breath.",
"   </p>",
"   <p>",
"    Bad breath almost never arises from the esophagus, stomach, or intestines. The esophagus is normally collapsed and closed; an occasional belch may carry odor up from the stomach, but the possibility of air escaping continuously is remote. Thus, bad breath alone should not be an indication for gastroscopy in an otherwise healthy ambulatory patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients with heartburn, regurgitation, sour taste, and belching often complain of halitosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/39\">",
"     39",
"    </a>",
"    ], but self-estimation of breath is subjective and requires objective confirmation.",
"   </p>",
"   <p>",
"    Improvement in halitosis following systemic antibiotic treatment for stomach disorders does not implicate the stomach as the cause of the malodor, as a transient improvement in halitosis is observed following systemic antibiotic treatment in general. Most cases of halitosis involve oral bacteria susceptible to the same antibiotics. Helicobacter pylori can produce volatile sulfur compounds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/40\">",
"     40",
"    </a>",
"    ]. One study found an association of malodor with H. pylori on the dorsal tongue in a population complaining of burning symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/41\">",
"     41",
"    </a>",
"    ] while another found no difference in the presence of H pylori (detected by PCR assay) in the saliva from 251 non-dyspeptic patients with and 75 without halitosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/42\">",
"     42",
"    </a>",
"    ]. The possibility of an association between oral H. pylori and malodor in the general population requires further study.",
"   </p>",
"   <p>",
"    People historically have smoked cigarettes or used other tobacco products to mask their bad breath, a practice that results in an unattractive odor in its own right. Cigarette odor can linger for over one day following cessation of smoking. In some cases, the odor of cigarette smoke can be detected on the breath of subjects who do not smoke but are continually exposed to the smoke of others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another potential, though rare, cause of bad breath can be an overt or incidentally noted malignancy involving the oral cavity, pharynx, tonsil, base of tongue, supraglottic larynx, nasopharynx, or sinonasal tract. Carcinomas, usually squamous cell carcinomas, in these sites can achieve considerable size while remaining relatively asymptomatic. Such tumors can outgrow their blood supply, become necrotic and subsequently malodorous. Patients with objective bad breath, especially those with risk factors for head and neck cancer (significant tobacco or alcohol consumption) deserve a thorough head and neck examination to rule out a malignancy.",
"   </p>",
"   <p>",
"    Trimethylaminuria may be suspected in patients complaining about a fishy type odor. This rare genetic condition involves the inability to breakdown N-oxidise trimethylamine. As a result, malodorous trimethylamine builds up in sweat, saliva, and urine. Malodor can be reduced by managing the diet to reduce the ingestion of precursors of trimethylamine such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    and particularly choline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who suffer from xerostomia do not appear to have excessive malodor despite the mouth dryness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/45\">",
"     45",
"    </a>",
"    ]. The reason for this is unknown, although it may be due to a low oral pH and its effects upon the oral flora. A negative correlation was observed between saliva flow and bad breath in patients with renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bad breath associated with garlic ingestion is particularly noticed during burping. Although we performed a study that found that most of the odor following garlic ingestion remains associated with the mouth, the oral malodor may be particularly tenacious, remaining for several hours after meticulous oral hygiene. A study attempting to explain this phenomenon found that one gas, allyl methyl sulfide, was exhaled for prolonged periods of time after garlic ingestion as a result of gastrointestinal absorption, systemic circulation, and ultimately excretion through the lungs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/46\">",
"     46",
"    </a>",
"    ]. This gas was distinguished from other oral VSCs by its lack of metabolism by gut mucosal and hepatic tissues. This suggests that breath odor after garlic intake originates from the mouth and subsequently from the gut, thereby explaining why oral hygiene does not completely eliminate the odor.",
"   </p>",
"   <p>",
"    A number of common factors that can exacerbate bad breath are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef54269 \" href=\"mobipreview.htm?9/40/9868\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who complain of bad breath often have great difficulty objectively assessing their disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/6\">",
"     6",
"    </a>",
"    ]. For this reason, such patients should bring along a confidant to the appointment; that is, an adult close to the patient, usually a family member or close friend. The confidant can confirm the existence of a breath problem, compare the intensity and quality of the odor at the appointment with the patient's usual odor and subsequently provide feedback on improvement (or lack thereof) following the consultation. Bad breath varies with the time of day (as an inverse function of saliva flow) and day of the month (eg, is sometimes worse during menstruation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Thus, the odor present at the consultation may or may not be similar to the odor at other times.",
"   </p>",
"   <p>",
"    Patients should refrain from any oral activity, including eating, drinking, chewing, smoking, or brushing, at least three hours prior to the appointment. Patients also should refrain from any perfumed products (including scented lipstick) the day of the evaluation. Reschedule patients who are or have been on antibiotics during the past month since the malodor is often bacterial in origin and usually decreases transiently during antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation begins by taking a thorough medical history. Concentrate on trying to find out whether the patient practices good oral hygiene, has full or partial dentures, is a mouth breather, snores, has excess nasal discharge (ie, hayfever), has any nasal obstruction (or history of nasal problems), or any other underlying medical problem that may be involved. Ask both the patient and the confidant where they think the odor is coming from and why. Some potential answers include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"My",
"      <span class=\"nowrap\">",
"       wife/husband/brother/sister/mother/father",
"      </span>",
"      told me.\" Again, ask that the spouse be brought in as a confidant who can verify the history, frequency, quantity and type of the odor, and can report back on whether it resolves following the consultation.",
"     </li>",
"     <li>",
"      \"Nobody has actually told me I have bad breath, but I know because people cover their mouths when they talk to me, people open windows in my presence, people touch their nose when talking to me, I have a bad taste in my mouth, my father had it, someone told me when I was in fourth grade.\" These types of answers are typical of halitophobics who have an exaggerated fear of having bad breath.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately 25 percent of individuals seeking professional counsel for complaints of bad breath are halitophobics. Halitophobics are often women, impeccably groomed, and commonly break down in tears during the patient history. Many of these patients need psychological input but often resist it, convinced that their problem is organic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/20,47\">",
"     20,47",
"    </a>",
"    ]. Many halitophobics have read the scientific literature on bad breath, and frequently brush their teeth and tongue, frequently floss and gargle, and have no observable bad breath. They may misinterpret having a bad taste or the presence of tonsilloliths as evidence their breath is malodorous. It should always be kept in mind, however, that halitophobics, like everyone, may have episodic bad breath.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several companies are working on the development of electronic noses and other analyzers of volatile sulfides and amines that can analyze bad breath [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/48\">",
"     48",
"    </a>",
"    ], but no instrument is currently able to replace the human nose. Current instruments estimate the volatile sulfur component of malodor (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Sulfide monitors'",
"    </a>",
"    below). The results are associated with malodor levels, but cannot be relied upon as stand-alone measurements. Several colorimetric enzymatic tests have the same limitation. Thus, clinicians interested in diagnosing bad breath must still rely upon their noses to distinguish the main types of oral odors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Periodontal-type odor, which may come from gingival inflammation, periodontal pockets, and interdental spaces",
"     </li>",
"     <li>",
"      Odor from the posterior tongue dorsum, which can easily be determined using the \"spoon test\" (see below)",
"     </li>",
"     <li>",
"      Denture odor (readily detected by directly smelling both sides of each denture, or by placing the dentures into a plastic bag for several minutes and smelling the air inside the bag)",
"     </li>",
"     <li>",
"      Nasal odor (easily identified on the breath exiting the nose)",
"     </li>",
"     <li>",
"      Smoker's breath",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With practice and experience these odors become distinct and recognizable, even when found in various combinations.",
"   </p>",
"   <p>",
"    Ask the patient to breathe out through the mouth. Smell the odor from about 5 to 10 cm and make a quantitative (eg, on a zero to five scale where zero is no odor; one is barely detectable odor; two is slight odor; three is moderate odor; four is strong foul odor; and five is unbearably strong foul odor) and a qualitative (eg,",
"    <span class=\"nowrap\">",
"     typical/not",
"    </span>",
"    typical;",
"    <span class=\"nowrap\">",
"     periodontal/tongue)",
"    </span>",
"    judgment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/18,49\">",
"     18,49",
"    </a>",
"    ]. In addition, it may be helpful to ask the patient to count out loud to twenty and repeat the above. This is because the odor is sometimes more obvious when the patient is speaking.",
"   </p>",
"   <p>",
"    After evaluating mouth odor, ask the patient to close his or her mouth and breathe out through the nose. Score as above. An oral or pharyngeal origin is suspected if the odor is largely confined to the mouth and not the nose; nasal involvement is suspected if the odor is largely confined to the nose or has a telltale characteristic odor. A systemic origin is suspected in the rare cases in which the odor emanates both from the mouth and nose and has the same quality.",
"   </p>",
"   <p>",
"    The tongue odor can be evaluated by taking a plastic spoon in one hand, a piece of gauze in the other, and asking the patient to stick out the tongue as far as possible and to hold his or her breath. Wrap the gauze around the tip of the tongue and hold it with one hand, use the spoon with the other hand to scoop up some of the mucus at the very back of the tongue dorsum towards the throat (about 12 cm from the tip of the adult tongue). Wait a few seconds. Smell and score the spoon. Ask the confidant to smell the spoon and answer whether this is the quality of the odor the patient suffers from (if so, tongue cleaning and gargling should handle the problem). In many cases a yellowish discharge is collected on the spoon; although there is no direct evidence, this discharge is probably postnasal drip. The center of the tongue dorsum may produce malodor in patients with hairy coated tongues.",
"   </p>",
"   <p>",
"    Excessive or viscous postnasal drip is extremely common and is usually not indicative of any frank nasal infection or other pathology. Although the postnasal drip might not smell initially when it first reaches the tongue, it can subsequently be putrefied by the abundant tongue microbiota. In subjects with periodontal disease, the tongue may be even more malodorous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An oral source can be confirmed by instructing the patient to rinse and gargle twice daily, including once at bedtime, with a strong antibacterial mouthwash. Gargling is more important than rinsing.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     Chlorhexidine gluconate",
"    </a>",
"    (0.2 percent, if available) mouthrinse may be used, preferentially at bedtime. Rinsing and gargling should continue for one week, but not longer. Advise the patient to discontinue the mouthrinse immediately if ulceration or other discomfort arises. Ulceration occurs in about 5 percent of patients, perhaps more in Asian populations.",
"   </p>",
"   <p>",
"    Removable full or partial dentures should be taken from the mouth and smelled separately. They can be cleaned by ultrasonic bath if they smell foul. If this is not helpful, they may need replacement. Encourage patients to leave them overnight in an appropriate disinfectant unless there is a medical reason to leave them in the mouth.",
"   </p>",
"   <p>",
"    Patients should not automatically be labeled halitophobic if no odor is initially discovered. Test the breath again on another occasion and try to get confirmation that there is an odor from a confidant and family members. If the presence of an objective odor still cannot be confirmed, the patient may be advised to consult a psychologist or psychiatrist although, as previously mentioned, many halitophobics are convinced that they have an actual odor and that there is no psychological basis whatsoever for their complaint. In such instances, it is very difficult to persuade them to seek psychological counsel, and the physician must try to allay their concerns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sulfide monitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The level of intraoral volatile sulfur compounds can be estimated using portable sulfide monitors. Sulfide monitor readings are sensitive to reductions in mouth odor levels following the use of mouthrinses. The association between sulfide monitor results and odor judge scores is significant (coefficient correlations ranging from about 0.45 to 0.65, p &lt;0.001 in various studies) and relatively reproducible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/18,49\">",
"     18,49",
"    </a>",
"    ]. Nevertheless, while such quantitative and semiquantitative measurements can be helpful (eg, to apprise the patient of the improvement which has taken place), they do not obviate the need for the clinician to actually smell the breath emanating from the mouth, nose, and tongue of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with an identifiable cause of bad breath (eg, periodontal disease, gingivitis, postnasal drip, systemic illness) can be treated for these conditions. Many cases of bad breath may be readily alleviated by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Proper dental care and oral hygiene, including daily flossing.",
"     </li>",
"     <li>",
"      Gentle cleaning of the posterior portion of the tongue dorsum (eg, with a plastic tongue cleaner).",
"     </li>",
"     <li>",
"      Rinsing and deep gargling with an effective mouthwash (in order to get the liquid as far back as possible without swallowing it, one can extend the tongue while gargling). This is most effective when done at bedtime.",
"     </li>",
"     <li>",
"      Eating fibrous foods (a healthy breakfast can be recommended).",
"     </li>",
"     <li>",
"      Chewing gum briefly (five minutes is often sufficient) if the mouth is dry, or after meals, especially with high protein intake. Sugar-free gum is preferable.",
"     </li>",
"     <li>",
"      Sufficient water intake.",
"     </li>",
"     <li>",
"      Decreasing alcohol and coffee intake.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some clinicians prescribe antibiotics for complaints of bad breath. However, this only results in transient relief and, in my opinion, is not advisable.",
"   </p>",
"   <p>",
"    Encourage patients to floss their teeth (properly), to smell the floss between each passage, and to clean the malodorous sites carefully. Flossing should include cleaning the posterior surface of the back teeth as well. Interdental brushes may also be useful for cleaning between teeth. They are portable and easy to use, and may be dipped in mouthwash or toothpaste prior to use for added benefit.",
"   </p>",
"   <p>",
"    The posterior portion of the dorsum of the tongue can be gently cleaned with a tongue cleaner or toothbrush. Effective tongue cleaning requires access to the deep posterior part of the dorsal tongue; odors often lurk 10 cm or more back from the tongue tip. The basic idea is to sweep away the mucus, desquamated cells, and other debris. Many patients experience gagging when they clean far back, which may sometimes be overcome with continued practice. Avoid brittle plastic tongue cleaners that might break, as well as sharp metal cleaners. The importance of gentle cleaning, rather than outright scraping which may traumatize the tongue, should be stressed. A systematic review found only weak evidence that tongue scrapers are more effective than toothbrushes in reducing bad breath [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/50\">",
"     50",
"    </a>",
"    ]; this may reflect difficulty with effective tongue brushing technique.",
"   </p>",
"   <p>",
"    Gargling and rinsing with mouthrinse can be advised for patients in whom mechanical cleansing does not sufficiently reduce the odor. However, some mouthwashes contain components that may harm soft oral tissues (eg, alcohol, sodium dodecyl sulfate, strong oxidizing agents). Mouthwashes containing alcohol have been associated with oral carcinogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/51\">",
"     51",
"    </a>",
"    ]. The most efficacious mouthrinses for short-term use are probably those containing 0.2 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine gluconate",
"    </a>",
"    , but in the United States only 0.12 percent is readily available.",
"   </p>",
"   <p>",
"    The best time to use a mouthwash is probably before bedtime since the residue of the mouthrinse may remain in the mouth for a longer period of time and have a greater effect. In addition, bacterial activity leading to bad breath is greatest during the nighttime, when saliva flow is practically zero and microbial activity is highest. The quaternary agents active in many mouthwashes (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26802?source=see_link\">",
"     cetylpyridinium",
"    </a>",
"    chloride,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    ) may be inactivated by the anionic detergents in toothpastes; thus patients should be advised to use mouthrinse an hour or more following use of toothpaste. Since much of the odor is associated with the posterior dorsal tongue, it is important to gargle, in addition to oral rinsing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Patient referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dentists often become involved in the evaluation of bad breath since most cases can be traced to problems with the tongue, teeth, and periodontum. In addition, oral hygiene, an important component of bad breath therapy in many patients, is typically taught by dentists and hygienists.",
"   </p>",
"   <p>",
"    There are no clear guidelines for when to refer patients to dentists. One possible approach is to compare the odor coming from the mouth and nose (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Physical examination'",
"    </a>",
"    above). If the odor is deemed to be coming solely from the mouth, a dentist may be consulted. The dentist should be caring and have a good understanding of bad breath. Unfortunately, some dentists who claim to be \"bad breath experts\" are involved in pyramid marketing operations in which they make considerable profit selling a specific brand of mouthwash to the unknowing customer, and earn additional profits by getting other dentists involved in the process. Dentists may charge up to $600 for a set of consultations on bad breath.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SOURCES OF INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information on bad breath is available on the Internet (www.smellwell.com). A scientific review for a lay audience has been published as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43527/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malodorous breath affects millions of people, although some individuals (\"halitophobics\") have greatly exaggerated concerns. Approximately 25 percent of individuals seeking professional counsel for complaints of bad breath are halitophobics. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bad breath originates most commonly from the mouth. A number of common factors that can exacerbate bad breath are shown in a table (",
"      <a class=\"graphic graphic_table graphicRef54269 \" href=\"mobipreview.htm?9/40/9868\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although electronic noses and other analyzers of volatile substances can analyze bad breath, no instrument is currently able to replace the human nose for diagnosis of bad breath. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many cases of bad breath may be readily alleviated by the following simple measures:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Proper dental care and oral hygiene",
"     </li>",
"     <li>",
"      Gentle cleaning with a plastic tongue cleaner",
"     </li>",
"     <li>",
"      Deep gargling with a mouthwash, particularly at bedtime",
"     </li>",
"     <li>",
"      Eating fibrous foods",
"     </li>",
"     <li>",
"      Chewing gum briefly if the mouth is dry, or after meals",
"     </li>",
"     <li>",
"      Sufficient water intake",
"     </li>",
"     <li>",
"      Decreasing alcohol, coffee, or intake of other foods or beverages that might precipitate bad breath",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/1\">",
"      Porter SR, Scully C. Oral malodour (halitosis). BMJ 2006; 333:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/2\">",
"      Rosenberg M, Knaan T, Cohen D. Association among bad breath, body mass index, and alcohol intake. J Dent Res 2007; 86:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/3\">",
"      Liu XN, Shinada K, Chen XC, et al. Oral malodor-related parameters in the Chinese general population. J Clin Periodontol 2006; 33:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/4\">",
"      Nadanovsky P, Carvalho LB, Ponce de Leon A. Oral malodour and its association with age and sex in a general population in Brazil. Oral Dis 2007; 13:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/5\">",
"      Bornstein MM, Kislig K, Hoti BB, et al. Prevalence of halitosis in the population of the city of Bern, Switzerland: a study comparing self-reported and clinical data. Eur J Oral Sci 2009; 117:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/6\">",
"      Rosenberg M, Kozlovsky A, Gelernter I, et al. Self-estimation of oral malodor. J Dent Res 1995; 74:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/7\">",
"      Seemann R, Bizhang M, Djamchidi C, et al. The proportion of pseudo-halitosis patients in a multidisciplinary breath malodour consultation. Int Dent J 2006; 56:77.",
"     </a>",
"    </li>",
"    <li>",
"     Rosenberg M. Introduction. In: Bad Breath: Research Perspectives, Rosenberg M (Ed), Ramot Publishing, Tel Aviv 1995. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/9\">",
"      van den Broek AM, Feenstra L, de Baat C. A review of the current literature on management of halitosis. Oral Dis 2008; 14:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/10\">",
"      Delanghe G, Ghyselen J, van Steenberghe D, Feenstra L. Multidisciplinary breath-odour clinic. Lancet 1997; 350:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/11\">",
"      Quirynen M, Dadamio J, Van den Velde S, et al. Characteristics of 2000 patients who visited a halitosis clinic. J Clin Periodontol 2009; 36:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/12\">",
"      Sopapornamorn P, Ueno M, Shinada K, et al. Relationship between total salivary protein content and volatile sulfur compounds levels in malodor patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/13\">",
"      Tonzetich J. Oral malodour: an indicator of health status and oral cleanliness. Int Dent J 1978; 28:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/14\">",
"      Tonzetich J. Production and origin of oral malodor: a review of mechanisms and methods of analysis. J Periodontol 1977; 48:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/15\">",
"      Tonzetich J, Preti G, Huggins GR. Changes in concentration of volatile sulphur compounds of mouth air during the menstrual cycle. J Int Med Res 1978; 6:245.",
"     </a>",
"    </li>",
"    <li>",
"     Kleinberg I, Codipilly M. The biological basis of oral malodor formation. In: Bad Breath: Research Perspectives, Rosenberg M (Ed), Ramot Publishing, Tel Aviv 1995. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/17\">",
"      Persson S, Claesson R, Carlsson J. The capacity of subgingival microbiotas to produce volatile sulfur compounds in human serum. Oral Microbiol Immunol 1989; 4:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/18\">",
"      Rosenberg M, Kulkarni GV, Bosy A, McCulloch CA. Reproducibility and sensitivity of oral malodor measurements with a portable sulphide monitor. J Dent Res 1991; 70:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/19\">",
"      Goldberg S, Kozlovsky A, Gordon D, et al. Cadaverine as a putative component of oral malodor. J Dent Res 1994; 73:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/20\">",
"      Rosenberg M. Clinical assessment of bad breath: current concepts. J Am Dent Assoc 1996; 127:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/21\">",
"      Sterer N, Rosenberg M. Effect of deglycosylation of salivary glycoproteins on oral malodour production. Int Dent J 2002; 52 Suppl 3:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/22\">",
"      Sterer N, Rosenberg M. Streptococcus salivarius promotes mucin putrefaction and malodor production by Porphyromonas gingivalis. J Dent Res 2006; 85:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/23\">",
"      Haraszthy VI, Zambon JJ, Sreenivasan PK, et al. Identification of oral bacterial species associated with halitosis. J Am Dent Assoc 2007; 138:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/24\">",
"      Kleinberg I, Westbay G. Salivary and metabolic factors involved in oral malodor formation. J Periodontol 1992; 63:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/25\">",
"      Kozlovsky A, Gordon D, Gelernter I, et al. Correlation between the BANA test and oral malodor parameters. J Dent Res 1994; 73:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/26\">",
"      Bosy A, Kulkarni GV, Rosenberg M, McCulloch CA. Relationship of oral malodor to periodontitis: evidence of independence in discrete subpopulations. J Periodontol 1994; 65:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/27\">",
"      van den Broek AM, Feenstra L, de Baat C. A review of the current literature on aetiology and measurement methods of halitosis. J Dent 2007; 35:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/28\">",
"      Rosenberg M. Bad breath and periodontal disease: how related are they? J Clin Periodontol 2006; 33:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/29\">",
"      Biesbrock A, Corby PM, Bartizek R, et al. Assessment of treatment responses to dental flossing in twins. J Periodontol 2006; 77:1386.",
"     </a>",
"    </li>",
"    <li>",
"     Finkelstein Y. The otolaryngologist and the patient with halitosis. In: Bad Breath: Research Perspectives, Rosenberg M (Ed), Ramot Publishing, Tel Aviv 1995. p.175.",
"    </li>",
"    <li>",
"     Sterer N, Rosenberg M. Breath Odors: Origin, Diagnosis, and Managment, Springer, 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/32\">",
"      Katz HP, Katz JR, Bernstein M, Marcin J. Unusual presentation of nasal foreign bodies in children. JAMA 1979; 241:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/33\">",
"      Tsuneishi M, Yamamoto T, Kokeguchi S, et al. Composition of the bacterial flora in tonsilloliths. Microbes Infect 2006; 8:2384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/34\">",
"      Finkelstein Y, Talmi YP, Ophir D, Berger G. Laser cryptolysis for the treatment of halitosis. Otolaryngol Head Neck Surg 2004; 131:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/35\">",
"      Attia EL, Marshall KG. Halitosis. Can Med Assoc J 1982; 126:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/36\">",
"      Durham TM, Malloy T, Hodges ED. Halitosis: knowing when 'bad breath' signals systemic disease. Geriatrics 1993; 48:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/37\">",
"      Keles M, Tozoglu U, Uyanik A, et al. Does peritoneal dialysis affect halitosis in patients with end-stage renal disease? Perit Dial Int 2011; 31:168.",
"     </a>",
"    </li>",
"    <li>",
"     Dr. Charles Hollenberg, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/39\">",
"      Moshkowitz M, Horowitz N, Leshno M, Halpern Z. Halitosis and gastroesophageal reflux disease: a possible association. Oral Dis 2007; 13:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/40\">",
"      Lee H, Kho HS, Chung JW, et al. Volatile sulfur compounds produced by Helicobacter pylori. J Clin Gastroenterol 2006; 40:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/41\">",
"      Adler I, Denninghoff VC, Alvarez MI, et al. Helicobacter pylori associated with glossitis and halitosis. Helicobacter 2005; 10:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/42\">",
"      Suzuki N, Yoneda M, Naito T, et al. Detection of Helicobacter pylori DNA in the saliva of patients complaining of halitosis. J Med Microbiol 2008; 57:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/43\">",
"      Ayesh R, Mitchell SC, Zhang A, Smith RL. The fish odour syndrome: biochemical, familial, and clinical aspects. BMJ 1993; 307:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/44\">",
"      Preti G, Clark L, Cowart BJ, et al. Non-oral etiologies of oral malodor and altered chemosensation. J Periodontol 1992; 63:790.",
"     </a>",
"    </li>",
"    <li>",
"     Leo Sreebny, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/46\">",
"      Suarez F, Springfield J, Furne J, Levitt M. Differentiation of mouth versus gut as site of origin of odoriferous breath gases after garlic ingestion. Am J Physiol 1999; 276:G425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/47\">",
"      Eli I, Baht R, Kozlovsky A, Rosenberg M. The complaint of oral malodor: possible psychopathological aspects. Psychosom Med 1996; 58:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/48\">",
"      Murata T, Rahardjo A, Fujiyama Y, et al. Development of a compact and simple gas chromatography for oral malodor measurement. J Periodontol 2006; 77:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/49\">",
"      Rosenberg M, McCulloch CA. Measurement of oral malodor: current methods and future prospects. J Periodontol 1992; 63:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/50\">",
"      Outhouse TL, Al-Alawi R, Fedorowicz Z, Keenan JV. Tongue scraping for treating halitosis. Cochrane Database Syst Rev 2006; :CD005519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/51\">",
"      McCullough MJ, Farah CS. The role of alcohol in oral carcinogenesis with particular reference to alcohol-containing mouthwashes. Aust Dent J 2008; 53:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43527/abstract/52\">",
"      Rosenberg M. The science of bad breath. Sci Am 2002; 286:72.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6843 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-617C8121F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_32_43527=[""].join("\n");
var outline_f42_32_43527=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BRIEF HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Oral cavity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nasal passages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Tonsils",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sulfide monitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Patient referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SOURCES OF INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6843\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6843|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/40/9868\" title=\"table 1\">",
"      Common factors bad breath",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39688?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/53/20313?source=related_link\">",
"      Complications, diagnosis, and treatment of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16873?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18777?source=related_link\">",
"      Gingivitis and periodontitis in adults: Classification and dental treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/22/35176?source=related_link\">",
"      Tonsillectomy in adults: Indications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_32_43528="Mechanisms of thrombogenesis in atrial fibrillation";
var content_f42_32_43528=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mechanisms of thrombogenesis in atrial fibrillation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/32/43528/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43528/contributors\">",
"     Gregory YH Lip, MD, FRCPE, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/32/43528/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43528/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/32/43528/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43528/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/32/43528/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) is associated with substantial mortality and morbidity, largely due to thromboembolism, particularly stroke. This complication can occur with either paroxysmal (intermittent) or chronic (permanent) atrial fibrillation. A number of randomized trials have demonstrated the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in reducing this risk both during the course of chronic AF and in the period prior to and after the restoration of sinus rhythm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The factors that promote thromboembolism in AF will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FACTORS PROMOTING THROMBOEMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost 150 years ago, Virchow proposed that three conditions should be present for development of thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormalities in blood flow",
"     </li>",
"     <li>",
"      Abnormalities in the blood vessel wall",
"     </li>",
"     <li>",
"      Interaction with blood constituents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these abnormalities may contribute to thromboembolism in AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, dilated atria, poorly contracting dilated left ventricles, valvular heart disease (particularly mitral stenosis), and congestive heart failure are clinical features commonly associated with stroke and thromboembolism in patients with AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/2\">",
"     2",
"    </a>",
"    ]. These abnormalities in blood flow and vessels (the first two components of Virchow's triad) can be related to the presence of structural heart disease or extrinsic interventions such as cardioversion. As will be described below, AF also may confer a hypercoagulable or prothrombotic state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pooled data from a meta-analysis have demonstrated that independent clinical risk factors for stroke in nonvalvular AF include a history of hypertension and diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients with heart failure are also at high risk, particularly those with left ventricular systolic dysfunction or aneurysm formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=see_link\">",
"     \"Risk of embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These clinical criteria are complemented by echocardiographic findings, which have demonstrated that a dilated left atrium, impaired left atrial function, and impaired left ventricular systolic function are independent risk factors for stroke in patients with AF (",
"    <a class=\"graphic graphic_table graphicRef64291 \" href=\"mobipreview.htm?39/50/40747\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72745 \" href=\"mobipreview.htm?2/29/2523\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2856?source=see_link\">",
"     \"Role of echocardiography in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Left atrial abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A dilated left atrium and reduced left atrial and left atrial appendage blood flow on echocardiography are independent risk factors for thromboembolism. Patients with these abnormalities are more likely to have stasis of blood as demonstrated by the presence of spontaneous echo contrast or \"smoke\" on transesophageal echocardiography; this increase in echogenicity is thought to represent aggregation of red cells at low shear stress (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66980 \" href=\"mobipreview.htm?17/50/18223\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef66795 \" href=\"mobipreview.htm?4/61/5072\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef51472 \" href=\"mobipreview.htm?10/61/11231\">",
"     movie 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spontaneous echo contrast has been related to hemodynamic and hemostatic abnormalities and an increased risk of stroke and thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/8-13\">",
"     8-13",
"    </a>",
"    ]. The presence of both left atrial spontaneous echo contrast and chamber enlargement among patients with nonrheumatic AF is strongly associated with an increased risk for cerebral ischemic events (odds ratio 33.7 in one report) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/11\">",
"     11",
"    </a>",
"    ]. Left atrial spontaneous echo contrast does not appear to be affected by anticoagulant therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2856?source=see_link\">",
"     \"Role of echocardiography in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Atrial stunning after cardioversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardioversion of atrial fibrillation leads to an increased risk of thromboembolism, particularly if patients are not anticoagulated before, during, and after cardioversion. In addition to dislodgement of preexisting thrombi, embolization may result from de novo thrombus formation induced by impaired left atrial systolic function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The transient atrial contractile dysfunction is also known as atrial \"stunning,\" and can occur whether sinus rhythm is restored spontaneously, by external or internal DC (electric) cardioversion, or by drugs. The duration of the left atrial dysfunction appears to be related in part to the duration of AF. In one report, full recovery of atrial mechanical function was attained within 24 hours in patients with AF for &le;2 weeks, within one week in patients with AF for two to six weeks, and within one month with more prolonged AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/15\">",
"     15",
"    </a>",
"    ]. The time course of recovery of left atrial function could explain why the great majority of embolic events in patients who remain in sinus rhythm occur within the first 10 days after cardioversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/28/6601?source=see_link&amp;anchor=H10#H10\">",
"     \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\", section on 'Atrial stunning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Paroxysmal atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from a recent meta-analysis suggest that paroxysmal AF also confers an increased risk of stroke, with an event rate similar to that of chronic atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31384?source=see_link\">",
"     \"Paroxysmal atrial fibrillation\"",
"    </a>",
"    .) In comparison, previous reports from the Framingham study and Montreal Heart study had suggested thromboembolic rates for paroxysmal AF that were intermediate between those associated with chronic atrial fibrillation and sinus rhythm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. This variability in risk is probably related to the frequency and duration of the arrhythmia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/20\">",
"     20",
"    </a>",
"    ]. A single, short paroxysm of AF once a year is unlikely to have the same thromboembolic risk as more prolonged and more frequent paroxysms of AF. The effect of age and presence of structural heart disease are also considerations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Paroxysmal AF is associated with abnormalities in atrial function, as evidenced by the appearance of spontaneous echo contrast on transesophageal echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/21\">",
"     21",
"    </a>",
"    ], and in hemostasis which presumably contribute to the increase in thrombotic risk. One report supported the importance of AF duration as levels of beta-thromboglobulin and platelet factor 4 (markers of platelet activation) were significantly increased during episodes more than 12 hours in duration; there was also a trend toward an elevation in fibrinogen levels in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/22\">",
"     22",
"    </a>",
"    ]. In another series, patients with paroxysmal AF had intermediate values of fibrinogen and fibrin D-dimer between normals and elevations seen in patients with chronic AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/23\">",
"     23",
"    </a>",
"    ]. In contrast, patients with paroxysmal supraventricular tachycardia, who retain active atrial contraction and have a low risk of stroke, had levels of hemostatic markers that were similar to controls in sinus rhythm.",
"   </p>",
"   <p>",
"    The transient nature of hemodynamic and hemostatic abnormalities in paroxysmal AF is in keeping with the following clinical observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thromboembolism is more likely in patients with frequent paroxysms of atrial fibrillation",
"     </li>",
"     <li>",
"      There is a clustering of thromboembolic episodes during the transition from paroxysmal AF to chronic AF",
"     </li>",
"     <li>",
"      Spontaneous echo contrast is present during paroxysms of AF, and there is a higher risk of thromboembolism occurring soon after cardioversion from AF to sinus rhythm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Left ventricular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure by itself confers a risk of stroke and thromboembolism; the risk is additive to that of AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/5,7,24\">",
"     5,7,24",
"    </a>",
"    ]. A report from the SAVE trial, for example, found a progressive increase in stroke risk during a 42 month follow-up in patients with left ventricular dysfunction; furthermore, every 5 percentage point decrease in LVEF was associated with an 18 percent increase in the risk of stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, there was a significant reduction in longitudinal stroke risk associated with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (relative risk 0.19) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (relative risk 0.44). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7048?source=see_link\">",
"     \"Indications for antithrombotic therapy in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar findings were noted in a prospective study of 1066 patients entered into three clinical trials evaluating the role of anticoagulation in nonvalvular AF (BAATAF, SPINAF, and SPAF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/25\">",
"     25",
"    </a>",
"    ]. The incidence of a stroke was 9.3 percent per year in patients with moderate to severe left ventricular dysfunction, even in the absence of congestive heart failure, compared to 4.4 percent per year in those with normal or mildly abnormal left ventricular function (",
"    <a class=\"graphic graphic_figure graphicRef70244 \" href=\"mobipreview.htm?13/51/14141\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The presence of a poorly contracting, dilated left ventricle is likely to promote stasis of blood and lead to an increased risk of intracardiac thrombus formation and subsequent embolism. A left ventricular aneurysm has both diastolic and systolic bulging or dyssynergy which results in severe stasis of blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/5\">",
"     5",
"    </a>",
"    ]. The incidence of thrombi within left ventricular aneurysms ranges from 14 to 68 percent at postmortem, an observation that is consistent with a 50 to 95 percent incidence at the time of aneurysmectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/26\">",
"     26",
"    </a>",
"    ]. The reported incidence of systemic embolism in patients with a left ventricular aneurysm ranges widely, from 0 to 52 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with heart failure, particularly those with a left ventricular aneurysm, also demonstrate abnormalities of blood rheology, coagulation, and endothelial function, suggesting the presence of a prothrombotic or hypercoagulable state. As an example, both plasma fibrinogen and von Willebrand factor concentrations may be elevated in heart failure, and platelet abnormalities are evident [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Since AF also confers a hypercoagulable state, this may be additive to the hemodynamic and hemostatic abnormalities conferred by heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a risk factor for stroke (usually thrombotic) and it increases the risk of stroke associated with AF twofold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/2,4,6\">",
"     2,4,6",
"    </a>",
"    ]. How this occurs is unclear. Hypertension may be associated with a hypercoagulable state due in part to abnormalities in blood rheology and endothelial function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Valvular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valvular heart disease, especially mitral stenosis, increases the risk of stroke in atrial fibrillation seventeen-fold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/34\">",
"     34",
"    </a>",
"    ]. There is some evidence that the presence of mitral regurgitation is protective against the development of intracardiac thrombi in chronic AF, presumably due to enhanced turbulence and decreased stasis within the left atrium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/5\">",
"     5",
"    </a>",
"    ]. As an example, one transesophageal echocardiography study of 169 patients with rheumatic heart disease, 63 percent of whom were in AF, found a preoperative incidence of left atrial spontaneous contrast echo of 1, 30, and 54 percent and of thrombus of 1, 13 and 17 percent for those with mitral regurgitation, combined mitral regurgitation and stenosis, and isolated mitral stenosis, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/35\">",
"     35",
"    </a>",
"    ]. Further support for this observation comes from a report of 32 patients with mitral regurgitation undergoing mitral valve repair; atrial indexes of hypercoagulability were significantly lower than peripheral venous levels, consistent with the clinical observations of reduced echo contrast and left atrial thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings correlate with a reduced incidence of embolism in mitral regurgitation. The Stroke Prevention in Atrial Fibrillation (SPAF) study, for example, reported that the annual rate of clinical thromboembolism in patients with an enlarged left atrium and abnormal left ventricular wall motion was lower in those with than in those without mitral regurgitation (7.2 versus 15.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/37\">",
"     37",
"    </a>",
"    ]. Chronic mitral regurgitation often leads to left atrial dilatation and dysfunction and associated complications. However, even in the presence of left atrial enlargement, severe mitral regurgitation is associated with a lower incidence of embolism (9 versus 25 percent at 7.4 years in those in whom regurgitation was absent or mild) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hypercoagulable state",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies that measured indices of coagulability suggest that AF confers a hypercoagulable state, increasing the risk of thromboembolism and stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/3,12,32,39\">",
"     3,12,32,39",
"    </a>",
"    ]. One report of 109 patients with AF fibrillation evaluated the relationship between hemostatic and hemodynamic parameters obtained with TEE and the presence of left atrial thrombus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/12\">",
"     12",
"    </a>",
"    ]. Compared to patients without evidence of thrombus, those with thrombus had spontaneous echo contrast, reduced left atrial appendage velocity, increased plasma concentrations of markers of platelet activation (beta-thromboglobulin and platelet factor 4), increased plasma markers of thrombogenesis (thrombin-antithrombin complexes, D-dimers), and evidence of endothelial",
"    <span class=\"nowrap\">",
"     damage/dysfunction",
"    </span>",
"    (elevated plasma and endocardial levels of von Willebrand factor, which is released from damaged endothelium) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23162?source=see_link\">",
"     \"Endothelial dysfunction\"",
"    </a>",
"    .) A multiple logistic model identified left atrial appendage velocity, beta-thromboglobulin, and von Willebrand factor, but not spontaneous echo contrast, as independent associates of left atrial thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activation of the coagulation system have been identified in other reports of both paroxysmal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] and chronic AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/41-47\">",
"     41-47",
"    </a>",
"    ]. This effect is independent of the presence or absence of underlying structural heart disease. As noted above, reversion to sinus rhythm results in normalization of hemostatic markers within two to four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anticoagulation in patients with AF also alters the hypercoagulable state as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibrin D-dimer levels are increased in patients with AF. In one study, fibrin D-dimer levels were highest in patients who were not receiving any antithrombotic therapy, intermediate in those on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , and lowest in those treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/44\">",
"       44",
"      </a>",
"      ]. Similar findings were noted in another report in which patients with AF treated with warfarin had lower levels of prothrombin fragment F1 + 2 and thrombin-antithrombin complex than those treated with aspirin or no antithrombotic therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High fibrin D-dimer levels have been associated with an increased rate of embolic events in patients with AF on oral anticoagulant therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/50\">",
"       50",
"      </a>",
"      ]. In one study, elevated D-dimer levers (&ge;.5",
"      <span class=\"nowrap\">",
"       &micro;g/ml)",
"      </span>",
"      were associated with more thromboembolic events compared to those with low D-dimer levels (hazard ratio 15.8; 95% CI 3.33 to 75.5) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/51\">",
"       51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In a substudy from the AFASAK trial, 100 patients with chronic AF were randomized to treatment with fixed minidose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      1.25 mg daily alone or in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      300",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      conventional warfarin therapy with dose adjusted to maintain an INR between 2.0 and 3.0 or aspirin 300 mg daily. Patients treated with warfarin at any dose demonstrated a significant rise in the INR with a corresponding reduction in prothrombin fragment F1 + 2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The degree of anticoagulation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      appears to be important. In one report, ultra low-dose warfarin (1",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      did not significantly alter plasma fibrin D-dimer or beta-thromboglobulin levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/53\">",
"       53",
"      </a>",
"      ]. A second study found that treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (300 mg daily) plus low-dose warfarin (1 or 2 mg daily) or low-dose warfarin alone (2 mg daily) did not significantly reduce any of the hemostatic markers; in contrast, there was a significant reduction of fibrinogen and fibrin D-dimer with dose-adjusted warfarin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence of endothelial",
"    <span class=\"nowrap\">",
"     damage/dysfunction",
"    </span>",
"    in AF is provided by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endocardial damage and disorganization of the left atrial appendage endocardium has been described in the setting of mitral valve disease, especially where AF is present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormal plasma indices of endothelial",
"      <span class=\"nowrap\">",
"       damage/dysfunction,",
"      </span>",
"      such as vWf, which have been related to thrombogenesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/44\">",
"       44",
"      </a>",
"      ], stroke risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/56\">",
"       56",
"      </a>",
"      ], and adverse prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/57\">",
"       57",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Left ventricular dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased levels of circulating endothelial cells (CECs), an index of endothelial damage in the setting of AF and target organ damage (heart failure, stroke, myocardial infarction) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although these observations suggest that AF is associated with a hypercoagulable state and endothelial dysfunction, the precise mechanisms by which this might occur are uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/3,12,20\">",
"     3,12,20",
"    </a>",
"    ]. Abnormalities in cardiac blood flow (sluggish, slow flow within the atria) may be partly responsible, adding to an endothelial disturbance in the pulmonary vasculature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/44,46\">",
"     44,46",
"    </a>",
"    ]. The latter effect may stimulate lung macrophages to produce hepatocyte stimulating factor (now known to be interleukin IL-6), increasing the hepatic synthesis of fibrinogen, perhaps in a similar manner to smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other data suggest that inflammation may contribute to the hypercoagulable state in AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/60\">",
"     60",
"    </a>",
"    ]. As an example, high plasma levels of CRP and interleukin-6 (IL-6) among patients with AF are independently related to indices of the prothrombotic state in AF (eg, CRP to fibrinogen, IL-6 to tissue factor) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/61\">",
"     61",
"    </a>",
"    ]. CRP has also been related to the presence of dense spontaneous echo contrast (SEC) in the left atrium or left atrial appendage on transesophageal echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/62\">",
"     62",
"    </a>",
"    ]. SEC is a well-recognized independent predictor for stroke and thromboembolism in AF. Indices of the prothrombotic state and inflammatory markers (IL-6, but not CRP) may predict stroke and vascular events in AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/57,63\">",
"     57,63",
"    </a>",
"    ]. In a larger series of 880 AF patients, CRP was positively correlated to stroke risk and related to stroke risk factors and prognosis (mortality, vascular events) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other mechanisms stimulating the prothrombotic state in AF that have been explored include matrix metalloproteinases (MMPs) and their inhibitors (tissue inhibitors of matrix metalloproteinases, TIMPs) as well as growth factors. In one report, plasma levels of MMP-1 were lower and plasma levels of TIMP-1 were higher in 48 consecutive patients with permanent nonvalvular AF compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/65\">",
"     65",
"    </a>",
"    ]. However, these values were not independently associated with the presence of AF on multivariate analysis. Instead, clinical factors (that is, age, ischemic heart disease or hypertension) and echocardiographic variables (end-diastolic left ventricular diameter or left ventricular mass index) were found to be independently associated with MMP system.",
"   </p>",
"   <p>",
"    Abnormal growth factors, such as vascular endothelial growth factor (VEGF, also a marker of angiogenesis) have been related to tissue factor (TF) upregulation &mdash; and therefore coagulation &mdash; at least in cancer pathophysiology. Among AF patients, TF levels have been shown to be significantly correlated with plasma VEGF levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/66\">",
"     66",
"    </a>",
"    ]. In separate studies, plasma levels of TF and VEGF have also been shown to be increased in atherosclerosis, a condition whose pathophysiology involves a tendency to thrombosis and angiogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Similar observations have been noted for angiopoietin, another index of angiogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other possible mechanisms which have been proposed for the hemostatic abnormalities include neuroendocrine activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/70\">",
"     70",
"    </a>",
"    ], slow flow itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/71\">",
"     71",
"    </a>",
"    ], increased expression of markers of platelet activation including P-selectin and CD63 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/72,73\">",
"     72,73",
"    </a>",
"    ], and elevated serum levels of lipoprotein(a) which is structurally similar to plasminogen and may have antifibrinolytic action [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series that included 121 patients with AF, 78 with a history of AF but in sinus rhythm at the time of the study, and 65 control subjects, markers of platelet activation were increased in patients with AF and in those with a history of AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/73\">",
"     73",
"    </a>",
"    ]. However, multivariable analysis suggested that the degree of platelet activation was probably due to the underlying cardiovascular diseases associated with AF rather than the AF itself. Indeed, another marker of platelet activation, soluble CD40 ligand levels were not related to the risk of stroke nor to prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29446784\">",
"    <span class=\"h3\">",
"     Prognostic value of elevated biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures of the prothrombotic state in patients with AF, using biomarkers such as von Willebrand factor (vWF) or D-dimer (both of which are discussed in the section above), have been evaluated for their prognostic value. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/41/17049?source=see_link\">",
"     \"Biology and normal function of von Willebrand factor\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical use of coagulation tests\", section on 'Fibrin D-dimer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With regard to vWF, the following observations have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 1321 patients with AF, there was a significant stepwise increase in plasma vWf levels as the risk of stroke increased [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two studies have suggested that the addition of plasma vWf levels to traditional risk predictors may improve the ability to predict stroke and vascular events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/57,75\">",
"       57,75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 229 patients with permanent AF who were stabilized on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy for at least six months, high plasma vWF levels (&gt;221",
"      <span class=\"nowrap\">",
"       IU/dl)",
"      </span>",
"      were an independent predictor for adverse events, including death, stroke and bleeding during two years of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two studies have found that D-dimer levels add to the ability of traditional risk factors to predict adverse outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/50,51\">",
"     50,51",
"    </a>",
"    ], while one did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43528/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms leading to an increased risk of stroke, thrombus, and embolism in AF are multiple, complex, and closely interact with each other. Many of these factors can be explained by Virchow's triad for thrombogenesis. Consideration must be given to the patient's age, the presence of structural heart disease, and clinical risk factors such as previous hypertension, diabetes, or heart failure (particularly depressed left ventricular systolic function). In addition, AF appears to be associated with a reversible hypercoagulable state, which complements the clinical and echocardiographic features in explaining the mechanisms of thrombosis in this common disorder.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Virchow R. Gesammelte abhandlungen zur wissenschaftlichen medizin, Medinger Sohn &amp; Co, Frankfurt 1856. p.219.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/2\">",
"      Lip GY, Lowe GD. ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. BMJ 1996; 312:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/3\">",
"      Lip GY. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995; 346:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/4\">",
"      Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/5\">",
"      Lip GY. Intracardiac thrombus formation in cardiac impairment: the role of anticoagulant therapy. Postgrad Med J 1996; 72:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/6\">",
"      Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med 1992; 116:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/7\">",
"      Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med 1992; 116:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/8\">",
"      Black IW, Hopkins AP, Lee LC, Walsh WF. Left atrial spontaneous echo contrast: a clinical and echocardiographic analysis. J Am Coll Cardiol 1991; 18:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/9\">",
"      Daniel WG, Nellessen U, Schr&ouml;der E, et al. Left atrial spontaneous echo contrast in mitral valve disease: an indicator for an increased thromboembolic risk. J Am Coll Cardiol 1988; 11:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/10\">",
"      Black IW, Chesterman CN, Hopkins AP, et al. Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol 1993; 21:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/11\">",
"      Jones EF, Calafiore P, McNeil JJ, et al. Atrial fibrillation with left atrial spontaneous contrast detected by transesophageal echocardiography is a potent risk factor for stroke. Am J Cardiol 1996; 78:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/12\">",
"      Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart 1997; 77:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/13\">",
"      Bernhardt P, Schmidt H, Hammerstingl C, et al. Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging. J Am Coll Cardiol 2005; 45:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/14\">",
"      Tsai LM, Chen JH, Lin LJ, Teng JK. Natural history of left atrial spontaneous echo contrast in nonrheumatic atrial fibrillation. Am J Cardiol 1997; 80:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/15\">",
"      Manning WJ, Silverman DI, Katz SE, et al. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol 1994; 23:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/16\">",
"      Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol 1998; 82:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/17\">",
"      Gentile F, Elhendy A, Khandheria BK, et al. Safety of electrical cardioversion in patients with atrial fibrillation. Mayo Clin Proc 2002; 77:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/18\">",
"      Wolf PA, Kannel WB, McGee DL, et al. Duration of atrial fibrillation and imminence of stroke: the Framingham study. Stroke 1983; 14:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/19\">",
"      Roy D, Marchand E, Gagn&eacute; P, et al. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J 1986; 112:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/20\">",
"      Lip GY. Does paroxysmal atrial fibrillation confer a paroxysmal thromboembolic risk? Lancet 1997; 349:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/21\">",
"      Obarski TP, Salcedo EE, Castle LW, Stewart WJ. Spontaneous echo contrast in the left atrium during paroxysmal atrial fibrillation. Am Heart J 1990; 120:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/22\">",
"      Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 1997; 29:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/23\">",
"      Lip GY, Lowe GD, Rumley A, Dunn FG. Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am Heart J 1996; 131:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/24\">",
"      Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997; 336:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/25\">",
"      Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998; 158:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/26\">",
"      Nixon JV. Left ventricular mural thrombus. Arch Intern Med 1983; 143:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/27\">",
"      Lapeyre AC 3rd, Steele PM, Kazmier FJ, et al. Systemic embolism in chronic left ventricular aneurysm: incidence and the role of anticoagulation. J Am Coll Cardiol 1985; 6:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/28\">",
"      Mullen DC, Posey L, Gabriel R, et al. Prognostic considerations in the management of left ventricular aneurysms. Ann Thorac Surg 1977; 23:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/29\">",
"      SCHLICHTER J, HELLERSTEIN HK, KATZ LN. Aneurysm of the heart: a correlative study of one hundred and two proved cases. Medicine (Baltimore) 1954; 33:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/30\">",
"      Lip GY, Lowe GD, Metcalfe MJ, et al. Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. Am J Cardiol 1995; 76:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/31\">",
"      Chung I, Lip GY. Platelets and heart failure. Eur Heart J 2006; 27:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/32\">",
"      Lip GY. Hypercoagulability and haemodynamic abnormalities in atrial fibrillation. Heart 1997; 77:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/33\">",
"      Lip GY, Beevers DG. Abnormalities of rheology and coagulation in hypertension. J Hum Hypertens 1994; 8:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/34\">",
"      Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/35\">",
"      Ozkan M, Kaymaz C, Kirma C, et al. Predictors of left atrial thrombus and spontaneous echo contrast in rheumatic valve disease before and after mitral valve replacement. Am J Cardiol 1998; 82:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/36\">",
"      Goldsmith IR, Blann AD, Patel RL, Lip GY. Reduced indexes of left atrial hypercoagulability in patients with severe mitral regurgitation. Am J Cardiol 2000; 86:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/37\">",
"      Blackshear JL, Pearce LA, Asinger RW, et al. Mitral regurgitation associated with reduced thromboembolic events in high-risk patients with nonrheumatic atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Am J Cardiol 1993; 72:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/38\">",
"      Nakagami H, Yamamoto K, Ikeda U, et al. Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation. Am Heart J 1998; 136:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/39\">",
"      Feng D, D'Agostino RB, Silbershatz H, et al. Hemostatic state and atrial fibrillation (the Framingham Offspring Study). Am J Cardiol 2001; 87:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/40\">",
"      Fukuchi M, Watanabe J, Kumagai K, et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol 2001; 37:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/41\">",
"      O'Neill PG, Puleo PR, Bolli R, Rokey R. Return of atrial mechanical function following electrical conversion of atrial dysrhythmias. Am Heart J 1990; 120:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/42\">",
"      Kumagai K, Fukunami M, Ohmori M, et al. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol 1990; 16:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/43\">",
"      Gustafsson C, Blomb&auml;ck M, Britton M, et al. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 1990; 21:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/44\">",
"      Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J 1995; 73:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/45\">",
"      Asakura H, Hifumi S, Jokaji H, et al. Prothrombin fragment F1 + 2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. Blood Coagul Fibrinolysis 1992; 3:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/46\">",
"      Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997; 34:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/47\">",
"      Lip GY, Lowe GD. Fibrin D-dimer: a useful clinical marker of thrombogenesis? Clin Sci (Lond) 1995; 89:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/48\">",
"      Lip GY, Rumley A, Dunn FG, Lowe GD. Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm. Int J Cardiol 1995; 51:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/49\">",
"      Abe, Y, Kim, J, Fukunami, M, et al. Evidence for the intravascular hyperclotting state induced by atrial fibrillation itself (abstract). J Am Coll Cardiol 1996; 27(Suppl A):35A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/50\">",
"      Vene N, Mavri A, Kosmelj K, Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost 2003; 90:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/51\">",
"      Sadanaga T, Sadanaga M, Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol 2010; 55:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/52\">",
"      Petersen P, Kastrup J, Helweg-Larsen S, et al. Risk factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Arch Intern Med 1990; 150:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/53\">",
"      Lip GY, Lip PL, Zarifis J, et al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996; 94:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/54\">",
"      Li-Saw-Hee FL, Blann AD, Lip GY. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000; 31:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/55\">",
"      Goldsmith I, Kumar P, Carter P, et al. Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study. Am Heart J 2000; 140:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/56\">",
"      Conway DS, Pearce LA, Chin BS, et al. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002; 106:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/57\">",
"      Conway DS, Pearce LA, Chin BS, et al. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107:3141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/58\">",
"      Freestone B, Lip GY, Chong AY, et al. Circulating endothelial cells in atrial fibrillation with and without acute cardiovascular disease. Thromb Haemost 2005; 94:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/59\">",
"      Ritchie DG, Levy BA, Adams MA, Fuller GM. Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: an indirect feedback pathway. Proc Natl Acad Sci U S A 1982; 79:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/60\">",
"      Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006; 27:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/61\">",
"      Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004; 43:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/62\">",
"      Conway DS, Buggins P, Hughes E, Lip GY. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation. Am J Cardiol 2004; 93:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/63\">",
"      Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004; 148:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/64\">",
"      Lip GY, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 2007; 38:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/65\">",
"      Mar&iacute;n F, Rold&aacute;n V, Climent V, et al. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? Stroke 2003; 34:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/66\">",
"      Chung NA, Belgore F, Li-Saw-Hee FL, et al. Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor? Stroke 2002; 33:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/67\">",
"      Blann AD, Belgore FM, McCollum CN, et al. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci (Lond) 2002; 102:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/68\">",
"      Makin AJ, Chung NA, Silverman SH, Lip GY. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis? Clin Sci (Lond) 2003; 104:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/69\">",
"      Freestone B, Chong AY, Lim HS, et al. Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis? Ann Med 2005; 37:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/70\">",
"      Sbarouni E, Bradshaw A, Andreotti F, et al. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994; 127:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/71\">",
"      Lip GY, Lowe GD, Metcalfe MJ, et al. Is diastolic dysfunction associated with thrombogenesis? A study of circulating markers of a prothrombotic state in patients with coronary artery disease. Int J Cardiol 1995; 50:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/72\">",
"      Minamino T, Kitakaze M, Sanada S, et al. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. Circulation 1998; 98:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/73\">",
"      Choudhury A, Chung I, Blann AD, Lip GY. Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of \"healthy control subjects\" and \"disease control subjects\" in sinus rhythm. J Am Coll Cardiol 2007; 49:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/74\">",
"      Igarashi Y, Yamaura M, Ito M, et al. Elevated serum lipoprotein(a) is a risk factor for left atrial thrombus in patients with chronic atrial fibrillation: a transesophageal echocardiographic study. Am Heart J 1998; 136:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/75\">",
"      Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 2006; 37:2294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43528/abstract/76\">",
"      Rold&aacute;n V, Mar&iacute;n F, Mui&ntilde;a B, et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2011; 57:2496.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 981 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_32_43528=[""].join("\n");
var outline_f42_32_43528=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FACTORS PROMOTING THROMBOEMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Left atrial abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Atrial stunning after cardioversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Paroxysmal atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Left ventricular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Valvular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hypercoagulable state",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29446784\">",
"      - Prognostic value of elevated biomarkers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/981\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/981|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/50/18223\" title=\"diagnostic image 1\">",
"      Spontaneous echo contrast seen in the left atrium on TEE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/981|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/51/14141\" title=\"figure 1\">",
"      LV function stroke risk in AF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/981|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?4/61/5072\" title=\"movie 1\">",
"      TEE left atrial appendage thrombus and spontaneous echo contrast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?10/61/11231\" title=\"movie 2\">",
"      TEE LA thrombus and spontaneous echo contrast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/981|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/50/40747\" title=\"table 1\">",
"      Predictors of stroke in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/29/2523\" title=\"table 2\">",
"      TEE factors for embolism AF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/41/17049?source=related_link\">",
"      Biology and normal function of von Willebrand factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/28/6601?source=related_link\">",
"      Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31384?source=related_link\">",
"      Paroxysmal atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2856?source=related_link\">",
"      Role of echocardiography in atrial fibrillation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_32_43529="Clinical features, evaluation, and diagnosis of croup";
var content_f42_32_43529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features, evaluation, and diagnosis of croup",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/32/43529/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43529/contributors\">",
"     Charles R Woods, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/32/43529/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43529/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43529/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43529/contributors\">",
"     Ellen M Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/32/43529/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43529/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/32/43529/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Croup is a respiratory illness characterized by inspiratory stridor, cough, and hoarseness. These symptoms result from inflammation in the larynx and subglottic airway. A barking cough is the hallmark of croup among infants and young children, whereas hoarseness predominates in older children and adults. Although croup usually is a mild and self-limited illness, significant upper airway obstruction, respiratory distress, and, rarely, death, can occur.",
"   </p>",
"   <p>",
"    The clinical features, evaluation, and diagnosis of croup will be discussed here. The management of croup is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/26/31144?source=see_link\">",
"     \"Approach to the management of croup\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31928?source=see_link\">",
"     \"Pharmacologic and supportive interventions for croup\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term croup has been used to describe a variety of upper respiratory conditions in children, including laryngitis, laryngotracheitis, laryngotracheobronchitis, bacterial tracheitis, or spasmodic croup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/1\">",
"     1",
"    </a>",
"    ]. These terms are defined below. In the past, the term croup also has been applied to laryngeal diphtheria (diphtheritic or membranous croup), which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29287?source=see_link\">",
"     \"Epidemiology, pathophysiology and clinical manifestations of diphtheria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11046?source=see_link\">",
"     \"Diagnosis and treatment of diphtheria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Throughout this review, the term croup will be used to refer to laryngotracheitis. Laryngotracheobronchitis, laryngotracheobronchopneumonitis, bacterial tracheitis, and spasmodic croup are designated specifically as such.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laryngitis refers to inflammation limited to the larynx and manifests itself as hoarseness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/2\">",
"       2",
"      </a>",
"      ]. It usually occurs in older children and adults and, similar to croup, is frequently caused by a viral infection. The etiology, management, and evaluation of other causes of hoarseness are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/29/44505?source=see_link\">",
"       \"Etiology and management of hoarseness in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4102?source=see_link\">",
"       \"Evaluation of the child with hoarseness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Laryngotracheitis (croup) refers to inflammation of the larynx and trachea. Although lower airway signs are absent, the typical barking cough will be present.",
"     </li>",
"     <li>",
"      Laryngotracheobronchitis (LTB) occurs when inflammation extends into the bronchi, resulting in lower airway signs (eg, wheezing, rales, air trapping, increased tachypnea) and sometimes more severe illness than laryngotracheitis alone. This term commonly is used interchangeably with laryngotracheitis, and the entities are often indistinct clinically. Further extension of inflammation into the lower airways results in laryngotracheobronchopneumonitis, which sometimes can be complicated by bacterial superinfection. Bacterial superinfection can be manifest as pneumonia, bronchopneumonia, or bacterial tracheitis.",
"     </li>",
"     <li>",
"      Bacterial tracheitis (also called bacterial croup) describes bacterial infection of the subglottic trachea, resulting in a thick, purulent exudate, which causes symptoms of upper airway obstruction (",
"      <a class=\"graphic graphic_picture graphicRef55364 \" href=\"mobipreview.htm?16/55/17264\">",
"       picture 1",
"      </a>",
"      ). The bronchi and lungs are typically involved, as well (ie, bacterial tracheobronchitis). Bacterial tracheitis may occur as a complication of viral respiratory infections (usually those which manifest themselves as LTB or laryngotracheobronchopneumonitis) or as a primary bacterial infection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32536?source=see_link\">",
"       \"Bacterial tracheitis in children: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Spasmodic croup is characterized by the sudden onset of inspiratory stridor at night, short duration (several hours), and sudden cessation. This is often in the setting of a mild upper respiratory infection, but without fever or inflammation. A striking feature of spasmodic croup is its recurrent nature, hence the alternate descriptive term, \"frequently recurrent croup\". Because of some clinical overlap with atopic diseases, it is sometimes referred to as \"allergic croup\".",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Croup is usually caused by viruses. Bacterial infection may occur secondarily, as described above.",
"   </p>",
"   <p>",
"    Parainfluenza virus type 1 is the most common cause of acute laryngotracheitis, especially the fall and winter epidemics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Parainfluenza type 2 sometimes causes croup outbreaks, but usually with milder disease than type 1. Parainfluenza type 3 causes sporadic cases of croup that often are more severe than those due to types 1 and 2. In multicenter surveillance of children &lt;5 years who were hospitalized with febrile or acute respiratory illnesses, 43 percent of children with confirmed parainfluenza infection were diagnosed with croup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/6\">",
"     6",
"    </a>",
"    ]. Croup was the most common discharge diagnosis for children with confirmed parainfluenza 1 (42 percent) and parainfluenza 2 (48 percent) infections but was only diagnosed in 11 percent of children with confirmed parainfluenza 3 infections.",
"   </p>",
"   <p>",
"    The microbiology, pathogenesis, and epidemiology of parainfluenza infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36808?source=see_link\">",
"     \"Parainfluenza viruses in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of other viruses that typically cause lower respiratory tract disease also can cause upper respiratory tract symptoms, including croup, as described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory syncytial virus (RSV) and adenoviruses are relatively frequent causes of croup. The laryngotracheal component of disease is usually less significant than that of the lower airways. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7050?source=see_link&amp;anchor=H15#H15\">",
"       \"Respiratory syncytial virus infection: Clinical features and diagnosis\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=see_link&amp;anchor=H9#H9\">",
"       \"Epidemiology and clinical manifestations of adenovirus infection\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Human coronavirus NL63 (HCoV-NL63), first identified in 2004, has been implicated in croup and other respiratory illnesses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/7-9\">",
"       7-9",
"      </a>",
"      ]. The prevalence of HCoV-NL63 varies geographically. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41176?source=see_link&amp;anchor=H7#H7\">",
"       \"Coronaviruses\", section on 'Respiratory'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Measles is an important cause of croup in areas where measles remains prevalent. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43192?source=see_link\">",
"       \"Clinical presentation and diagnosis of measles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Influenza virus is a relatively uncommon cause of croup. However, children hospitalized with influenzal croup tend to have longer hospitalization and greater risk of readmission for relapse of laryngeal symptoms than those with parainfluenzal croup. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24346?source=see_link\">",
"       \"Clinical features and diagnosis of seasonal influenza in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rhinoviruses, enteroviruses (especially Coxsackie types A9, B4, and B5, and echovirus types 4, 11, and 21), and herpes simplex virus are occasional causes of sporadic cases of croup that are usually mild. (See appropriate topic reviews).",
"     </li>",
"     <li>",
"      Metapneumoviruses cause primarily lower respiratory tract disease similar to RSV, but upper respiratory tract symptoms have been described in some patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/33/33304?source=see_link\">",
"       \"Human metapneumovirus infections\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Croup also may be caused by bacteria.",
"    <em>",
"     Mycoplasma pneumoniae",
"    </em>",
"    has been associated with mild cases of croup. In addition, secondary bacterial infection may occur in children with laryngotracheitis, laryngotracheobronchitis, or laryngotracheobronchopneumonitis. The most common secondary bacterial pathogens include",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    ,",
"    <em>",
"     Streptococcus pyogenes",
"    </em>",
"    , and",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Croup most commonly occurs in children 6 to 36 months of age. It is seen in younger infants (as young as three months) and in preschool children, but it is rare beyond age six years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]. It is more common in boys, with a male:female ratio of about 1.4:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/1,11-13\">",
"     1,11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Family history of croup is a risk factor for croup and recurrent croup. In a case-control study, children whose parents had a history of croup were 3.2 times as likely to have an episode of croup and 4.1 times as likely to have recurrent croup as children with no parental history of croup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/14\">",
"     14",
"    </a>",
"    ]. Parental smoking, a well-recognized risk factor for respiratory tract infections in children, does not appear to increase the risk of croup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/4/5194?source=see_link&amp;anchor=H10#H10\">",
"     \"Secondhand smoke exposure: Effects in children\", section on 'Respiratory symptoms and illness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most cases of croup occur in the fall or early winter, with the major incidence peaks coinciding with parainfluenza type 1 activity (often in October) and minor peaks occurring during periods of respiratory syncytial virus or influenza virus activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7050?source=see_link&amp;anchor=H3#H3\">",
"     \"Respiratory syncytial virus infection: Clinical features and diagnosis\", section on 'Seasonality'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24346?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Influenza activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Emergency department (ED) visits for croup are most frequent between 10:00 PM and 4:00 AM. However, children seen for croup between noon and 6:00 PM are more likely to be admitted to the hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/3,16\">",
"     3,16",
"    </a>",
"    ]. A morning peak between 7:00 AM and 11:00 AM in ED visits for croup also has been noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hospital admissions for croup have declined steadily since the late 1970s. In an analysis of data from the National Hospital Discharge Surveys from 1979 through 1997, the estimated number of annual hospitalizations for croup decreased from 48,900 to 33,500 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/4\">",
"     4",
"    </a>",
"    ]. Estimates of annual hospitalization rates for croup caused by parainfluenza virus types 1 to 3 from 1994 to 1997 were 0.4 to 1.1 per 1000 children for children younger than one year and 0.24 to 0.61 per 1000 children for children between one and four years. Approximately one-half of these hospitalizations were attributed to parainfluenza type 1.",
"   </p>",
"   <p>",
"    In a six-year (1999 to 2005) population-based study, 5.6 percent of children with a diagnosis of croup in the ED required hospital admission. Among those discharged home, 4.4 percent had a repeat ED visit within 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The viruses that cause croup typically infect the nasal and pharyngeal mucosal epithelia initially and then spread locally along the respiratory epithelium to the larynx and trachea.",
"   </p>",
"   <p>",
"    The anatomic hallmark of croup is narrowing of the trachea in the subglottic region. This portion of the trachea is surrounded by a firm cartilaginous ring such that any inflammation results in narrowing of the airway. In addition to this \"fixed\" obstruction, dynamic obstruction of the extrathoracic trachea below the cartilaginous ring may occur when the child struggles, cries, or becomes agitated. The dynamic obstruction occurs as a result of the combination of high negative pressure in the distal extrathoracic trachea and the floppiness of the tracheal wall in children.",
"   </p>",
"   <p>",
"    Laryngoscopic evaluation of patients during acute laryngotracheitis shows redness and swelling of the lateral walls of the trachea. In severe cases, the subglottic airway may be reduced to a diameter of 1 to 2 mm. In addition to mucosal edema and swelling, fibrinous exudates and, occasionally, pseudomembranes can build up on the tracheal surfaces and contribute to airway narrowing. The vocal cords and laryngeal tissues also can become swollen, and cord mobility may be impaired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/2,17-19\">",
"     2,17-19",
"    </a>",
"    ]. Autopsy studies in children with laryngotracheitis show infiltration of histiocytes, lymphocytes, plasma cells, and neutrophils into edematous lamina propria, submucosa, and adventitia of the larynx and trachea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In spasmodic croup, findings on direct laryngoscopy demonstrate noninflammatory edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/17\">",
"     17",
"    </a>",
"    ]. This suggests that there is no direct viral involvement of the tracheal epithelium.",
"   </p>",
"   <p>",
"    Patients with bacterial tracheitis have a bacterial superinfection that causes thick pus to develop within the lumen of the subglottic trachea (",
"    <a class=\"graphic graphic_picture graphicRef55364 \" href=\"mobipreview.htm?16/55/17264\">",
"     picture 1",
"    </a>",
"    ). Ulcerations, pseudomembranes, and microabscesses of the mucosal surface occur. The supraglottic tissues usually are normal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32536?source=see_link&amp;anchor=H3#H3\">",
"     \"Bacterial tracheitis in children: Clinical features and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Host factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a small fraction of children with parainfluenza virus infections develop overt croup. This suggests that host (or genetic) factors play a role in the pathogenesis. Host factors that may contribute to the development of croup include functional or anatomic susceptibility to upper airway narrowing, variations in immune response, and predisposition to atopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Underlying host factors that predispose to clinically significant narrowing of the upper airway include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anatomic narrowing of the airway, such as subglottic stenosis or laryngeal web",
"     </li>",
"     <li>",
"      Hyperactive airways, perhaps aggravated by atopy or gastroesophageal reflux, as suggested in some children with spasmodic croup or recurrent croup [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/23-25\">",
"       23-25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Acquired airway narrowing from respiratory tract papillomas (human papillomavirus) or post-intubation scarring",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential role of the immune response was demonstrated in studies that demonstrated increased production of parainfluenza virus-specific IgE and increased lymphoproliferative response to parainfluenza virus antigen, and diminished histamine-induced suppression of lymphocyte transformation responses to parainfluenza virus in children with parainfluenza virus and croup compared with those with parainfluenza virus without croup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of croup depends upon the specific croup syndrome and the degree of upper airway obstruction. Although croup usually is a mild and self-limited illness, specific features of the history and physical examination identify children who are seriously ill or at risk for rapid progression of disease. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laryngotracheitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngotracheitis typically occurs in children three months to three years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/2\">",
"     2",
"    </a>",
"    ]. The onset of symptoms is usually gradual, beginning with nasal irritation, congestion, and coryza. Symptoms generally progress over 12 to 48 hours to include fever, hoarseness, barking cough, and stridor. Respiratory distress increases as upper airway obstruction becomes more severe. Rapid progression or signs of lower airway involvement suggests a more serious illness. Symptoms typically persist for three to seven days with a gradual return to normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/2\">",
"     2",
"    </a>",
"    ]. Deviations from this expected course should prompt consideration of diagnoses other than laryngotracheitis. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The degree of upper airway obstruction is evident on physical examination, as described below. In mild cases, the child is hoarse and has nasal congestion. There is minimal, if any, pharyngitis. As airway obstruction progresses, stridor develops, and there may be mild tachypnea with a prolonged inspiratory phase. The presence of stridor is a key element in the assessment of severity. Stridor at rest is a sign of significant upper airway obstruction. As upper airway obstruction progresses, the child may become restless or anxious. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Severity assessment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When airway obstruction becomes severe, suprasternal, subcostal, and intercostal retractions may be seen. Breath sounds can be diminished. Agitation, which generally is accompanied by increased inspiratory effort, exacerbates the subglottic narrowing by creating negative pressure in the airway. This can lead to further respiratory distress and agitation.",
"   </p>",
"   <p>",
"    Hypoxia and cyanosis can develop, as can respiratory fatigue from sustained increased respiratory effort. High respiratory rates also tend to correlate with the presence of hypoxia. Without intervention, the hypoxia or fatigue can sometimes lead to death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Spasmodic croup",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spasmodic croup also occurs in children three months to three years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast to laryngotracheitis, spasmodic croup always occurs at night; the duration of symptoms is short, often with symptoms subsiding by the time of presentation for medical attention; and the onset and cessation of symptoms are abrupt. Fever is typically absent, but mild upper respiratory tract symptoms (eg, coryza) may be present. Episodes can recur within the same night and for two to four successive evenings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/28\">",
"     28",
"    </a>",
"    ]. A striking feature of spasmodic croup is its recurrent nature, hence the alternate descriptive term, \"frequently recurrent croup\". There may be a familial predisposition to spasmodic croup, and it may be more common in children with a family history of allergies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early in the clinical course, spasmodic croup may be difficult to distinguish from laryngotracheitis. As the course progresses, the episodic nature of spasmodic croup and relative wellness of the child between attacks differentiate it from classic croup, in which the symptoms are continuous.",
"   </p>",
"   <p>",
"    Although the initial presentation can be dramatic, the clinical course is usually benign. Symptoms are almost always relieved by comforting the anxious child and administering humidified air. Rarely, children may benefit from treatment with corticosteroids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nebulized epinephrine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/29\">",
"     29",
"    </a>",
"    ]. Other therapies generally are not indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/26/31144?source=see_link\">",
"     \"Approach to the management of croup\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Bacterial tracheitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial tracheitis may present as a primary or secondary infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/30\">",
"     30",
"    </a>",
"    ]. In primary infection, there is acute onset of symptoms of upper airway obstruction with fever and toxic appearance. In secondary infection, there is marked worsening during the clinical course of viral laryngotracheitis, with high fever, toxic appearance, and increasing respiratory distress secondary to tracheal obstruction from purulent secretions. In both of these presentations, signs of lower airway disease, such as rales and wheezes, may be present. However, the upper airway obstruction is the more clinically significant manifestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/2,31\">",
"     2,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32536?source=see_link&amp;anchor=H11#H11\">",
"     \"Bacterial tracheitis in children: Clinical features and diagnosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Recurrent croup",
"    </span>",
"    &nbsp;&mdash;&nbsp;A child who has had recurrent episodes of classic viral croup may have an underlying condition that predisposes him or her to develop clinically significant narrowing of the upper airway. Such children may require radiographic evaluation or bronchoscopy. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Host factors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18\">",
"     'Imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of children with suspected croup has several objectives, including prompt identification of patients with significant upper airway obstruction or at risk for rapid progression of upper airway obstruction. In addition, there are some conditions with presentations similar to that of croup that require specific evaluations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interventions; these too must be promptly identified. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    During the evaluation, efforts should be made to make the child as comfortable as possible. The increased inspiratory effort that accompanies anxiety and fear in young children can exacerbate subglottic narrowing, further diminishing air exchange and oxygenation. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Rapid assessment and initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid assessment of general appearance (including the presence of stridor at rest), vital signs, pulse oximetry, airway stability, and mental status is necessary to identify children with severe respiratory distress",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impending respiratory failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/26/31144?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to the management of croup\", section on 'Intubation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endotracheal intubation is required in less than 1 percent of children with croup who are seen in the emergency department. However, the need for endotracheal intubation should be anticipated in children with progressive respiratory failure so that it can be performed in as controlled a setting as possible. Respiratory failure is heralded by the following signs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/1,32,33\">",
"     1,32,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatigue and listlessness",
"     </li>",
"     <li>",
"      Marked retractions (although retractions may decrease with increased obstruction and decreased air entry)",
"     </li>",
"     <li>",
"      Decreased or absent breath sounds",
"     </li>",
"     <li>",
"      Depressed level of consciousness",
"     </li>",
"     <li>",
"      Tachycardia out of proportion to fever",
"     </li>",
"     <li>",
"      Cyanosis or pallor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A tracheal tube that is 0.5 to 1 mm smaller than would typically be used may be required. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link&amp;anchor=H10#H10\">",
"     \"Emergent endotracheal intubation in children\", section on 'Endotracheal tube'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to establishment of an airway, children who have severe respiratory distress require immediate pharmacologic treatment, including administration of nebulized epinephrine and systemic or nebulized corticosteroids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/26/31144?source=see_link&amp;anchor=H10#H10\">",
"     \"Approach to the management of croup\", section on 'Moderate to severe croup'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once control of the airway is established and pharmacologic treatment, if necessary, is under way, the remainder of the evaluation can proceed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should include a description of the onset, duration, and progression of symptoms. Factors that are associated with increased severity of illness include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sudden onset of symptoms",
"     </li>",
"     <li>",
"      Rapidly progressing symptoms (ie, symptoms of upper airway obstruction after fewer than 12 hours of illness)",
"     </li>",
"     <li>",
"      Previous episodes of croup",
"     </li>",
"     <li>",
"      Underlying abnormality of the upper airway",
"     </li>",
"     <li>",
"      Medical conditions that predispose to respiratory failure (eg, neuromuscular disorders)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Aspects of the history that are helpful in distinguishing croup from other causes of acute upper airway obstruction include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/1,34\">",
"     1,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever &ndash; The absence of fever from onset of symptoms to the time of presentation is suggestive of spasmodic croup or a noninfectious etiology (eg, foreign body aspiration or ingestion, acute angioneurotic edema).",
"     </li>",
"     <li>",
"      Hoarseness and barking cough &ndash; Hoarseness and barking cough, characteristic findings in croup, are typically absent in children with acute epiglottitis, foreign body aspiration, and angioneurotic edema.",
"     </li>",
"     <li>",
"      Difficulty swallowing &ndash; Difficulty swallowing may occur in acute epiglottitis and foreign body aspiration. A large ingested foreign body may lodge in the upper esophagus, where it distorts and narrows the upper trachea, thus mimicking the croup syndrome (including barking cough and inspiratory stridor).",
"     </li>",
"     <li>",
"      Drooling &ndash; Drooling may occur in children with peritonsillar or retropharyngeal abscesses, retropharyngeal cellulitis, and epiglottitis. In an observational study, drooling was present in approximately 80 percent of children with epiglottitis, but only 10 percent of those with croup [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Throat pain &ndash; Complaints of dysphagia and sore throat are more common in children with epiglottitis than croup (approximately 60 to 70 percent versus &lt;10 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differential diagnosis of croup is discussed in greater detail below. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The objectives of the examination of the child with croup include assessment of severity of upper airway obstruction and exclusion of other infectious and non-infectious causes of acute upper airway obstruction, both of which are necessary in making management decisions.",
"   </p>",
"   <p>",
"    The initial examination often can be accomplished by observing the child in a comfortable position with the caretaker. Every effort should be made to measure the child's weight and vital signs.",
"   </p>",
"   <p>",
"    Aspects of the examination that are helpful in assessing the degree of upper airway obstruction and severity of illness include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall appearance &ndash; Is the child comfortable and interactive, anxious and quiet, or obtunded? Is there stridor at rest? Stridor at rest is a sign of significant upper airway obstruction. Children with significant upper airway obstruction may prefer to sit up and lean forward in a \"sniffing\" position (neck is mildly flexed, and head is mildly extended). This position tends to improve the patency of the upper airway.",
"     </li>",
"     <li>",
"      Quality of the voice &ndash; Does the child have a hoarse or diminished cry? Is the voice muffled? A muffled \"hot potato\" voice is suggestive of epiglottitis, retropharyngeal abscess, or peritonsillar abscess.",
"     </li>",
"     <li>",
"      Degree of respiratory distress &ndash; Signs of respiratory distress include tachypnea, hypoxemia, and increased work of breathing (intercostal, subcostal, or suprasternal retractions; nasal flaring; grunting; use of accessory muscles)",
"     </li>",
"     <li>",
"      Tidal volume &ndash; Does there appear to be good chest expansion with inspiration, indicating adequate air entry?",
"     </li>",
"     <li>",
"      Lung examination &ndash; Are there abnormal respiratory sounds during inspiration or expiration? Inspiratory stridor indicates upper airway obstruction, whereas expiratory wheezing is a sign of lower airway obstruction. If there is stridor, is it present at rest or only with agitation? As discussed above, stridor at rest is a sign of significant upper airway obstruction. Stridor will be more obvious on auscultation, since the inspiratory noise is transmitted through the chest. The presence of rales (crackles) also suggests lower respiratory tract involvement (eg, laryngotracheobronchitis, laryngotracheobronchopneumonitis, or bacterial tracheitis).",
"     </li>",
"     <li>",
"      Assessment of hydration status &ndash; Decreased oral intake and increased insensible losses from fever and tachypnea may result in dehydration. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3607?source=see_link\">",
"       \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These aspects of the examination are often used in clinical scoring systems to evaluate the severity of illness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in making decisions regarding the need for hospital admission. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Severity assessment'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/26/31144?source=see_link&amp;anchor=H18#H18\">",
"     \"Approach to the management of croup\", section on 'Hospitalization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Components of the examination that are useful in distinguishing croup from other causes of acute upper airway obstruction include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/32,34\">",
"     32,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preferred posture &ndash; Children with epiglottitis usually prefer to sit up in the &ldquo;tripod&rdquo; or &ldquo;sniffing position&rdquo; (",
"      <a class=\"graphic graphic_picture graphicRef79826 graphicRef76538 \" href=\"mobipreview.htm?22/22/22888\">",
"       picture 2A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Examination of the oropharynx for the following signs:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cherry red, swollen epiglottis, suggestive of epiglottitis",
"     </li>",
"     <li>",
"      Pharyngitis, typically minimal in laryngotracheitis, may be more pronounced in epiglottitis or laryngitis",
"     </li>",
"     <li>",
"      Excessive salivation, suggestive of acute epiglottitis, peritonsillar abscess, or retropharyngeal abscess",
"     </li>",
"     <li>",
"      Diphtheritic membrane",
"     </li>",
"     <li>",
"      Tonsillar asymmetry or deviation of the uvula suggestive of peritonsillar abscess",
"     </li>",
"     <li>",
"      Midline or unilateral swelling of the posterior pharyngeal wall suggestive of retropharyngeal abscess",
"      <br/>",
"      <br/>",
"      Concerns have been raised about safety of examining the pharynx in children with upper airway obstruction and possible epiglottitis since such efforts have been reported to precipitate cardiorespiratory arrest. However, in two series, each including more than 200 patients with epiglottitis or viral croup, direct examination of the oropharynx was not associated with sudden clinical deterioration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/30,35\">",
"       30,35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Examination of the cervical lymph nodes, which can be enlarged in patients with retropharyngeal or peritonsillar abscesses.",
"     </li>",
"     <li>",
"      Other physical findings may be present, depending on the particular inciting virus. As an example, rash, conjunctivitis, exudative pharyngitis, and adenopathy are suggestive of adenovirus infection.",
"     </li>",
"     <li>",
"      Otitis media (acute or with effusion) may be present as a primary viral or secondary bacterial process.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differential diagnosis of croup is discussed in greater detail below. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Severity assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of croup is often determined by the clinical scoring systems. Although there are a number of validated croup scoring systems, the Westley croup score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/36\">",
"     36",
"    </a>",
"    ] has been the most extensively studied; it is described below. No matter which system is used to assess severity, the presence of chest wall retractions and stridor at rest are the two critical clinical features.",
"   </p>",
"   <p>",
"    The elements of the Westley croup score describe key features of the physical examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/36\">",
"     36",
"    </a>",
"    ]. Each element is assigned a score, as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Level of consciousness: Normal, including sleep = 0; disoriented = 5",
"     </li>",
"     <li>",
"      Cyanosis: None = 0; with agitation = 4; at rest = 5",
"     </li>",
"     <li>",
"      Stridor: None = 0; with agitation = 1; at rest = 2",
"     </li>",
"     <li>",
"      Air entry: Normal = 0; decreased = 1; markedly decreased = 2",
"     </li>",
"     <li>",
"      Retractions: None = 0; mild = 1; moderate = 2; severe = 3",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mild croup is defined by a Westley croup score of &le;2. Typically, these children have a barking cough and hoarse cry, but no stridor at rest. Children with mild croup may have stridor when upset or crying (ie, agitated) and either no, or only mild, chest",
"    <span class=\"nowrap\">",
"     wall/subcostal",
"    </span>",
"    retractions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/1,32\">",
"     1,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Moderate croup is defined by a Westley croup score of 3 to 7. Children with moderate croup have stridor at rest, at least mild retractions, and may have other symptoms or signs of respiratory distress, but little or no agitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/1,32\">",
"     1,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe croup is defined by a Westley croup score of &ge;8. Children with severe croup have significant stridor at rest, although stridor may decrease with worsening upper airway obstruction and decreased air entry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/1,32\">",
"     1,32",
"    </a>",
"    ]. Retractions are severe (including indrawing of the sternum) and the child may appear anxious, agitated, or fatigued. Prompt recognition and treatment of children with severe croup are paramount.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic confirmation of acute laryngotracheitis is not required in the vast majority of children with croup. Radiographic evaluation of the chest",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    upper trachea is indicated if the diagnosis is in question, the course is atypical, an inhaled or swallowed foreign body is suspected (although the majority are not radio-opaque), croup is recurrent,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    there is a failure to respond as expected to therapeutic interventions. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/26/31144?source=see_link\">",
"     \"Approach to the management of croup\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with croup, a posterior-anterior chest radiograph demonstrates subglottic narrowing, commonly called the \"steeple sign\" (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52418 \" href=\"mobipreview.htm?2/56/2959\">",
"     image 1",
"    </a>",
"    ). The lateral view may demonstrate overdistention of the hypopharynx during inspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/37\">",
"     37",
"    </a>",
"    ] and subglottic haziness (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64727 \" href=\"mobipreview.htm?41/59/42943\">",
"     image 2",
"    </a>",
"    ). The epiglottis should have a normal appearance.",
"   </p>",
"   <p>",
"    In contrast, the lateral radiograph in virtually all children with epiglottitis demonstrates swelling of the epiglottis, sometimes called the \"thumb sign\" (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67878 \" href=\"mobipreview.htm?22/26/22958\">",
"     image 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lateral radiograph in children with bacterial tracheitis may demonstrate only nonspecific edema or intraluminal membranes and irregularities of the tracheal wall (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80331 \" href=\"mobipreview.htm?33/50/34606\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory studies, which are rarely indicated in children with croup, are of limited diagnostic utility but may help guide management in more severe cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Blood tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The white blood cell (WBC) count can be low, normal, or elevated; WBC counts &gt;10,000",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    are common. Neutrophil or lymphocyte predominance may be present on the differential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The presence of a large number of band-form neutrophils is suggestive of primary or secondary bacterial infection. Croup is not associated with any specific alterations in serum chemistries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirmation of etiologic diagnosis is not necessary for most children with croup, since croup is a self-limited illness that usually requires only symptomatic therapy. When an etiologic diagnosis is necessary, viral culture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rapid diagnostic tests that detect viral antigens are performed on secretions from the nasopharynx or throat. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Etiologic diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Clinical diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of croup is clinical, based on the presence of a barking cough and stridor, especially during a typical community epidemic of one of the causative viruses. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Neither radiographs nor laboratory tests are necessary to make the diagnosis. However, radiographs may be helpful in excluding other causes if the diagnosis is in question. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Etiologic diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not typically required in most cases of croup, identification of a specific viral etiology may be necessary to make decisions regarding isolation for patients requiring hospitalization, for initiation of antiviral therapy (particularly when influenza is a consideration), or for public",
"    <span class=\"nowrap\">",
"     health/epidemiologic",
"    </span>",
"    monitoring purposes.",
"   </p>",
"   <p>",
"    Diagnosis of a specific viral etiology can be made by viral culture of secretions from the nasopharynx or throat. Rapid tests that detect viral antigens in these secretions are commercially available for many respiratory viruses. The diagnosis of specific viral infections is discussed in detail in individual topic reviews:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parainfluenza (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36808?source=see_link&amp;anchor=H11#H11\">",
"       \"Parainfluenza viruses in children\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Influenza (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24346?source=see_link&amp;anchor=H17#H17\">",
"       \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Respiratory syncytial virus (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7050?source=see_link&amp;anchor=H27#H27\">",
"       \"Respiratory syncytial virus infection: Clinical features and diagnosis\", section on 'Laboratory diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Adenovirus (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/40/37513?source=see_link&amp;anchor=H10#H10\">",
"       \"Diagnosis and treatment of adenovirus infection\", section on 'Diagnostic tests of choice for different adenovirus syndromes'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Measles (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43192?source=see_link&amp;anchor=H25#H25\">",
"       \"Clinical presentation and diagnosis of measles\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Enteroviruses (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=see_link&amp;anchor=H18#H18\">",
"       \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\", section on 'Laboratory diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Metapneumovirus (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/33/33304?source=see_link&amp;anchor=H14#H14\">",
"       \"Human metapneumovirus infections\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Coronavirus (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41176?source=see_link&amp;anchor=H12#H12\">",
"       \"Coronaviruses\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, multiplex tests, which assess the presence of multiple agents at the same time, and PCR-based tests are becoming more widely available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of croup includes other causes of stridor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory distress. The primary considerations are those with acute onset, particularly those that may rapidly progress to complete upper airway obstruction, and those that require specific therapy. Underlying anatomic anomalies of the upper airway also must be considered, since they may contribute to more severe disease. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Host factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Important considerations include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute epiglottitis",
"     </li>",
"     <li>",
"      Peritonsillar and retropharyngeal abscesses",
"     </li>",
"     <li>",
"      Foreign body aspiration or ingestion",
"     </li>",
"     <li>",
"      Allergic reaction",
"     </li>",
"     <li>",
"      Acute angioneurotic edema",
"     </li>",
"     <li>",
"      Upper airway injury",
"     </li>",
"     <li>",
"      Congenital anomalies of the upper airway",
"     </li>",
"     <li>",
"      Laryngeal diphtheria (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11046?source=see_link\">",
"       \"Diagnosis and treatment of diphtheria\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Acute epiglottitis",
"    </strong>",
"    &ndash; Epiglottitis, which is rare in the era of vaccination against",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    type b, is distinguished from croup by the absence of barking cough and the presence of anxiety that is out of proportion to the degree of respiratory distress. Onset of symptoms is rapid, and because of the associated bacteremia, the child is highly febrile, pale, toxic, and ill-appearing. Because of the swollen epiglottis, the child will have difficulty swallowing and is often drooling. The children usually prefer to sit up and seldom have observed cough [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/34\">",
"     34",
"    </a>",
"    ]. Epiglottitis occurs infrequently, and there is no predominant etiologic pathogen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Peritonsillar or retropharyngeal abscesses",
"    </strong>",
"    &ndash; Children with deep neck space abscesses, cellulitis of the cervical prevertebral tissues, or other painful infections of the oropharynx may present with drooling and neck extension and varying degrees of toxicity. Barking cough is usually absent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/61/31705?source=see_link&amp;anchor=H7#H7\">",
"     \"Peritonsillar cellulitis and abscess\", section on 'Presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=see_link&amp;anchor=H5#H5\">",
"     \"Retropharyngeal infections in children\", section on 'Presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Foreign body",
"    </strong>",
"    &ndash; In foreign body aspiration, there often is a history of the sudden onset of choking and symptoms of upper airway obstruction in a previously healthy child. If an inhaled foreign body lodges in the larynx, it will produce hoarseness and stridor. If a large foreign body is swallowed, it may lodge in the upper esophagus, resulting in distortion of the adjacent soft extrathoracic trachea, producing a barking cough and inspiratory stridor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2585?source=see_link\">",
"     \"Airway foreign bodies in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/22/1386?source=see_link\">",
"     \"Foreign bodies of the esophagus and gastrointestinal tract in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Allergic reaction or acute angioneurotic edema",
"    </strong>",
"    &ndash; Allergic reaction or acute angioneurotic edema has rapid onset without antecedent cold symptoms or fever. The primary manifestations are swelling of the lips and tongue, urticarial rash, dysphagia without hoarseness, and sometimes inspiratory stridor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]. There may be a history of allergy or a previous attack. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=see_link&amp;anchor=H2#H2\">",
"     \"An overview of angioedema: Clinical features, diagnosis, and management\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Upper airway injury",
"    </strong>",
"    &ndash; Injury to the airway from smoke or thermal or chemical burns should be evident from the history. The child typically does not have fever or a viral prodrome.",
"   </p>",
"   <p>",
"    <strong>",
"     Anomalies of the upper airway",
"    </strong>",
"    &ndash; Hoarseness and stridor caused by anomalies of the upper airway (eg, laryngeal webs, laryngomalacia, vocal cord paralysis, congenital subglottic stenosis, and subglottic hemangioma) and laryngeal papillomas have a more chronic course with absence of fever and symptoms of upper respiratory tract illness, unless the presentation is due to exacerbation of airway narrowing from the impact of a concomitant viral infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21464?source=see_link\">",
"     \"Assessment of stridor in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/29/44505?source=see_link\">",
"     \"Etiology and management of hoarseness in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/42/37543?source=see_link\">",
"     \"Congenital anomalies of the larynx\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Other potential mimickers of croup",
"    </strong>",
"    &ndash; Other potential mimickers of croup include bronchogenic cyst (which can cause airway compression) and early Guillain-Barr&eacute; syndrome (involvement of the laryngeal nerve may cause vocal cord paralysis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43529/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=see_link&amp;anchor=H29#H29\">",
"     \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\", section on 'Bronchogenic cyst'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27705?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of Guillain-Barr&eacute; syndrome in children\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/29/44505?source=see_link&amp;anchor=H7#H7\">",
"     \"Etiology and management of hoarseness in children\", section on 'Vocal fold paralysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/63/32754?source=see_link\">",
"       \"Patient information: Croup (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/28/2500?source=see_link\">",
"       \"Patient information: Croup in infants and children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term croup has been used to describe a variety of upper respiratory conditions in children, including laryngitis, laryngotracheitis, laryngotracheobronchitis, bacterial tracheitis, or spasmodic croup. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Croup is usually caused by viruses. Bacterial infection may occur secondarily. Parainfluenza virus type 1 is the most common cause of croup; other causes include respiratory syncytial virus and influenza virus. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Croup most commonly occurs in children 6 to 36 months of age. Most cases occur in the fall or early winter. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Host factors that may contribute to the development of croup include functional or anatomic susceptibility to upper airway narrowing. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of croup depends upon the specific croup syndrome and the degree of upper airway obstruction. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The onset of symptoms in laryngotracheitis is gradual, beginning with nasal irritation, congestion, and coryza. Fever, hoarseness, barking cough, and stridor usually develop during the next 12 to 48 hours. Rapid progression or signs of lower airway involvement suggest a more serious illness. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laryngotracheitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The onset of symptoms in spasmodic croup is sudden and always occurs at night. Fever is typically absent, but mild upper respiratory tract symptoms may be present. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Spasmodic croup'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacterial tracheitis (",
"      <a class=\"graphic graphic_picture graphicRef55364 \" href=\"mobipreview.htm?16/55/17264\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80331 \" href=\"mobipreview.htm?33/50/34606\">",
"       image 4",
"      </a>",
"      ) may present acutely or as marked worsening during the course of an antecedent viral upper respiratory infection. Clinical manifestations of bacterial tracheitis include fever, toxic appearance, and severe respiratory distress. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Bacterial tracheitis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32536?source=see_link\">",
"       \"Bacterial tracheitis in children: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The objectives of the evaluation of the child with croup include assessment of severity and exclusion of other causes of upper airway obstruction. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapid assessment of general appearance, vital signs, pulse oximetry, airway stability, and mental status are necessary to identify children with severe respiratory distress",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      impending respiratory failure. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Rapid assessment and initial management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The history should include a description of the onset, duration and progression of symptoms, and ascertain whether there are any underlying conditions that predispose to a more severe course. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aspects of the examination that are useful in assessing the severity of upper airway obstruction include overall appearance (including the presence of stridor at rest or only with agitation), quality of voice, work of breathing, tidal volume and air entry, and the presence of wheezing. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of croup is clinical, based upon the presence of a barking cough and stridor. Neither radiographs nor laboratory tests are necessary to make the diagnosis. However, radiographs may be helpful in excluding other causes if the diagnosis is in question. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of croup includes other causes of stridor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      respiratory distress. The primary considerations are those with acute onset, particularly those that may rapidly progress to complete upper airway obstruction, and those that require specific therapy. Important considerations include acute epiglottitis, peritonsillar and retropharyngeal abscesses, foreign body aspiration, acute angioneurotic edema, upper airway injury, and congenital anomalies of the upper airway. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/1\">",
"      Cherry JD. Clinical practice. Croup. N Engl J Med 2008; 358:384.",
"     </a>",
"    </li>",
"    <li>",
"     Cherry JD. Croup (Laryngitis, laryngotracheitis, spasmodic croup, laryngotracheobronchitis, bacterial tracheitis, and laryngotracheobronchopneumonitis). In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.254.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/3\">",
"      Peltola V, Heikkinen T, Ruuskanen O. Clinical courses of croup caused by influenza and parainfluenza viruses. Pediatr Infect Dis J 2002; 21:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/4\">",
"      Counihan ME, Shay DK, Holman RC, et al. Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States. Pediatr Infect Dis J 2001; 20:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/5\">",
"      Rihkanen H, R&ouml;nkk&ouml; E, Nieminen T, et al. Respiratory viruses in laryngeal croup of young children. J Pediatr 2008; 152:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/6\">",
"      Weinberg GA, Hall CB, Iwane MK, et al. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr 2009; 154:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/7\">",
"      Kuypers J, Martin ET, Heugel J, et al. Clinical disease in children associated with newly described coronavirus subtypes. Pediatrics 2007; 119:e70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/8\">",
"      Sung JY, Lee HJ, Eun BW, et al. Role of human coronavirus NL63 in hospitalized children with croup. Pediatr Infect Dis J 2010; 29:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/9\">",
"      van der Hoek L, Sure K, Ihorst G, et al. Croup is associated with the novel coronavirus NL63. PLoS Med 2005; 2:e240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/10\">",
"      D&oslash;llner H, Risnes K, Radtke A, Nordb&oslash; SA. Outbreak of human metapneumovirus infection in norwegian children. Pediatr Infect Dis J 2004; 23:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/11\">",
"      Bjornson CL, Johnson DW. Croup. Lancet 2008; 371:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/12\">",
"      Segal AO, Crighton EJ, Moineddin R, et al. Croup hospitalizations in Ontario: a 14-year time-series analysis. Pediatrics 2005; 116:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/13\">",
"      Rosychuk RJ, Klassen TP, Metes D, et al. Croup presentations to emergency departments in Alberta, Canada: a large population-based study. Pediatr Pulmonol 2010; 45:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/14\">",
"      Pruikkonen H, Dunder T, Renko M, et al. Risk factors for croup in children with recurrent respiratory infections: a case-control study. Paediatr Perinat Epidemiol 2009; 23:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/15\">",
"      Salzman MB, Filler HF, Schechter CB. Passive smoking and croup. Arch Otolaryngol Head Neck Surg 1987; 113:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/16\">",
"      Marx A, T&ouml;r&ouml;k TJ, Holman RC, et al. Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics. J Infect Dis 1997; 176:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/17\">",
"      DAVISON FW. Acute laryngeal obstruction in children. J Am Med Assoc 1959; 171:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/18\">",
"      Davison FW. Acute obstructive laryngitis in children. Penn Med J 1950; 53:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/19\">",
"      Szpunar J, Glowacki J, Laskowski A, Miszke A. Fibrinous laryngotracheobronchitis in children. Arch Otolaryngol 1971; 93:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/20\">",
"      Morgan EA, Wishart DE. LARYNGO-TRACHEO-BRONCHITIS : (A statistical review of 549 cases). Can Med Assoc J 1947; 56:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/21\">",
"      Orton HB, Smith EL, Bell HO, et al. Acute laryngotracheobronchitis: analysis of sixty-two cases with report of autopsies in eight cases. Arch Otolaryngol 1941; 33:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/22\">",
"      Richards L. A further study of the pathology of acute laryngo-tracheobronchitis in children. Ann Otol Rhinol Laryngol 1938; 47:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/23\">",
"      Hide DW, Guyer BM. Recurrent croup. Arch Dis Child 1985; 60:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/24\">",
"      Van Bever HP, Wieringa MH, Weyler JJ, et al. Croup and recurrent croup: their association with asthma and allergy. An epidemiological study on 5-8-year-old children. Eur J Pediatr 1999; 158:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/25\">",
"      Gilger MA. Pediatric otolaryngologic manifestations of gastroesophageal reflux disease. Curr Gastroenterol Rep 2003; 5:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/26\">",
"      Welliver RC, Sun M, Rinaldo D. Defective regulation of immune responses in croup due to parainfluenza virus. Pediatr Res 1985; 19:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/27\">",
"      Welliver RC, Wong DT, Middleton E Jr, et al. Role of parainfluenza virus-specific IgE in pathogenesis of croup and wheezing subsequent to infection. J Pediatr 1982; 101:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/28\">",
"      Cherry JD. The treatment of croup: continued controversy due to failure of recognition of historic, ecologic, etiologic and clinical perspectives. J Pediatr 1979; 94:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/29\">",
"      Kaditis AG, Wald ER. Viral croup: current diagnosis and treatment. Pediatr Infect Dis J 1998; 17:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/30\">",
"      Mauro RD, Poole SR, Lockhart CH. Differentiation of epiglottitis from laryngotracheitis in the child with stridor. Am J Dis Child 1988; 142:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/31\">",
"      Kasian GF, Bingham WT, Steinberg J, et al. Bacterial tracheitis in children. CMAJ 1989; 140:46.",
"     </a>",
"    </li>",
"    <li>",
"     Alberta Clinical Practice Guidelines Guideline Working Group. Guidelines for the diagnosis and management of croup file://www.topalbertadoctors.org/informed_practice/cpgs/croup.html (Accessed on February 22, 2011).",
"    </li>",
"    <li>",
"     Fleisher G. Infectious disease emergencies. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.783.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/34\">",
"      Tibballs J, Watson T. Symptoms and signs differentiating croup and epiglottitis. J Paediatr Child Health 2011; 47:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/35\">",
"      Diaz JH, Lockhart CH. Early diagnosis and airway management of acute epiglottitis in children. South Med J 1982; 75:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/36\">",
"      Westley CR, Cotton EK, Brooks JG. Nebulized racemic epinephrine by IPPB for the treatment of croup: a double-blind study. Am J Dis Child 1978; 132:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/37\">",
"      Mills JL, Spackman TJ, Borns P, et al. The usefulness of lateral neck roentgenograms in laryngotracheobronchitis. Am J Dis Child 1979; 133:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/38\">",
"      Bernstein T, Brilli R, Jacobs B. Is bacterial tracheitis changing? A 14-month experience in a pediatric intensive care unit. Clin Infect Dis 1998; 27:458.",
"     </a>",
"    </li>",
"    <li>",
"     Cherry JD. Newer respiratory viruses: their role in respiratory illnesses of children. In: Advances in Pediatrics, Vol 20, Schulman I (Ed), Mosby Year Book, Chicago 1973. p.225.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/40\">",
"      Denny FW, Clyde WA Jr. Acute lower respiratory tract infections in nonhospitalized children. J Pediatr 1986; 108:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/41\">",
"      Henrickson KJ, Hoover S, Kehl KS, Hua W. National disease burden of respiratory viruses detected in children by polymerase chain reaction. Pediatr Infect Dis J 2004; 23:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/42\">",
"      Lin CY, Chi H, Shih SL, et al. A 4-year-old boy presenting with recurrent croup. Eur J Pediatr 2010; 169:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43529/abstract/43\">",
"      Hsia SH, Lin JJ, Wu CT, et al. Guillain-Barr&eacute; syndrome presenting as mimicking croup. Am J Emerg Med 2010; 28:749.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6002 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-E03BC582ED-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_32_43529=[""].join("\n");
var outline_f42_32_43529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Host factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laryngotracheitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Spasmodic croup",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Bacterial tracheitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Recurrent croup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Rapid assessment and initial management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Severity assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Blood tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Microbiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Clinical diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Etiologic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6002\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6002|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/56/2959\" title=\"diagnostic image 1\">",
"      Steeple sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/59/42943\" title=\"diagnostic image 2\">",
"      Croup lateral neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?22/26/22958\" title=\"diagnostic image 3\">",
"      Epiglottitis x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/50/34606\" title=\"diagnostic image 4\">",
"      Bacterial tracheitis x-ray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6002|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/55/17264\" title=\"picture 1\">",
"      Bacterial tracheitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/54/26465\" title=\"picture 2A\">",
"      Epiglottitis tripod posture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/0/8197\" title=\"picture 2B\">",
"      Epiglottitis classic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=related_link\">",
"      An overview of angioedema: Clinical features, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/26/31144?source=related_link\">",
"      Approach to the management of croup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21464?source=related_link\">",
"      Assessment of stridor in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32536?source=related_link\">",
"      Bacterial tracheitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24346?source=related_link\">",
"      Clinical features and diagnosis of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43192?source=related_link\">",
"      Clinical presentation and diagnosis of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/42/37543?source=related_link\">",
"      Congenital anomalies of the larynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41176?source=related_link\">",
"      Coronaviruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/40/37513?source=related_link\">",
"      Diagnosis and treatment of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11046?source=related_link\">",
"      Diagnosis and treatment of diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29287?source=related_link\">",
"      Epidemiology, pathophysiology and clinical manifestations of diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/29/44505?source=related_link\">",
"      Etiology and management of hoarseness in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4102?source=related_link\">",
"      Evaluation of the child with hoarseness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/22/1386?source=related_link\">",
"      Foreign bodies of the esophagus and gastrointestinal tract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/33/33304?source=related_link\">",
"      Human metapneumovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27705?source=related_link\">",
"      Overview of Guillain-Barr&eacute; syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36808?source=related_link\">",
"      Parainfluenza viruses in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/63/32754?source=related_link\">",
"      Patient information: Croup (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/28/2500?source=related_link\">",
"      Patient information: Croup in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/61/31705?source=related_link\">",
"      Peritonsillar cellulitis and abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31928?source=related_link\">",
"      Pharmacologic and supportive interventions for croup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7050?source=related_link\">",
"      Respiratory syncytial virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=related_link\">",
"      Retropharyngeal infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/4/5194?source=related_link\">",
"      Secondhand smoke exposure: Effects in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_32_43530="Neurologic complications of non-platinum cancer chemotherapy";
var content_f42_32_43530=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurologic complications of non-platinum cancer chemotherapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/32/43530/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43530/contributors\">",
"     Eudocia Quant Lee, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43530/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/32/43530/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43530/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43530/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/32/43530/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/32/43530/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/32/43530/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complications of anticancer therapy may result from direct toxic effects on the nervous system or indirectly from drug-induced metabolic derangements or cerebrovascular disorders. A wide range of neurologic complications is associated with antineoplastic drug treatment (",
"    <a class=\"graphic graphic_table graphicRef55758 \" href=\"mobipreview.htm?35/9/35998\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recognition of neurologic complication of anticancer therapy is important because of potential confusion with metastatic disease, paraneoplastic syndromes, or comorbid neurologic disorders that do not require dose reduction or discontinuation. If the neurologic disorder is caused by the chemotherapy, discontinuation of the offending agent may prevent irreversible injury.",
"   </p>",
"   <p>",
"    The presence of a preexisting neuropathy may be a risk factor for developing severe neurotoxicity with agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    , or taxanes. Compelling case reports describe severe neuropathy following single doses of potentially neurotoxic chemotherapeutic agents in patients with underlying neuropathic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/5\">",
"     5",
"    </a>",
"    ], including Charcot-Marie-Tooth, whether clinical or subclinical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/6\">",
"     6",
"    </a>",
"    ], other hereditary neuropathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], and recovered poliomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/9\">",
"     9",
"    </a>",
"    ]. Whether diabetes with or without neuropathy or idiopathic peripheral neuropathy are significant risk factors remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic makeup may also be a significant risk factor for the development of neurotoxicity in patients receiving cancer therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Although the available data are not sufficiently conclusive to allow any molecular genetic test to be used in the clinic to predict neurotoxicity, they provide promise for future individualization of cancer chemotherapy with respect to both efficacy and toxicity.",
"   </p>",
"   <p>",
"    The neurotoxicity of cytotoxic chemotherapy agents will be reviewed here. The neurologic complications of the platinum compounds (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ), biological response modifiers, and monoclonal antibodies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=see_link\">",
"     \"Neurologic complications of platinum-based chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43064?source=see_link\">",
"     \"Neurologic complications of cancer treatment with biologic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     METHOTREXATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    (MTX), a dihydrofolate reductase inhibitor, is used systemically for a wide range of cancers, both in conventional doses and in high doses with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue. It is also administered intrathecally to treat leptomeningeal metastases and for prophylaxis in hematologic malignancies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=see_link\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;MTX neurotoxicity can be manifested in several different ways: aseptic meningitis, transverse myelopathy, acute and subacute encephalopathy, and leukoencephalopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Aseptic meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aseptic meningitis is typically seen following intrathecal (IT) administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and is indistinguishable clinically from other types of aseptic meningitis. Characteristic symptoms include headache, nuchal rigidity, back pain, nausea, vomiting, fever, and lethargy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/3/15417?source=see_link\">",
"     \"Aseptic meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aseptic meningitis is the most common neurotoxic effect of IT MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Approximately 10 percent of patients are affected, but incidence rates as high as 50 percent have been reported. Symptoms of aseptic meningitis usually begin two to four hours after the drug is injected (in contradistinction to an iatrogenic bacterial meningitis from a contaminated product that takes hours to days to develop), and they may last for 12 to 72 hours. Cerebrospinal fluid (CSF) analysis usually demonstrates a pleocytosis with an elevated protein content, but cultures are negative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/10/17576?source=see_link\">",
"     \"Cerebrospinal fluid: Physiology and utility of an examination in disease states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms are usually self-limited, and treatment is usually not required. Aseptic meningitis can be prevented to some extent by coadministering MTX with IT",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    or oral corticosteroids. Some patients who develop aseptic meningitis can be subsequently retreated with MTX without problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Transverse myelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transverse myelopathy is an uncommon complication of IT MTX manifested by the development of isolated spinal cord dysfunction over hours to days in the absence of a compressive lesion. Transverse myelopathy is associated with IT MTX and is generally seen in patients receiving concurrent radiotherapy (RT) or frequent IT injections of MTX. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/1/7190?source=see_link\">",
"     \"Complications of spinal cord irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Affected patients typically develop back or leg pain followed by paraplegia, sensory loss, and sphincter dysfunction. The onset is usually between 30 minutes and 48 hours after treatment but can occur up to two weeks later. Although the majority of cases show clinical improvement, the extent of recovery is variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/15\">",
"     15",
"    </a>",
"    ]. Further administration of IT MTX is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Acute and subacute encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute neurotoxicity is most frequently seen after high-dose MTX and is characterized by somnolence, confusion, and seizures within 24 hours of treatment. Symptoms usually resolve spontaneously without sequelae, and retreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is often possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/1,13,16\">",
"     1,13,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weekly or biweekly administration of high-dose MTX may produce a subacute \"stroke-like\" syndrome, characterized by transient focal neurologic deficits, confusion, and occasionally seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/17\">",
"     17",
"    </a>",
"    ]. Symptoms develop approximately six days after drug administration, last from 15 minutes to 72 hours, and then resolve spontaneously without sequelae. Neuroimaging studies are usually normal, although changes have been described on MRI, including areas of restricted diffusion on diffusion-weighted imaging, and non-enhancing T2 hyperintense lesions in the white matter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. CSF analysis is usually normal, but the electroencephalogram (EEG) may show diffuse slowing, and diffusion-weighted images may be abnormal.",
"   </p>",
"   <p>",
"    The pathogenesis is unclear, although several hypotheses have been proposed, including homocysteine toxicity and altered folate homeostasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Subsequent administration of high-dose MTX may be accomplished without recurrent subacute encephalopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=see_link\">",
"     \"Clinical neurophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Leukoencephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major delayed complication of MTX is leukoencephalopathy, which is dependent upon dose and route of administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/13,22,23\">",
"     13,22,23",
"    </a>",
"    ]. Although this syndrome may be produced by MTX alone, it is more common in the setting of concurrent or past RT.",
"   </p>",
"   <p>",
"    The mechanism of MTX-related leukoencephalopathy is unknown; it is possible that cranial irradiation either potentiates the toxic effects of MTX or disrupts the blood-brain barrier, allowing high concentrations of MTX to reach the brain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link&amp;anchor=H15#H15\">",
"     \"Complications of cranial irradiation\", section on 'Late reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristic feature of leukoencephalopathy is a gradual impairment of cognitive function months to years following treatment with MTX. Clinical manifestations range from mild learning disability to severe progressive dementia accompanied by somnolence, seizures, ataxia, and hemiparesis.",
"   </p>",
"   <p>",
"    The clinical course is also variable. Many patients stabilize or improve following discontinuation of MTX, but the course is progressive in others. Disseminated necrotizing leukoencephalopathy, a rare manifestation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    leukoencephalopathy, is irreversible and may be fatal. No effective treatment is available.",
"   </p>",
"   <p>",
"    The diagnosis is supported by cranial computed tomography (CT) and magnetic resonance imaging (MRI), which typically show cerebral atrophy and diffuse white matter lesions. On CT, these are characteristically hypodense nonenhancing lesions, while on MRI, areas of high signal intensity are noted on T2-weighted images. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26681?source=see_link&amp;anchor=H60052309#H60052309\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\", section on 'Neuroimaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dose and route of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manifestations of MTX neurotoxicity are largely determined by its dose and route of administration:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     High-dose systemic MTX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of high doses of intravenous MTX (&ge;1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    permits high drug concentrations to be achieved within the CNS, which can be useful in the treatment of some types of leukemia, primary CNS lymphoma, and neoplastic meningitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37914?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and prognosis of primary central nervous system lymphoma\", section on 'Methotrexate-based induction chemotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=see_link\">",
"     \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=see_link\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic high-dose MTX can cause acute, subacute, or chronic neurotoxicity. The risk of neurotoxicity may be altered by drug excretion (which is related to renal function, hydration, and urinary alkalinization), the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue, coadministration of other antineoplastic agents, and pharmacogenetic factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=see_link\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=see_link\">",
"     \"Overview of pharmacogenomics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     IT MTX",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, IT MTX is commonly associated with aseptic meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In addition, IT administration is rarely associated with posterior reversible leukoencephalopathy syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/25\">",
"     25",
"    </a>",
"    ], seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/26\">",
"     26",
"    </a>",
"    ], subacute focal neurologic deficits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/27\">",
"     27",
"    </a>",
"    ], lumbosacral polyradiculopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/28-30\">",
"     28-30",
"    </a>",
"    ], noncardiogenic pulmonary edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/31\">",
"     31",
"    </a>",
"    ], pneumonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/32\">",
"     32",
"    </a>",
"    ], and sudden death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/1,2,31,33\">",
"     1,2,31,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leukoencephalopathy is a delayed complication of IT MTX, usually occurring after six months of therapy and when the cumulative IT dose of MTX exceeds 140 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/33\">",
"     33",
"    </a>",
"    ]. It is more likely in patients who receive concurrent whole brain radiotherapy or have previously received chemotherapy with intravenous MTX.",
"   </p>",
"   <p>",
"    The administration of intraventricular MTX through an Ommaya reservoir can cause leukoencephalopathy even at conventional doses if there is a block to egress of the drug from the ventricular system. Therefore, flow studies to assure normal CSF flow in patients with leptomeningeal metastases are important. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\", section on 'Pretreatment CSF flow study'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Management of accidental overdose of IT MTX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant overdosage with IT MTX, particularly a dose &gt;500 mg compared to the usual dose of 10 or 12 mg, must be treated vigorously since it can lead to acute myelopathy, encephalopathy, seizures and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients with such overdoses are treated with the combination of intrathecal administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"     glucarpidase",
"    </a>",
"    (carboxypeptidase G2, CPDG2) to metabolize the MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], rapid CSF drainage by lumbar puncture, CSF exchange, ventriculolumbar perfusion to reduce the amount of MTX in the CSF, systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue (using either the d,l-racemic mixture of leucovorin or l-leucovorin [",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/63/14326?source=see_link\">",
"     LEVOleucovorin",
"    </a>",
"    ], the biologically active isomer), plus alkaline diuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/2,36-38\">",
"     2,36-38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=see_link&amp;anchor=H8#H8\">",
"     \"Enhanced elimination of poisons\", section on 'Urinary alkalinization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The success of these approaches can be illustrated by a report of seven patients who accidentally received 155 to 600 mg of IT MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/36\">",
"     36",
"    </a>",
"    ]. Symptoms included seizures, coma, severe cardiopulmonary compromise, confusion, tachycardia, hypertension, severe headache, intense back pain, and nausea and vomiting. All were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"     glucarpidase",
"    </a>",
"    (2000 units reconstituted in 12 mL of normal saline), administered intrathecally over a period of five minutes immediately after reconstitution. In addition, all received concurrent IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (100 mg every six hours for four doses) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (4 mg every six hours for four doses). In four of the seven patients, a ventricular catheter was inserted and ventriculolumbar perfusion was performed to remove MTX via CSF exchange. CSF concentrations of MTX were reduced by 99 percent in all patients, with the levels being lowest in those who received both glucarpidase and CSF exchange. All patients recovered, although two suffered memory loss.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"     Glucarpidase",
"    </a>",
"    for IT use is not available commercially. In the United States, glucarpidase for IT administration is available free of charge from its manufacturer, BTG International, through a compassionate-use protocol that has been approved by the US Food and Drug Administration (FDA) and that requires a single patient IND [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/39\">",
"     39",
"    </a>",
"    ]. The emergency use procedure is outlined at the",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm107434.htm\">",
"     FDA",
"    </a>",
"    website. For clinicians in the US, inquiries and supply details can also be directed to the manufacturer (BTG International) during regular business hours (Monday through Friday, 1-888-327-1027); or the FDA may be contacted directly at any time (301-796-2320, workday phone; or 301-796-9848, fax; or 301-443-1240, after hours telephone) to obtain an emergency IND number. Because of the emergency nature of the situation, the FDA may authorize shipment of the drug in advance of the submission of the IND. For US FDA emergency, use IND information and procedures, refer to the",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm107434.htm\">",
"     FDA",
"    </a>",
"    website.",
"   </p>",
"   <p>",
"    Outside of the United States, the contact number to obtain IT",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"     glucarpidase",
"    </a>",
"    differs according to country and is provided on the BTG International website [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/39\">",
"     39",
"    </a>",
"    ]. The drug is usually shipped overnight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TAXANES",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     Paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    are important antimicrotubule agents that are used to treat a variety of tumors. Both are frequently associated with sensory neuropathy (",
"    <a class=\"graphic graphic_table graphicRef67516 \" href=\"mobipreview.htm?34/34/35373\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Motor neuropathy is uncommon, and if it is significant, should prompt investigation of another possible cause. The peripheral neuropathy associated with taxanes may sometimes be confused with those of hand-foot syndrome (acral erythema). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link&amp;anchor=H23#H23\">",
"     \"Cutaneous complications of conventional chemotherapy agents\", section on 'Acral erythema (hand-foot skin reaction)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Paclitaxel",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Manifestations and incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common neuropathy caused by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    involves sensory nerve fibers. The major manifestations are burning paresthesias of the hands and feet and loss of reflexes. The frequency and time to onset are dose-dependent. In patients treated with higher doses (&ge;250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    symptoms may develop after the first cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     Paclitaxel",
"    </a>",
"    also causes a motor neuropathy, which predominantly affects proximal muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/40\">",
"     40",
"    </a>",
"    ]. The incidence of grade 3 or 4 motor neuropathy (",
"    <a class=\"graphic graphic_table graphicRef78736 \" href=\"mobipreview.htm?11/35/11836\">",
"     table 3",
"    </a>",
"    ) is between 0 and 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other, less common manifestations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    neurotoxicity include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Perioral numbness",
"     </li>",
"     <li>",
"      Autonomic neuropathies (rare) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"      -associated acute pain syndrome, which is characterized by severe arthralgias and myalgias accompanied by numbness and tingling, beginning within one to two days after treatment and lasting a median of four to five days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/43-45\">",
"       43-45",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Seizures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/46\">",
"       46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Transient encephalopathies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Phantom limb pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The neuropathies caused by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    often do not progress even if treatment is continued, and there are reports of symptomatic improvement despite continued therapy. After completing treatment, approximately one-half of patients improve over a period of months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neurotoxicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    is synergistic with that of concomitant platinum administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=see_link\">",
"     \"Neurologic complications of platinum-based chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link&amp;anchor=H250842535#H250842535\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Platinum and taxane combination therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is substantial interindividual variability in prevalence, severity, and onset of peripheral neuropathy related to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , and there is some suggestion that inherited polymorphisms in some genes, including FGD4, a congenital peripheral neuropathy gene associated with Charcot-Marie-Tooth disease, may contribute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/59/35770?source=see_link&amp;anchor=H14#H14\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\", section on 'CMT 4'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Dose and schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of sensory neuropathy is proportional to dose. Grade 3 or 4 sensory neurotoxicity (",
"    <a class=\"graphic graphic_table graphicRef78736 \" href=\"mobipreview.htm?11/35/11836\">",
"     table 3",
"    </a>",
"    ) occurs in 20 to 35 percent of patients receiving 250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks compared to 5 to 12 percent in large series using doses &le;200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The time to onset was illustrated in a phase III trial of patients with metastatic breast cancer treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (135 or 175",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    every three weeks; the mean total dose at the onset of grade 2 neurotoxicity was 715",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    is less myelosuppressive than an every three-week schedule, thereby allowing increased dose intensity. However, the weekly schedule is associated with worse neurotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/53\">",
"     53",
"    </a>",
"    ]. This was illustrated in two separate phase III randomized trials in which women with breast cancer were randomly assigned to paclitaxel weekly (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    or every three weeks (175",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. In one study of women with metastatic breast cancer, grade 3 neuropathy (",
"    <a class=\"graphic graphic_table graphicRef78736 \" href=\"mobipreview.htm?11/35/11836\">",
"     table 3",
"    </a>",
"    ) occurred significantly more often with the weekly regimen (24 versus 12 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/54\">",
"     54",
"    </a>",
"    ]. In another study comparing weekly versus every three week paclitaxel dosing for the adjuvant treatment of breast cancer following standard",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , grade 2, 3, or 4 neuropathy (",
"    <a class=\"graphic graphic_table graphicRef78736 \" href=\"mobipreview.htm?11/35/11836\">",
"     table 3",
"    </a>",
"    ) occurred more frequently with weekly paclitaxel (27 percent versus 20 percent with treatment every three weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of infusion duration on the incidence of severe neurotoxicity is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/41\">",
"     41",
"    </a>",
"    ]. Extending the duration of infusion from 3 to 24 hours has given conflicting results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial in women with metastatic breast cancer treated with 250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      the longer infusion was associated with a lower incidence of severe chronic neurotoxicity (13 versus 22 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/56\">",
"       56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In contrast, in women with ovarian cancer treated with a lower dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (135 or 175",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      no significant differences were observed between infusion rates of 3 versus 24 hours (0.6 versus 0.7 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, at least some data suggest that the incidence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -associated acute pain syndrome (arthralgias and myalgias with numbness and tingling two to three days after chemotherapy) is higher with 3 versus 96 hour infusion duration (25 versus 2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Nab-paclitaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical experience with the nanoparticle albumin bound nanoparticle formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (nab-paclitaxel, Abraxane&reg;) is more limited. Although the overall toxicity profile is better as compared to conventional paclitaxel, the incidence of transient sensory neurotoxicity may be slightly higher, as illustrated by a phase III randomized trial comparing nab-paclitaxel 260",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks to standard paclitaxel 175",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/58\">",
"     58",
"    </a>",
"    ]. Nab-paclitaxel was associated with a higher rate of grade 3 sensory neuropathy (10 percent versus 2 percent in the standard paclitaxel) (",
"    <a class=\"graphic graphic_table graphicRef78736 \" href=\"mobipreview.htm?11/35/11836\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/58\">",
"     58",
"    </a>",
"    ]. However, the dose of paclitaxel was 49 percent higher in the nab-paclitaxel arm, a fact that could easily have accounted for the higher frequency of neuropathy.",
"   </p>",
"   <p>",
"    On the other hand, the incidence of sensory neurotoxicity may be similar with nab-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    . This was demonstrated in a phase II study of women with metastatic breast cancer who were randomly assigned to docetaxel 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks, nab-paclitaxel 300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks, nab-paclitaxel 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly, or nab-paclitaxel 150",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/59\">",
"     59",
"    </a>",
"    ]. The frequency and severity of peripheral neuropathy was similar in all groups, although sensory neuropathy resolved more rapidly in the nab-paclitaxel arms compared to docetaxel. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29528?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: Single agent chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Docetaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     Docetaxel",
"    </a>",
"    causes both sensory and motor neuropathies, although both of these occur less frequently than with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/55\">",
"     55",
"    </a>",
"    ]. Grade 3 or 4 neuropathies (",
"    <a class=\"graphic graphic_table graphicRef78736 \" href=\"mobipreview.htm?11/35/11836\">",
"     table 3",
"    </a>",
"    ) occur in 10 percent or less [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/41,60\">",
"     41,60",
"    </a>",
"    ]. Treatment with docetaxel has been associated with the development of Lhermitte's sign, a nonpainful but unpleasant electric shock-like sensation that shoots down the spine during neck flexion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    neurotoxicity is proportional to the cumulative dose. The time to onset was illustrated in a phase III trial of women with metastatic breast cancer treated with docetaxel (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks); the onset of grade 2 or greater neuropathy (",
"    <a class=\"graphic graphic_table graphicRef78736 \" href=\"mobipreview.htm?11/35/11836\">",
"     table 3",
"    </a>",
"    ) occurred at a median cumulative dose of 371",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of frequency of administration on the incidence of severe neurotoxicity is uncertain; phase III studies randomizing patients to weekly versus every three week",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    have yielded conflicting results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial directly comparing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every three weeks versus 35",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly in patients with metastatic breast cancer, the rate of grade 3 or 4 neuropathy (",
"      <a class=\"graphic graphic_table graphicRef78736 \" href=\"mobipreview.htm?11/35/11836\">",
"       table 3",
"      </a>",
"      ) was higher with every three week therapy (10 versus 5 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, a meta-analysis of all randomized trials comparing the two regimens in patients with advanced non-small cell lung cancer yielded similar rates of grade 3 or 4 neurotoxicity (2.5 versus 3 percent for the every three week, and weekly regimens, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H710933\">",
"    <span class=\"h2\">",
"     Cabazitaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/47/31478?source=see_link\">",
"     Cabazitaxel",
"    </a>",
"    is a semisynthetic taxane that is approved for treatment of advanced prostate cancer. Peripheral neuropathy of any grade is reported in 13 to 17 percent of treated patients, but fewer than 1 percent are severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6280?source=see_link&amp;anchor=H12#H12\">",
"     \"Chemotherapy in castrate-resistant prostate cancer\", section on 'Second-line chemotherapy: cabazitaxel'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment and prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, taxane-induced motor and sensory neuropathies are cumulative and dose and schedule-dependent. Early recognition and subsequent treatment delay or dose reduction can improve symptoms in most cases.",
"   </p>",
"   <p>",
"    Many agents have been evaluated for treatment or prophylaxis of neurotoxicity, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/66-71\">",
"     66-71",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/72\">",
"     72",
"    </a>",
"    ], vitamin E [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/73-75\">",
"     73-75",
"    </a>",
"    ], glutamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/76-80\">",
"     76-80",
"    </a>",
"    ], acetyl-L-carnitine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/81,82\">",
"     81,82",
"    </a>",
"    ], BNP 7877 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/83\">",
"     83",
"    </a>",
"    ], and omega-3 fatty acids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/84\">",
"     84",
"    </a>",
"    ]. None has an established role for treatment or prophylaxis of taxane-induced neuropathy. Updated guidelines from the American Society of Clinical Oncology for use of chemotherapy and radiotherapy protectants state that the data are insufficient to support the routine use of amifostine for the prevention of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -related neurotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/85\">",
"     85",
"    </a>",
"    ]. Given a preliminary report from a randomized placebo-controlled trial that prophylactic use of acetyl-L-carnitine may actually worsen taxane-related neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/86\">",
"     86",
"    </a>",
"    ], this agent should be avoided. Symptomatic treatment for painful peripheral neuropathy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link&amp;anchor=H18#H18\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Drugs used for neuropathic pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OTHER MICROTUBULE BINDING AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Vincristine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vinca alkaloids are plant-derived cytotoxic agents whose mechanism of action involves antimicrotubule activity. Of the available drugs in this class,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    is the most neurotoxic (",
"    <a class=\"graphic graphic_table graphicRef67516 \" href=\"mobipreview.htm?34/34/35373\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     Vincristine",
"    </a>",
"    is a useful agent for many cancers. The dose-limiting toxicity is an axonal neuropathy resulting from disruption of the microtubules within axons and interference with axonal transport [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. The neuropathy involves both sensory and motor fibers, although small sensory fibers are especially affected.",
"   </p>",
"   <p>",
"    Virtually all patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    have some degree of neuropathy. The clinical features resemble those of other axonal neuropathies such as diabetic neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16934?source=see_link\">",
"     \"Epidemiology and classification of diabetic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The earliest symptoms are usually paresthesias in the fingertips and feet, with or without muscle cramps (",
"    <a class=\"graphic graphic_table graphicRef67516 \" href=\"mobipreview.htm?34/34/35373\">",
"     table 2",
"    </a>",
"    ). These symptoms often develop after several weeks of treatment, but they may occur after the first dose. Furthermore, symptoms may appear even after the drug has been discontinued and progress for several months before improving [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initially, objective sensory findings tend to be relatively minor compared to the subjective complaints, but loss of ankle jerks is common. Occasionally there may be profound weakness, with bilateral foot drop, wrist drop, and loss of all sensory modalities. Neurophysiologic studies are compatible with a primarily axonal neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe neuropathies are particularly likely to develop in older or cachectic patients, those who have received prior irradiation to the peripheral nerves or concomitant hematopoietic colony-stimulating factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/91\">",
"     91",
"    </a>",
"    ], concurrent use of azole antifungal agents, and other inhibitors of CYP 3A4 drug metabolizing enzyme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/92,93\">",
"     92,93",
"    </a>",
"    ], those who have preexisting neurologic conditions such as Charcot-Marie Tooth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/94,95\">",
"     94,95",
"    </a>",
"    ], and with the use of high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/2/8231?source=see_link\">",
"     liposomal vincristine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/96\">",
"     96",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/59/35770?source=see_link\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38437?source=see_link\">",
"     \"Complications of peripheral nerve irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=see_link&amp;anchor=H33#H33\">",
"     \"Pharmacology of azoles\", section on 'Major drug interactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21753?source=see_link&amp;anchor=H2914156#H2914156\">",
"     \"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults\", section on 'Liposomal vincristine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Autonomic neuropathies can also develop in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    . Colicky abdominal pain and constipation occur in almost 50 percent of patients, and rarely, a paralytic ileus may result [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/88\">",
"     88",
"    </a>",
"    ]. Less commonly, patients may develop impotence, postural hypotension, or an atonic bladder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link&amp;anchor=H37#H37\">",
"     \"Enterotoxicity of chemotherapeutic agents\", section on 'Vinca alkaloids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     Vincristine",
"    </a>",
"    may also cause focal mononeuropathies, sometimes involving the cranial nerves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/1,97\">",
"     1,97",
"    </a>",
"    ]; the most commonly involved is the oculomotor nerve. Other nerves that may be involved include recurrent laryngeal nerve, optic nerve, facial nerve, and auditory nerve. Vincristine may also cause retinal damage and night blindness, and some patients may experience jaw and parotid pain during treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36856?source=see_link\">",
"     \"Third cranial nerve (oculomotor nerve) palsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    may cause SIADH, resulting in hyponatremia, confusion, and seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/98\">",
"     98",
"    </a>",
"    ]. Other rare CNS complications that are unrelated to SIADH include seizures, encephalopathy, transient cortical blindness, ataxia, athetosis (slow, writhing movements of the limbs), and parkinsonism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\", section on 'Drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Treatment and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;While there are anecdotal reports that glutamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/99\">",
"     99",
"    </a>",
"    ] or pyridoxine plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/100\">",
"     100",
"    </a>",
"    ] may help some patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    neuropathy, benefit has not been proven for any intervention in a randomized, controlled trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/97\">",
"     97",
"    </a>",
"    ]. Such a trial of glutamine for the treatment of vincristine-induced neuropathy is ongoing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with mild neuropathy can usually continue to receive full doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , but when symptoms increase in severity and interfere with neurologic function, dose reduction or discontinuation of the drug may be necessary. The natural history following discontinuation of treatment is gradual improvement, which may take up to several months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/88\">",
"     88",
"    </a>",
"    ]. Children tend to recover more quickly than adults.",
"   </p>",
"   <p>",
"    Because of the high incidence of constipation, patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    should take prophylactic stool softeners",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laxatives.",
"   </p>",
"   <p>",
"    At least two trials have addressed the use of prophylactic glutamic acid in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first trial, 87 patients with breast cancer receiving weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      were randomly assigned to glutamic acid (500 mg three times a day during the entire six weeks of treatment) versus placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/103\">",
"       103",
"      </a>",
"      ]. Patients receiving glutamic acid developed significantly fewer moderate to severe subjective paresthesias (19 versus 36 percent), and there were fewer patients who lost the Achilles tendon reflex during treatment (19 versus 42 percent). There was also less clinician-assessed neurotoxicity (as determined by a neurotoxicity score derived by adding the grade of each neurotoxic parameter for the weekly clinic visit in which maximum neurotoxicity occurred); score &ge;6 in 21 versus 43 percent of the glutamic acid and placebo groups, respectively.",
"      <br/>",
"      <br/>",
"      However, there were no significant differences in the rates of constipation, or loss of other deep tendon reflexes. Long-term neurotoxicity was not addressed. Although differences between the groups in need for dose reduction due to neurotoxicity were not specified, there was a trend toward more patients achieving 100 percent of the adjusted ideal dosage of vincristine with glutamic acid (58 versus 41 percent, p = 0.11).",
"     </li>",
"     <li>",
"      In the second trial, 94 children receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      for a childhood malignancy were randomly assigned to glutamic acid (500 mg three times daily for the four weeks during induction therapy with vincristine) versus placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/102\">",
"       102",
"      </a>",
"      ]. The rate of loss of both the Achilles and patellar deep tendon reflexes was significantly lower in the glutamic acid group during weeks 3 and 4 (at week 4, loss of Achilles tendon reflex in 0 versus 10 percent); the difference in paresthesias was statistically significant only at week 4 (mild or moderate paresthesias in 7.4 and 1.9 percent of the glutamate group versus 20 and 7.5 percent of the placebo group). There were no significant differences in overall constipation, although by week 4, the number of patients with severe constipation was 0 versus 10 percent in the placebo group. As with the earlier study, differences in the need for dose reduction due to treatment-related neurotoxicity and long-term outcomes were not addressed,",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these results suggest some benefit for prophylactic use of glutamic acid, it is modest, and whether this translates to improved long-term neurologic outcomes or better disease control because of fewer patients requiring dose reduction is unclear.",
"   </p>",
"   <p>",
"    Symptomatic treatment for painful peripheral neuropathy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link&amp;anchor=H18#H18\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Drugs used for neuropathic pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other vinca alkaloids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The related vinca alkaloids",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31123?source=see_link\">",
"     vindesine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    tend to be associated with less neurotoxicity, possibly related to differences in lipid solubility, plasma clearance, and sensitivity of axoplasmic transport (",
"    <a class=\"graphic graphic_table graphicRef67516 \" href=\"mobipreview.htm?34/34/35373\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/1,97\">",
"     1,97",
"    </a>",
"    ]. Vinblastine is a useful agent for Hodgkin lymphoma, and vinorelbine, a semisynthetic analogue of vinblastine, is used for breast and lung cancer. Like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , vinblastine and vinorelbine inhibit microtubule assembly, but they have less affinity for neural tissue and are less neurotoxic as a result. Vinorelbine is associated with mild paresthesias in only about 20 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/104\">",
"     104",
"    </a>",
"    ], and severe neuropathy is rare, occurring most often in patients with prior",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/105,106\">",
"     105,106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Ixabepilone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10423?source=see_link\">",
"     Ixabepilone",
"    </a>",
"    is a microtubule inhibitor in the epothilone class. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29528?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: Single agent chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The neuropathy associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10423?source=see_link\">",
"     ixabepilone",
"    </a>",
"    is a dose-dependent predominantly sensory distal peripheral neuropathy although motor (and rarely autonomic) neuropathies have also been reported (",
"    <a class=\"graphic graphic_table graphicRef67516 \" href=\"mobipreview.htm?34/34/35373\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/107\">",
"     107",
"    </a>",
"    ] Overall, up to 88 percent of patients exposed to ixabepilone manifest a sensory neuropathy of any grade, while the incidence of grade 3 or 4 sensory neurotoxicity is between 6 and 24 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/107\">",
"     107",
"    </a>",
"    ]. In a randomized phase III clinical trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    with or without ixabepilone for metastatic breast cancer, the rate of grade 3 or 4 sensory neuropathy (",
"    <a class=\"graphic graphic_table graphicRef78736 \" href=\"mobipreview.htm?11/35/11836\">",
"     table 3",
"    </a>",
"    ) was 21 percent with combination therapy (versus zero with capecitabine alone) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/108\">",
"     108",
"    </a>",
"    ]. Neurotoxicity was cumulative, and the median time to onset of grade 3 or 4 peripheral neuropathy was four cycles. Symptoms were reversible and typically resolved within six weeks after dose reduction.",
"   </p>",
"   <p>",
"    A 20 percent decrease in dose is recommended for patients with grade 2 neuropathy persisting more than seven days or grade 3 neuropathy of less than seven days duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/109\">",
"     109",
"    </a>",
"    ]. More severe or persistent neuropathy should result in discontinuation of therapy. Special care is warranted in patients with diabetes or preexisting neuropathy, because of the increased risk of severe neuropathy.",
"   </p>",
"   <p>",
"    Symptomatic treatment for painful peripheral neuropathy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link&amp;anchor=H18#H18\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Drugs used for neuropathic pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30392699\">",
"    <span class=\"h2\">",
"     Eribulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/42/28325?source=see_link\">",
"     Eribulin",
"    </a>",
"    mesylate, a synthetic analogue of halichondrin B, a substance derived from a marine sponge, inhibits the polymerization of tubulin and microtubules. In a randomized trial in patients with metastatic breast cancer, peripheral neuropathy (sensory or motor neuropathy, polyneuropathy, or paresthesias) developed in 35 percent of the 508 patients who were randomly assigned to eribulin; it was severe (grade 3 or 4) in 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. Neuropathy was the most common drug toxicity leading to treatment discontinuation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     THALIDOMIDE AND LENALIDOMIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potent antiangiogenic activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    has led to its use in multiple myeloma, other malignancies, and chronic graft-versus-host disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18282?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/1/28698?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/1/34842?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease\", section on 'Thalidomide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    in patients with multiple myeloma reported severe (grade 3 or 4) peripheral neurotoxicity in about one-third of patients who received daily thalidomide doses of &gt;200 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/112\">",
"     112",
"    </a>",
"    ]. With the recognition that effects are dose-dependent and cumulative over time, efforts were made to reduce the dose and duration of thalidomide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/113-118\">",
"     113-118",
"    </a>",
"    ]. With modern treatment protocols (starting dose of thalidomide at 200 mg per day for patients &lt;75 years of age, and 100 mg per day for those 75 and older), peripheral neuropathy develops in approximately 50 percent of patients receiving first-line thalidomide for multiple myeloma, but fewer than 10 percent are severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/119-121\">",
"     119-121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation is typically that of a symmetric distal sensory neuropathy, although motor peripheral neuropathy can complicate treatment in 30 to 40 percent of patients (",
"    <a class=\"graphic graphic_table graphicRef67516 \" href=\"mobipreview.htm?34/34/35373\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/114-116,119,122,123\">",
"     114-116,119,122,123",
"    </a>",
"    ]. Data from nerve conduction studies suggest that the underlying pathophysiology is a dying-back degeneration of sensory and motor nerves, indicative of a toxic axonopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neuropathy is only partially reversible, and is the reason for dose reduction or cessation of treatment in up to 60 percent of patients. Toxicity due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    needs to be distinguished from a neuropathy due to the malignancy (particularly myeloma) or to antecedent chemotherapy with other neurotoxic agents such as the vinca alkaloids.",
"   </p>",
"   <p>",
"    Another common side effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    treatment is somnolence, affecting 43 to 55 percent of patients. The somnolence decreases in many patients after two or three weeks of continued therapy. Constipation is also common, particularly in the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/124\">",
"     124",
"    </a>",
"    ] and has been attributed to an autonomic nerve fiber injury. Other signs of thalidomide-induced autonomic peripheral neuropathy, which may be unrecognized, include impotence and bradycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other reported manifestations of neurotoxicity include a mild to moderate tremor in up to one-third of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/119,123\">",
"     119,123",
"    </a>",
"    ], dizziness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/115\">",
"     115",
"    </a>",
"    ] and rarely, seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/126\">",
"     126",
"    </a>",
"    ] and at least one case of severe encephalopathy with prolonged",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dose reduction guidelines for neuropathy are not provided in the US FDA-approved manufacturer&rsquo;s drug labeling or from the EMA (European Medicines Agency); suggested guidelines have been proposed by a group of European myeloma experts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     Lenalidomide",
"    </a>",
"    , a second-generation",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    derivative with more potent antiangiogenic properties, appears to be substantially less neurotoxic. In a long-term follow-up study of 704 patients enrolled in two multicenter, randomized phase III trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    plus either lenalidomide or placebo for relapsed or refractory multiple myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/129\">",
"     129",
"    </a>",
"    ], the rate of grade 3 peripheral neuropathy (",
"    <a class=\"graphic graphic_table graphicRef78736 \" href=\"mobipreview.htm?11/35/11836\">",
"     table 3",
"    </a>",
"    ) was 1.4 percent among patients treated with lenalidomide versus 0.6 percent in the dexamethasone alone group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     BORTEZOMIB AND CARFILZOMIB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     Bortezomib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"     carfilzomib",
"    </a>",
"    , proteasome inhibitors that are used in the treatment of multiple myeloma, have been associated peripheral neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10517786\">",
"    <span class=\"h2\">",
"     Bortezomib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral nerve damage is one of the most significant nonhematologic toxicities of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    When it occurs, the painful sensory neuropathy can interfere with quality of life and with performance of activities of daily living, and it may require dose modification",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/130-132\">",
"     130-132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment-emergent neuropathy of any grade (ie, developing or worsening neuropathy or pain during treatment) is reported in up to 75 and 60 percent of patients treated with twice weekly therapy for recurrent and newly diagnosed disease, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/130,131,133-137\">",
"     130,131,133-137",
"    </a>",
"    ]. It is severe (grade 3 or 4) in approximately 15 percent of patients treated with the twice weekly schedule. The risk of severe neuropathy appears to be significantly lower (5 percent or less) with once weekly dosing, which appears to be feasible without compromising efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/138-140\">",
"     138-140",
"    </a>",
"    ]. Both the incidence and severity of neurotoxicity appear to be higher in patients with preexisting baseline neuropathy, in those who receive a higher cumulative dose amount during the first five therapy courses, and in heavily pretreated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/130,132\">",
"     130,132",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Bortezomib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The predominant feature is a painful sensory neuropathy with burning dysesthesias of the fingers and toes (",
"    <a class=\"graphic graphic_table graphicRef67516 \" href=\"mobipreview.htm?34/34/35373\">",
"     table 2",
"    </a>",
"    ). Symptoms typically occur after the first few courses of treatment, usually by cycle 5 (corresponding to a cumulative dose of approximately 26",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/130,141,142\">",
"     130,141,142",
"    </a>",
"    ]. The mechanism is thought to be mainly a direct toxic effect on the dorsal root ganglion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/143\">",
"     143",
"    </a>",
"    ], with axonopathy to a lesser extent.",
"   </p>",
"   <p>",
"    Motor neuropathy, consisting of mild to severe distal weakness in the lower extremities, develops in up to 10 percent of patients with the twice weekly schedule, and may be immune-mediated (see below). Gastrointestinal side effects (diarrhea or constipation) and orthostatic hypotension, which complicate therapy in about 10 to 15 percent of patients who receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    , are thought to be mainly caused by autonomic peripheral neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/133,137,144\">",
"     133,137,144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available data suggest a neurotoxic dose threshold rather than a classic cumulative dose effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/128,132\">",
"     128,132",
"    </a>",
"    ]. Treatment discontinuation or dose modification leads to improvement or complete resolution in the majority of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/130,133,142,145\">",
"     130,133,142,145",
"    </a>",
"    ]. A dose adjustment algorithm for patients who develop treatment-related neuropathy is available from the US FDA (",
"    <a class=\"graphic graphic_table graphicRef70033 \" href=\"mobipreview.htm?7/59/8123\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/146\">",
"     146",
"    </a>",
"    ]. In general, the best way to reduce",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    -induced neurotoxicity appears to be the once weekly schedule, with dose reductions as outlined in the table for treatment emergent neuropathy. In a subanalysis of patients who were randomly assigned to bortezomib for treatment of relapsed myeloma in a phase III clinical trial, dose modification using this algorithm improved peripheral neuropathy management without adversely affecting outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/142\">",
"     142",
"    </a>",
"    ]. Of 91 patients with &ge;grade 2 peripheral neuropathy during treatment, 58 (64 percent) experienced improvement or resolution to baseline at a median of 110 days.",
"   </p>",
"   <p>",
"    A slightly different dose reduction algorithm has been proposed by a group of European myeloma experts.",
"   </p>",
"   <p>",
"    Besides dose reduction, there are no known proven methods to prevent treatment-related neuropathy in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    . However, the following observations are pertinent in this regard:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As noted previously, weekly administration (as compared to a standard twice weekly schedule) is associated with a lower incidence of severe neurotoxicity. In a phase III trial comparing two different",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -containing regimens, the risk of grade 3 or 4 neurotoxicity with once as compared to twice weekly therapy was 8 versus 28 percent, and the rate of treatment discontinuation because of peripheral neuropathy was also lower (5 versus 15 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/138,139,147\">",
"       138,139,147",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=see_link&amp;anchor=H16#H16\">",
"       \"Treatment of relapsed or refractory multiple myeloma\", section on 'Bortezomib'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Subcutaneous administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      eliminates the high peak levels of the drug that occur with intravenous use and was associated with a dramatic decrease in neurotoxicity in a preliminary report of a phase III trial reported at the 2010 meeting of the American Society of Hematology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/148\">",
"       148",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A single case report describes symptomatic improvement (neuropathy as well as pain) using twice daily application of topical menthol (0.5 percent in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/11/33969?source=see_link\">",
"       calamine lotion",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/149\">",
"       149",
"      </a>",
"      ], an approach that has been useful for the treatment of postherpetic neuralgia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/150\">",
"       150",
"      </a>",
"      ]. Whether",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      could then be resumed at a lower dose was not addressed.",
"     </li>",
"     <li>",
"      Limited data suggest the possibility that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      may cause an immune-mediated neuropathy with both motor and sensory involvement in addition to the usual neurotoxicity (a predominantly sensory neuropathy) and that this may be responsive to immunotherapy. A single report describes five patients with a peripheral neuropathy associated with severe motor involvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/151\">",
"       151",
"      </a>",
"      ]. Electrodiagnostic studies indicated either a demyelinated or a mixed axonal-demyelinated neuropathy. The protein concentration in the cerebrospinal fluid was elevated, and MRI of the lumbar spine revealed enhancement of nerve roots in two patients. Four of the five patients responded to intravenous immunoglobulin or corticosteroids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptomatic treatment for painful peripheral neuropathy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link&amp;anchor=H18#H18\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Drugs used for neuropathic pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10517793\">",
"    <span class=\"h2\">",
"     Carfilzomib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy appears to be less common and less severe with the second generation proteasome inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"     carfilzomib",
"    </a>",
"    . In phase II studies (in which most of the patients had been previously exposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ), the incidence of treatment-emergent peripheral neuropathy was 12 to 23 percent overall, and it was severe (grade 3 or 4) in &le;1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/152-155\">",
"     152-155",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=see_link&amp;anchor=H22222487#H22222487\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Carfilzomib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     NELARABINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/45/21206?source=see_link\">",
"     Nelarabine",
"    </a>",
"    , a purine analog used for T-cell acute lymphoblastic leukemia, is associated with peripheral neuropathy that can mimic Guillain-Barre syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/3\">",
"     3",
"    </a>",
"    ]. Reduced consciousness, headache and seizures have also been reported. In phase II studies, 40 to 72 percent of patients have had neurotoxicity of any grade attributed to nelarabine, 15 to 20 percent are grade 3 or 4 (",
"    <a class=\"graphic graphic_table graphicRef50359 \" href=\"mobipreview.htm?25/26/26029\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/156-158\">",
"     156-158",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Full recovery has not always occurred with treatment discontinuation. As a result, the FDA-approved labeling information suggests that treatment be discontinued for any neurologic toxicity grade 2 or higher (",
"    <a class=\"graphic graphic_table graphicRef50359 \" href=\"mobipreview.htm?25/26/26029\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     OTHER AGENTS CAUSING NEUROTOXICITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Cytarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     Cytarabine",
"    </a>",
"    (cytosine arabinoside) is a pyrimidine analog that is used for the treatment of leukemias, lymphomas, and intrathecally for neoplastic meningitis. Conventional doses are associated with little neurotoxicity. However, high doses (&ge;3",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every 12 hours) cause an acute cerebellar syndrome in 10 to 25 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/159-162\">",
"     159-162",
"    </a>",
"    ]. Patients over the age of 40 who have abnormal liver or renal function, underlying neurologic dysfunction, or who receive a total dose of &gt;30 g are particularly likely to develop cerebellar toxicity. The pathogenesis of this syndrome is unknown, but there is widespread loss of Purkinje cells in the cerebellum.",
"   </p>",
"   <p>",
"    The characteristic syndrome begins with somnolence and occasionally an encephalopathy that develops two to five days after beginning treatment. Immediately thereafter, cerebellar signs are noted on physical examination. Symptoms range in severity from mild ataxia to an inability to sit or walk unassisted. Rarely, seizures develop.",
"   </p>",
"   <p>",
"    No specific treatment is available, but",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    should be discontinued immediately. In some patients, the syndrome resolves spontaneously, but it is permanent in others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/163\">",
"     163",
"    </a>",
"    ]. Avoidance of very high doses of the drug, especially in patients with renal impairment, has led to a decrease in the incidence of this syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/162\">",
"     162",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    infrequently causes peripheral neuropathies resembling Guillain-Barr&eacute; syndrome, brachial plexopathy, encephalopathy, lateral rectus palsy, optic neuropathy or an extrapyramidal syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/161,164-170\">",
"     161,164-170",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Intrathecal cytarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrathecal (IT) administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    in patients with leptomeningeal metastases produces high drug levels in the CSF for at least 24 hours. Uncommonly, IT cytarabine can cause a transverse myelitis that is similar to that seen with IT MTX (see",
"    <a class=\"local\" href=\"#H10\">",
"     'IT MTX'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/161\">",
"     161",
"    </a>",
"    ]. Rarely, it has been associated with aseptic meningitis, encephalopathy, headaches, and seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Intrathecal liposomal cytarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;IT administration of liposomal (sustained release)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (DepoCyt) maintains cytotoxic concentrations of the drug in the CSF for up to 14 days. In two separate randomized studies, the side effect profile of DepoCyt was similar to that of IT MTX or standard IT cytarabine, although the incidence of aseptic meningitis was slightly higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/171,172\">",
"     171,172",
"    </a>",
"    ]. The incidence of chemical meningitis can be reduced with prophylactic glucocorticoids, which are usually started one day before therapy and continued for a total of five days. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\", section on 'Liposomal cytarabine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/53/34645?source=see_link\">",
"     liposomal cytarabine",
"    </a>",
"    given in conjunction with systemic chemotherapy for CNS prophylaxis in patients with acute lymphocytic leukemia has been associated with severe neurotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/173,174\">",
"     173,174",
"    </a>",
"    ]. In a series of 31 patients, five (16 percent) experienced serious, unexpected neurotoxicity, one of whom died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/173\">",
"     173",
"    </a>",
"    ]. These include seizures, pseudotumor cerebri causing decreased visual acuity, cauda equina syndrome with persistent fecal and urinary incontinence (two cases), and encephalitis resulting in death. The increased toxicity on this regimen was attributed to synergistic effects with concomitant high-dose chemotherapy that can penetrate the blood-brain barrier (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Fluoropyrimidines",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Fluorouracil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     Fluorouracil",
"    </a>",
"    (FU) is a fluorinated pyrimidine that impairs DNA synthesis by inhibiting thymidylate synthetase. It is a component of multidrug treatment for many cancers, including colon and breast cancer.",
"   </p>",
"   <p>",
"    An acute cerebellar syndrome occurs rarely in patients receiving FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/175,176\">",
"     175,176",
"    </a>",
"    ]. The characteristic syndrome is an acute onset of ataxia, dysmetria, dysarthria, and nystagmus that develops weeks to months after beginning treatment. FU should be discontinued in any patient who develops cerebellar toxicity; with time, symptoms usually resolve completely. The development of a cerebellar syndrome may be partly explained by the fact that FU readily crosses the blood-brain barrier, and the highest concentrations are found in the cerebellum.",
"   </p>",
"   <p>",
"    Multiple reports have described an encephalopathy with FU chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/177-180\">",
"     177-180",
"    </a>",
"    ]. This has been associated with markedly elevated serum ammonia levels in the absence of decompensated liver disease. Factors that may contribute to this complication include renal dysfunction, weight loss, and constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/180\">",
"     180",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other rarer neurologic side effects include an optic neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/181\">",
"     181",
"    </a>",
"    ], eye movement abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/182\">",
"     182",
"    </a>",
"    ], focal dystonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/183\">",
"     183",
"    </a>",
"    ], cerebrovascular disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/184\">",
"     184",
"    </a>",
"    ], a parkinsonian syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/185\">",
"     185",
"    </a>",
"    ], peripheral neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/186\">",
"     186",
"    </a>",
"    ] or seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/187\">",
"     187",
"    </a>",
"    ]. Patients who lack the metabolizing enzyme dihydropyrimidine dehydrogenase (DPD) are at increased risk for severe neurologic toxicity, including cerebellar toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/188\">",
"     188",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The FU derivatives doxifluridine, carmofur, and ftorafur (which is combined with uracil to slow degradation; the combination is called UFT) have also been reported to rarely cause encephalopathies and cerebellar syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/189-191\">",
"     189-191",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     Capecitabine",
"    </a>",
"    is an orally active fluorinated pyrimidine; it is metabolized to the active moiety, 5-FU, by the enzyme thymidine phosphorylase. Neurologic complications are uncommon; fewer than 10 percent of treated patients experience paresthesias, headaches, dizziness, or insomnia. Like 5-FU, cerebellar toxicity has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/192\">",
"     192",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a subacute encephalopathy, manifested by confusion, short-term memory loss, and white-matter changes on MRI, has been described that develops shortly after starting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/193,194\">",
"     193,194",
"    </a>",
"    ]. Symptoms resolved over several days following cessation of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Ifosfamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     Ifosfamide",
"    </a>",
"    is an analog of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ; in general, its systemic toxicities are similar. However, unlike cyclophosphamide, about 10 to 30 percent of patients treated with ifosfamide develop an encephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/195-198\">",
"     195-198",
"    </a>",
"    ]. Patients at increased risk for this complication include those with a prior history of ifosfamide-related encephalopathy, renal dysfunction, low serum albumin, concomitant use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    as an antiemetic, or prior",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/195,196,199-203\">",
"     195,196,199-203",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms begin hours or days after drug administration and usually resolve completely several days later. This encephalopathy is thought to result from accumulation of chloracetaldehyde, one of the breakdown products of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    . Some reports suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    (s sympathetic blocker), thiamine, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    , an inhibitor of monoamine oxidase, may be useful for the treatment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prevention of ifosfamide encephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/204-207\">",
"     204-207",
"    </a>",
"    ] . However, most patients do not require specific treatment, and the encephalopathy improves spontaneously.",
"   </p>",
"   <p>",
"    Other neurologic toxicities associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    are rare and are usually described in the context of encephalopathy. They include seizures, nonconvulsive (complex partial) status epilepticus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/208\">",
"     208",
"    </a>",
"    ], ataxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/209\">",
"     209",
"    </a>",
"    ], weakness, cranial nerve dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/196\">",
"     196",
"    </a>",
"    ], neuropathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/210\">",
"     210",
"    </a>",
"    ], or an extrapyramidal syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/211,212\">",
"     211,212",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19642?source=see_link\">",
"     \"Status epilepticus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Nitrosoureas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nitrosoureas (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    [BCNU],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    [CCNU], PCNU, and nimustine [ACNU]) are lipid-soluble alkylating agents that rapidly cross the blood-brain barrier; they are used to treat brain tumors, melanoma, and lymphomas. The nitrosoureas are associated with little neurotoxicity at conventional doses. In contrast, high-dose IV BCNU, as used in the setting of high dose therapy with hematopoietic cell transplantation, can cause an encephalomyelopathy and seizures. Typically, these symptoms develop over a period of weeks to months following drug administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/213\">",
"     213",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link\">",
"     \"Preparative regimens for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intraarterial administration of BCNU produces ocular toxicity and neurotoxicity in 30 to 48 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/214-216\">",
"     214-216",
"    </a>",
"    ]. Patients often complain of headache, eye and facial pain, and retinopathy and blindness may occur. Other neurotoxic effects include confusion, seizures, and progressive neurologic deficits. Imaging and pathologic studies show similarities to radiation necrosis, confined to the vascular territory perfused by the BCNU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/214,217\">",
"     214,217",
"    </a>",
"    ]. Concurrent radiotherapy increases the neurotoxicity of intracarotid BCNU. Injection of the drug above the origin of the ophthalmic artery (supraophthalmic injection) reduces the incidence of ocular toxicity but increases other neurotoxicities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19674?source=see_link&amp;anchor=H21#H21\">",
"     \"Experimental treatment approaches for malignant gliomas\", section on 'Intraarterial chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although generally well tolerated, the adjuvant use of Gliadel wafers (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    ) has been associated with potentially fatal cerebral edema. In addition, the use of Gliadel wafers has been associated with infection and poor wound healing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/218\">",
"     218",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42391?source=see_link&amp;anchor=H9#H9\">",
"     \"Adjuvant chemotherapy for malignant gliomas\", section on 'Carmustine polymer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Procarbazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     Procarbazine",
"    </a>",
"    is a weak monoamine oxidase inhibitor that probably acts as an alkylating agent. It is orally active and is used to treat Hodgkin lymphoma and brain tumors. At conventional doses (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for 14 of every 28 days), procarbazine can cause a mild reversible encephalopathy and neuropathy, and rarely psychosis and stupor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/1,97,219\">",
"     1,97,219",
"    </a>",
"    ]. The incidence of encephalopathy may be higher in patients receiving higher doses of procarbazine in chemotherapy regimens for malignant gliomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/220\">",
"     220",
"    </a>",
"    ]. Procarbazine also potentiates the sedative effects of opiates, phenothiazines, and barbiturates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Asparaginase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asparaginase is used mainly to treat acute lymphoblastic leukemia. Although direct neurotoxicity is uncommon, asparaginase is associated with a coagulopathy with hemorrhagic and thrombotic complications, including sagittal sinus thrombosis and cerebral infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/221\">",
"     221",
"    </a>",
"    ]. These complications typically occur after several weeks of treatment. At high doses, asparaginase may also produce a reversible encephalopathy. The related PEG-asparaginase (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/9/42133?source=see_link\">",
"     pegaspargase",
"    </a>",
"    ) has similar neurotoxicity; fatigue and disorientation are reported in about 10 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=see_link\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27907516\">",
"    <span class=\"h2\">",
"     Ipilimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/52/19270?source=see_link\">",
"     Ipilimumab",
"    </a>",
"    is a monoclonal antibody directed against CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule on the T cell surface. As a treatment for advanced melanoma, the presumed mechanism of action of ipilimumab is to break down tolerance to the tumor-associated antigens in the melanoma. At the same time, this may result in decreased tolerance to self antigens. A wide range of immune-mediated adverse events have been observed in patients treated with ipilimumab, including sensory and motor neuropathy, Guillain-Barre syndrome, and myasthenia gravis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/28/2506?source=see_link&amp;anchor=H177442771#H177442771\">",
"     \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\", section on 'Toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     RARE CAUSES OF NEUROTOXICITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Anthracyclines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apart from accidental intrathecal injection, which can cause a myelopathy encephalopathy and death, anthracyclines and their derivatives (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ) cause little neurotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients who receive doxorubicin in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    can develop coma which may be fatal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/222\">",
"     222",
"    </a>",
"    ]. In addition, doxorubicin can cause arrhythmias and a dose-related cardiomyopathy, which in turn can result in cerebrovascular complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/223\">",
"     223",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Busulfan",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     Busulfan",
"    </a>",
"    is associated with little neurotoxicity at conventional doses, but high dose therapy, commonly used in the setting of hematopoietic stem cell transplantation, can cause seizures (",
"    <a class=\"graphic graphic_table graphicRef78736 \" href=\"mobipreview.htm?11/35/11836\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/224\">",
"     224",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link&amp;anchor=H7#H7\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Chemotherapy without radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Chlorambucil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     Chlorambucil",
"    </a>",
"    is an uncommon cause of neurotoxicity, but encephalopathy, myoclonus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/225\">",
"     225",
"    </a>",
"    ], and seizures have been reported with high doses, particularly in children with the nephrotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/226\">",
"     226",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Estramustine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/4/35909?source=see_link\">",
"     Estramustine",
"    </a>",
"    is used in combination regimens to treat advanced castrate-resistant prostate cancer. It occasionally causes headaches and has rarely been associated with cerebrovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/227\">",
"     227",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6280?source=see_link&amp;anchor=H13#H13\">",
"     \"Chemotherapy in castrate-resistant prostate cancer\", section on 'Estramustine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Etoposide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     Etoposide",
"    </a>",
"    (VP-16) is a topoisomerase II inhibitor that is used extensively in the treatment of lung cancer, germ cell tumors, and refractory lymphomas. Although neurotoxicity is uncommon, even in high doses, peripheral neuropathy (less than 2 percent), mild disorientation, seizures, transient cortical blindness, and optic neuritis have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Gemcitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     Gemcitabine",
"    </a>",
"    is a deoxycytidine analogue that is used for the treatment of pancreatic, bladder, and lung cancer. Up to 10 percent of patients experience mild paresthesias during treatment, although occasionally, more severe peripheral and autonomic neuropathies are described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/228\">",
"     228",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An acute, inflammatory myopathy has been reported following chemotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , presenting as a symmetrical, painful, proximal muscle weakness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/229\">",
"     229",
"    </a>",
"    ]. Gemcitabine has also been implicated in a painful, focal myositis when the drug is given during or after radiation therapy (radiation recall phenomenon) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/230\">",
"     230",
"    </a>",
"    ]. Rarely, gemcitabine may cause acute confusion and seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/231\">",
"     231",
"    </a>",
"    ], and reversible posterior leukoencephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/232\">",
"     232",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    is used to treat chronic myeloid leukemia and head and neck cancers. It is also used for the treatment of sickle cell disease (to stimulate production of hemoglobin F) and polycythemia vera. Sedation is common with high doses and rare adverse effects include headaches, hallucinations, confusion, and seizures may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Irinotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     Irinotecan",
"    </a>",
"    (CPT-11) is a topoisomerase inhibitor that is useful in the treatment of colon cancer. Some patients experience transient visual disturbances and symptoms suggestive of cholinergic overactivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/233\">",
"     233",
"    </a>",
"    ]. Transient dysarthria, during or immediately after treatment, has also been described; the dysarthria can recur with subsequent irinotecan infusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/234\">",
"     234",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Mechlorethamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"     Mechlorethamine",
"    </a>",
"    (nitrogen mustard) is an alkylating agent used to treat Hodgkin lymphomas and for intracavitary instillation to control pleural or pericardial effusions. Rarely, it causes somnolence, headaches, and weakness. At high doses such as those used in the past for high dose therapy and hematopoietic cell transplantation, it has been reported to cause confusion and seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Mitomycin C",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     Mitomycin",
"    </a>",
"    C is an alkylating agent used to treat carcinomas of the gastrointestinal tract, breast cancer, and head and neck malignancies. Although it does not cause direct neurotoxicity, an associated encephalopathy may be caused by a thrombotic microangiopathy that resembles hemolytic uremic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/235\">",
"     235",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=see_link\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Purine analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     Fludarabine",
"    </a>",
"    , an inhibitor of DNA polymerase and ribonucleotide reductase, is used to treat chronic lymphocytic leukemia (CLL) and indolent lymphomas. Neurotoxicity is uncommon, but fludarabine can cause headache, somnolence, confusion, and paresthesias at low doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/1,236\">",
"     1,236",
"    </a>",
"    ]. A delayed progressive encephalopathy with seizures, cortical blindness, paralysis, and coma is more common at high doses; the incidence is 36 percent with doses &gt;96",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for five to seven days, compared to &lt;0.2 percent for doses &lt;125",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per cycle. Rarely, progressive multifocal leukoencephalopathy has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/237\">",
"     237",
"    </a>",
"    ]. The onset of neurologic symptoms may be delayed for three to four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/236,238\">",
"     236,238",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     \"Fludarabine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"     Cladribine",
"    </a>",
"    (2-chlordeoxyadenosine), a related drug used for hairy cell leukemia, CLL, and Waldenstrom macroglobulinemia, is associated with little neurotoxicity at conventional doses but can produce a paraparesis or quadriplegia at high doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/236\">",
"     236",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/9/40086?source=see_link\">",
"     Pentostatin",
"    </a>",
"    , an inhibitor of adenosine deaminase, is used for the treatment of a variety of leukemias, including hairy cell leukemia and cutaneous T-cell lymphomas. At low doses, lethargy and fatigue are common. Higher doses can cause a severe encephalopathy, seizures, and coma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/236\">",
"     236",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Retinoic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;All-trans-retinoic acid, which is used to treat acute promyelocytic leukemia, can rarely cause pseudotumor cerebri [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/239\">",
"     239",
"    </a>",
"    ] and multiple mononeuropathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/240\">",
"     240",
"    </a>",
"    ]. In contrast, headache and fatigue are common during treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Temozolomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     Temozolomide",
"    </a>",
"    is an alkylating agent used predominantly for treatment of malignant gliomas. Drug-induced headaches are experienced by 40 percent of patients, although serious neurologic complications are rare. As temozolomide is used mainly for malignant gliomas, many of the \"toxicities\" attributable to this drug may in fact due to the underlying disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Thioguanine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/54/35685?source=see_link\">",
"     Thioguanine",
"    </a>",
"    is used to treat various leukemias. Rarely, it causes loss of vibratory sense and ataxia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Thiotepa",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35414?source=see_link\">",
"     Thiotepa",
"    </a>",
"    is an alkylating agent occasionally used to treat leptomeningeal metastases and in high dose regimens in the setting of hematopoietic cell transplantation (",
"    <a class=\"graphic graphic_table graphicRef78736 \" href=\"mobipreview.htm?11/35/11836\">",
"     table 3",
"    </a>",
"    ). High intravenous doses of thiotepa can produce an encephalopathy that can be fatal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/241\">",
"     241",
"    </a>",
"    ]. Rarely, IT use of thiotepa has been associated with a myelopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/242\">",
"     242",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Sunitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    is a molecularly targeted agent that inhibits the epidermal growth factor receptor tyrosine kinase. A variety of types of neurotoxicity have been rarely reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single case report described transient coma in a patient treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      for sarcoma, which resolved when treatment was discontinued and recurred with rechallenge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/243\">",
"       243",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       Sunitinib",
"      </a>",
"      can also cause hypothyroidism, sometimes symptomatic and may induce hypothyroid coma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/244,245\">",
"       244,245",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651229244#H1651229244\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Thyroid dysfunction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A reversible cognitive disorder characterized by confusion, hallucinations, or extrapyramidal symptoms has also been described in elderly patients with preexisting arteriosclerotic leukoencephalopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reversible posterior leukoencephalopathy syndrome (RPLS) is characterized by headaches, altered consciousness, visual disturbances, and seizures; hypertension is frequent but not invariable. Multiple case reports describe this complication in patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/246-250\">",
"       246-250",
"      </a>",
"      ] and other agents targeting angiogenesis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651228679#H1651228679\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Reversible posterior leukoencephalopathy and brain capillary leak syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68497967\">",
"    <span class=\"h2\">",
"     Vemurafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=see_link\">",
"     Vemurafenib",
"    </a>",
"    is a potent inhibitor of the mutated",
"    <em>",
"     BRAF",
"    </em>",
"    gene, which is present in 40 to 60 percent of melanomas. There are isolated case reports of peripheral facial nerve palsy, which was bilateral in two patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/32/43530/abstract/251\">",
"     251",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complications of anticancer therapy may result from direct toxic effects on the nervous system or indirectly from drug-induced metabolic derangements or cerebrovascular disorders (",
"    <a class=\"graphic graphic_table graphicRef55758 \" href=\"mobipreview.htm?35/9/35998\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Among the non-platinum chemotherapy agents, neurotoxicity is most frequently seen with the following drugs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      , especially with intrathecal use (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Methotrexate'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"      , particularly when given on a weekly schedule (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Paclitaxel'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       Vincristine",
"      </a>",
"      &nbsp;(see",
"      <a class=\"local\" href=\"#H20\">",
"       'Vincristine'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       Thalidomide",
"      </a>",
"      &nbsp;(see",
"      <a class=\"local\" href=\"#H24\">",
"       'Thalidomide and lenalidomide'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      The proteasome inhibitors",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"       carfilzomib",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H25\">",
"       'Bortezomib and carfilzomib'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/42/28325?source=see_link\">",
"       Eribulin",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H30392699\">",
"       'Eribulin'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10423?source=see_link\">",
"       Ixabepilone",
"      </a>",
"      (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Ixabepilone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/45/21206?source=see_link\">",
"       Nelarabine",
"      </a>",
"      &nbsp;(see",
"      <a class=\"local\" href=\"#H26\">",
"       'Nelarabine'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H127140612\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to recognize Dr. Scott Plotkin, who contributed to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     DeAngelis LM, Posner JB. Side Effects of Chemotherapy. In: Neurologic Complications of Cancer, 2nd, Oxford University Press, New York 2009. p.447.",
"    </li>",
"    <li>",
"     Dietrich J, Wen PY. Neurologic complications of chemotherapy. In: Cancer Neurology in Clinical Practice, 2nd, Schiff D, Kesari S, Wen PY (Eds), Humana Press, Totowa, New Jersey 2008. p.287.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/3\">",
"      Schiff D, Wen PY, van den Bent MJ. Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol 2009; 6:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/4\">",
"      Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 2009; 63:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/5\">",
"      Chaudhry V, Chaudhry M, Crawford TO, et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003; 60:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/6\">",
"      Chauvenet AR, Shashi V, Selsky C, et al. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 2003; 25:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/7\">",
"      Trobaugh-Lotrario AD, Smith AA, Odom LF. Vincristine neurotoxicity in the presence of hereditary neuropathy. Med Pediatr Oncol 2003; 40:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/8\">",
"      Kalfakis N, Panas M, Karadima G, et al. Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment. Neurology 2002; 59:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/9\">",
"      Miller BR. Neurotoxicity and vincristine. JAMA 1985; 253:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/10\">",
"      Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/11\">",
"      Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol 2011; 12:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/12\">",
"      Baldwin RM, Owzar K, Zembutsu H, et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 2012; 18:5099.",
"     </a>",
"    </li>",
"    <li>",
"     Phillips PC. Phillips, PC. In: Neurological Complications of Cancer Treatment, Rottenberg DA (Ed), Butterworth-Heinemann, Boston 1991. p.115.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/14\">",
"      Geiser CF, Bishop Y, Jaffe N, et al. Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood 1975; 45:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/15\">",
"      Gagliano RG, Costanzi JJ. Paraplegia following intrathecal methotrexate: report of a case and review of the literature. Cancer 1976; 37:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/16\">",
"      Rubnitz JE, Relling MV, Harrison PL, et al. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia 1998; 12:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/17\">",
"      Walker RW, Allen JC, Rosen G, Caparros B. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 1986; 4:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/18\">",
"      Inaba H, Khan RB, Laningham FH, et al. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol 2008; 19:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/19\">",
"      Borgna-Pignatti C, Battisti L, Marradi P, et al. Transient neurologic disturbances in a child treated with moderate-dose methotrexate. Br J Haematol 1992; 81:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/20\">",
"      Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol 2010; 11:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/21\">",
"      Vagace JM, Caceres-Marzal C, Jimenez M, et al. Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis. Am J Hematol 2011; 86:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/22\">",
"      Rubinstein LJ, Herman MM, Long TF, Wilbur JR. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer 1975; 35:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/23\">",
"      Pizzo PA, Poplack DG, Bleyer WA. Neurotoxicities of current leukemia therapy. Am J Pediatr Hematol Oncol 1979; 1:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/24\">",
"      Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 2009; 146:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/25\">",
"      Dicuonzo F, Salvati A, Palma M, et al. Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings. J Child Neurol 2009; 24:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/26\">",
"      Winick NJ, Bowman WP, Kamen BA, et al. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 1992; 84:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/27\">",
"      Yim YS, Mahoney DH Jr, Oshman DG. Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphocytic leukemia. Cancer 1991; 67:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/28\">",
"      Anderson SC, Baquis GD, Jackson A, et al. Ventral polyradiculopathy with pediatric acute lymphocytic leukemia. Muscle Nerve 2002; 25:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/29\">",
"      Koh S, Nelson MD Jr, Kovanlikaya A, Chen LS. Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment. Pediatr Neurol 1999; 21:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/30\">",
"      Pascual AM, Coret F, Casanova B, L&aacute;inez MJ. Anterior lumbosacral polyradiculopathy after intrathecal administration of methotrexate. J Neurol Sci 2008; 267:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/31\">",
"      Bernstein ML, Sobel DB, Wimmer RS. Noncardiogenic pulmonary edema following injection of methotrexate into the cerebrospinal fluid. Cancer 1982; 50:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/32\">",
"      Gutin PH, Green MR, Bleyer WA, et al. Methotrexate pneumonitis induced by intrathecal methotrexate therapy: a case report with pharmacokinetic data. Cancer 1976; 38:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/33\">",
"      Boogerd W, vd Sande JJ, Moffie D. Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry 1988; 51:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/34\">",
"      Ettinger LJ. Pharmacokinetics and biochemical effects of a fatal intrathecal methotrexate overdose. Cancer 1982; 50:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/35\">",
"      O'Marcaigh AS, Johnson CM, Smithson WA, et al. Successful treatment of intrathecal methotrexate overdose by using ventriculolumbar perfusion and intrathecal instillation of carboxypeptidase G2. Mayo Clin Proc 1996; 71:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/36\">",
"      Widemann BC, Balis FM, Shalabi A, et al. Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst 2004; 96:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/37\">",
"      Spiegel RJ, Cooper PR, Blum RH, et al. Treatment of massive intrathecal methotrexate overdose by ventriculolumbar perfusion. N Engl J Med 1984; 311:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/38\">",
"      Addiego JE Jr, Ridgway D, Bleyer WA. The acute management of intrathecal methotrexate overdose: pharmacologic rationale and guidelines. J Pediatr 1981; 98:825.",
"     </a>",
"    </li>",
"    <li>",
"     www.btgplc.com/contact-us/contacts (Accessed on February 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/40\">",
"      Freilich RJ, Balmaceda C, Seidman AD, et al. Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996; 47:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/41\">",
"      Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006; 24:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/42\">",
"      Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/43\">",
"      Loprinzi CL, Maddocks-Christianson K, Wolf SL, et al. The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J 2007; 13:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/44\">",
"      Loprinzi CL, Reeves BN, Dakhil SR, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 2011; 29:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/45\">",
"      Reeves BN, Dakhil SR, Sloan JA, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer 2012; 118:5171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/46\">",
"      Perry JR, Warner E. Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology 1996; 46:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/47\">",
"      Rook J, Rosser T, Fangusaro J, Finlay J. Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. Pediatr Blood Cancer 2008; 50:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/48\">",
"      Khattab J, Terebelo HR, Dabas B. Phantom limb pain as a manifestation of paclitaxel neurotoxicity. Mayo Clin Proc 2000; 75:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/49\">",
"      Postma TJ, Vermorken JB, Liefting AJ, et al. Paclitaxel-induced neuropathy. Ann Oncol 1995; 6:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/50\">",
"      Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000; 18:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/51\">",
"      Piccart MJ. RESPONSE: re: randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/52\">",
"      Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12:2654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/53\">",
"      Akerley W 3rd. Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule. Chest 2000; 117:152S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/54\">",
"      Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/55\">",
"      Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/56\">",
"      Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 1999; 17:3403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/57\">",
"      Moulder SL, Holmes FA, Tolcher AW, et al. A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer 2010; 116:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/58\">",
"      Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/59\">",
"      Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27:3611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/60\">",
"      Rivera E, Mejia JA, Arun BK, et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 2008; 112:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/61\">",
"      van den Bent MJ, Hilkens PH, Sillevis Smitt PA, et al. Lhermitte's sign following chemotherapy with docetaxel. Neurology 1998; 50:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/62\">",
"      Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23:5542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/63\">",
"      Di Maio M, Perrone F, Chiodini P, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2007; 25:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/64\">",
"      Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/65\">",
"      de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/66\">",
"      Gelmon K, Eisenhauer E, Bryce C, et al. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 1999; 17:3038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/67\">",
"      Openshaw H, Beamon K, Synold TW, et al. Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res 2004; 10:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/68\">",
"      De Vos FY, Bos AM, Schaapveld M, et al. A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. Gynecol Oncol 2005; 97:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/69\">",
"      Hilpert F, St&auml;hle A, Tom&eacute; O, et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gyn&auml;kologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer 2005; 13:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/70\">",
"      Lorusso D, Ferrandina G, Greggi S, et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 2003; 14:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/71\">",
"      Leong SS, Tan EH, Fong KW, et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 2003; 21:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/72\">",
"      Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 2007; 110:2110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/73\">",
"      Argyriou AA, Chroni E, Koutras A, et al. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. J Pain Symptom Manage 2006; 32:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/74\">",
"      Kottschade LA, Sloan JA, Mazurczak MA, et al. The use of vitamin E for prevention of chemotherapy-induced peripheral neuropathy: A phase III double-blind, placebo controlled study--N05C31. J Clin Oncol (Meeting Abstracts) 2009; 27:abstr 9532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/75\">",
"      Argyriou AA, Chroni E, Koutras A, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 2005; 64:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/76\">",
"      Strasser F, Demmer R, B&ouml;hme C, et al. Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study. Oncologist 2008; 13:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/77\">",
"      Jacobson SD, Loprinzi CL, Sloan JA, et al. Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol 2003; 1:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/78\">",
"      Stubblefield MD, Vahdat LT, Balmaceda CM, et al. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study. Clin Oncol (R Coll Radiol) 2005; 17:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/79\">",
"      Vahdat L, Papadopoulos K, Lange D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 2001; 7:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/80\">",
"      Loven D, Levavi H, Sabach G, et al. Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel. Eur J Cancer Care (Engl) 2009; 18:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/81\">",
"      Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 2005; 41:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/82\">",
"      Maestri A, De Pasquale Ceratti A, Cundari S, et al. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 2005; 91:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/83\">",
"      Miller AA, Wang XF, Gu L, et al. Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). J Thorac Oncol 2008; 3:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/84\">",
"      Ghoreishi Z, Esfahani A, Djazayeri A, et al. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer 2012; 12:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/85\">",
"      Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27:127.",
"     </a>",
"    </li>",
"    <li>",
"     Hershman DL, et al. SWOG S0715: randomized placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy during adjuvant breast cancer therapy. J Clin Oncol 30, 2012 (suppl; abstr 9018). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=95515 (Accessed on June 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/87\">",
"      Casey EB, Jellife AM, Le Quesne PM, Millett YL. Vincristine neuropathy. Clinical and electrophysiological observations. Brain 1973; 96:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/88\">",
"      Legha SS. Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1986; 1:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/89\">",
"      Verstappen CC, Koeppen S, Heimans JJ, et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005; 64:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/90\">",
"      McLeod JG, Penny R. Vincristine neuropathy: an electrophysiological and histological study. J Neurol Neurosurg Psychiatry 1969; 32:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/91\">",
"      Weintraub M, Adde MA, Venzon DJ, et al. Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J Clin Oncol 1996; 14:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/92\">",
"      Teusink AC, Ragucci D, Shatat IF, Kalpatthi R. Potentiation of vincristine toxicity with concomitant fluconazole prophylaxis in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2012; 29:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/93\">",
"      Harnicar S, Adel N, Jurcic J. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients. J Oncol Pharm Pract 2009; 15:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/94\">",
"      Hogan-Dann CM, Fellmeth WG, McGuire SA, Kiley VA. Polyneuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome. JAMA 1984; 252:2862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/95\">",
"      Naumann R, Mohm J, Reuner U, et al. Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity. Br J Haematol 2001; 115:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/96\">",
"      O'Brien S, Schiller G, Lister J, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol 2013; 31:676.",
"     </a>",
"    </li>",
"    <li>",
"     Forsyth P, Cascino T. Neurological complications of chemotherapy. In: Neurological Complications of Cancer, Wiley R (Ed), Marcel Dekker, Inc., New York 1995. p.241.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/98\">",
"      Robertson GL, Bhoopalam N, Zelkowitz LJ. Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone. Arch Intern Med 1973; 132:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/99\">",
"      Dyke RW. Treatment of inadvertent intrathecal injection of vincristine. N Engl J Med 1989; 321:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/100\">",
"      Ozyurek H, Turker H, Akbalik M, et al. Pyridoxine and pyridostigmine treatment in vincristine-induced neuropathy. Pediatr Hematol Oncol 2007; 24:447.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.clinicaltrials.gov/ct2/show/NCT00365768 (Accessed on April 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/102\">",
"      Mokhtar GM, Shaaban SY, Elbarbary NS, Fayed WA. A trial to assess the efficacy of glutamic acid in prevention of vincristine-induced neurotoxicity in pediatric malignancies: a pilot study. J Pediatr Hematol Oncol 2010; 32:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/103\">",
"      Jackson DV, Wells HB, Atkins JN, et al. Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med 1988; 84:1016.",
"     </a>",
"    </li>",
"    <li>",
"     Paleologos N. Complications of chemotherapy. In: Iatrogenic Neurology, Biller J (Ed), Butterworth-Heinemann, Boston 1998. p.439.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/105\">",
"      Fazeny B, Zifko U, Meryn S, et al. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel--a phase II study. Cancer Chemother Pharmacol 1996; 39:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/106\">",
"      Norris B, Pritchard KI, James K, et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 2000; 18:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/107\">",
"      Argyriou AA, Marmiroli P, Cavaletti G, Kalofonos HP. Epothilone-induced peripheral neuropathy: a review of current knowledge. J Pain Symptom Manage 2011; 42:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/108\">",
"      Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25:5210.",
"     </a>",
"    </li>",
"    <li>",
"     Federal Drug Administration. Highlights of prescribing information for ixabepilone file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022065s002lbl.pdf (Accessed on April 15, 2011).",
"    </li>",
"    <li>",
"     Twelves, C, Loesch, D. Blum, JA, et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane (abstract CRA 1004). J Clin Oncol 2010; 28:958s. Abstract available online at  file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=50309 (Accessed on November 22, 2010).",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf (Accessed on November 22, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/112\">",
"      Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/113\">",
"      Kocer B, Sucak G, Kuruoglu R, et al. Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy. Acta Neurol Belg 2009; 109:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/114\">",
"      Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006; 24:4507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/115\">",
"      Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term (&gt;1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005; 74:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/116\">",
"      Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 2007; 69:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/117\">",
"      Isoardo G, Bergui M, Durelli L, et al. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol Scand 2004; 109:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/118\">",
"      Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 2004; 62:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/119\">",
"      Rajkumar SV, Rosi&ntilde;ol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008; 26:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/120\">",
"      Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/121\">",
"      Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009; 27:3664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/122\">",
"      Prince HM, Mileshkin L, Roberts A, et al. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. Clin Cancer Res 2005; 11:5504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/123\">",
"      Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009; 27:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/124\">",
"      Waage A, Gimsing P, Fayers P, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2010; 116:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/125\">",
"      Murphy PT, O'Donnell JR. Thalidomide induced impotence in male hematology patients: a common but ignored complication? Haematologica 2007; 92:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/126\">",
"      Clark TE, Edom N, Larson J, Lindsey LJ. Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Saf 2001; 24:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/127\">",
"      Hinterseer M, Becker A, K&auml;&auml;b S, et al. Thalidomide-induced symptomatic third-degree atrioventricular block. Clin Res Cardiol 2006; 95:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/128\">",
"      Delforge M, Blad&eacute; J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010; 11:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/129\">",
"      Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009; 23:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/130\">",
"      Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24:3113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/131\">",
"      Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007; 110:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/132\">",
"      Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008; 112:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/133\">",
"      Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/134\">",
"      Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/135\">",
"      Caravita T, Petrucci MT, Spagnoli A, et al. Neuropathy in Multiple Myeloma Patients Treated with Bortezomib: A Multicenter Experience. ASH Annual Meeting Abstracts 2007; 110:4823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/136\">",
"      Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/137\">",
"      San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/138\">",
"      Mateos MV, Oriol A, Mart&iacute;nez-L&oacute;pez J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010; 11:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/139\">",
"      Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010; 28:5101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/140\">",
"      Rajkumar SV. Optimising bortezomib in newly diagnosed multiple myeloma. Lancet Oncol 2010; 11:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/141\">",
"      Cata JP, Weng HR, Burton AW, et al. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 2007; 8:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/142\">",
"      Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009; 144:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/143\">",
"      Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007; 204:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/144\">",
"      Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/145\">",
"      Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007; 13:3320.",
"     </a>",
"    </li>",
"    <li>",
"     Highlights of prescribing information for bortezomib www.accessdata.fda.gov/drugsatfda_docs/label/2008/021602s015lbl.pdf (Accessed on April 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/147\">",
"      Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010; 116:4745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/148\">",
"      Moreau P, Pylypenko HV, Grosicki S, et al. A phase 3 prospective randomized international study (MMY-3021) comparing subcutaneous and intravenous administration of bortezomib in patients with relapsed multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2010; 116:Abstract 312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/149\">",
"      Colvin LA, Johnson PR, Mitchell R, et al. From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol. J Clin Oncol 2008; 26:4519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/150\">",
"      Davies SJ, Harding LM, Baranowski AP. A novel treatment of postherpetic neuralgia using peppermint oil. Clin J Pain 2002; 18:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/151\">",
"      Ravaglia S, Corso A, Piccolo G, et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol 2008; 119:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/152\">",
"      Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012; 119:5661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/153\">",
"      Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012; 120:1801.",
"     </a>",
"    </li>",
"    <li>",
"     Singhal S, Siegel DS, Martin T, et al. Integrated safety from phase II studies of monotherapy carfilzomib inpatients with relapsed and refractory multiple myeloma: An updated analysis (abstract). Blood 2011; 118:abstr 1876). Abstract available online at file://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/1876?maxtoshow=&amp;hits=10&amp;RESULTFORMAT=&amp;fulltext=1876&amp;searchid=1&amp;FIRSTINDEX=0&amp;sortspec=relevance&amp;resourcetype=HWCIT (Accessed on July 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/155\">",
"      Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/156\">",
"      Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 2005; 23:3376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/157\">",
"      DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 2007; 109:5136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/158\">",
"      Cohen MH, Johnson JR, Massie T, et al. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res 2006; 12:5329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/159\">",
"      Herzig RH, Hines JD, Herzig GP, et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 1987; 5:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/160\">",
"      Jolson HM, Bosco L, Bufton MG, et al. Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabine. J Natl Cancer Inst 1992; 84:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/161\">",
"      Dunton SF, Nitschke R, Spruce WE, et al. Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside. A Pediatric Oncology Group study. Cancer 1986; 57:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/162\">",
"      Smith GA, Damon LE, Rugo HS, et al. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 1997; 15:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/163\">",
"      Friedman JH, Shetty N. Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young woman. Mov Disord 2001; 16:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/164\">",
"      Openshaw H, Slatkin NE, Stein AS, et al. Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Cancer 1996; 78:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/165\">",
"      Nevill TJ, Benstead TJ, McCormick CW, Hayne OA. Horner's syndrome and demyelinating peripheral neuropathy caused by high-dose cytosine arabinoside. Am J Hematol 1989; 32:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/166\">",
"      Saito T, Asai O, Dobashi N, et al. Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia. J Infect Chemother 2006; 12:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/167\">",
"      Hoffman DL, Howard JR Jr, Sarma R, Riggs JE. Encephalopathy, myelopathy, optic neuropathy, and anosmia associated with intravenous cytosine arabinoside. Clin Neuropharmacol 1993; 16:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/168\">",
"      Hwang TL, Yung WK, Estey EH, Fields WS. Central nervous system toxicity with high-dose Ara-C. Neurology 1985; 35:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/169\">",
"      Luque FA, Selhorst JB, Petruska P. Parkinsonism induced by high-dose cytosine arabinoside. Mov Disord 1987; 2:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/170\">",
"      Ventura GJ, Keating MJ, Castellanos AM, Glass JP. Reversible bilateral lateral rectus muscle palsy associated with high-dose cytosine arabinoside and mitoxantrone therapy. Cancer 1986; 58:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/171\">",
"      Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999; 17:3110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/172\">",
"      Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999; 5:3394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/173\">",
"      Jabbour E, O'Brien S, Kantarjian H, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007; 109:3214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/174\">",
"      G&aacute;llego P&eacute;rez-Larraya J, Palma JA, Carmona-Iragui M, et al. Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma. J Neurooncol 2011; 103:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/175\">",
"      RIEHL JL, BROWN WJ. ACUTE CEREBELLAR SYNDROME SECONDARY TO 5-FLUOROURACIL THERAPY. Neurology 1964; 14:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/176\">",
"      Gottlieb JA, Luce JK. Cerebellar ataxia with weekly 5-fluorouracil administration. Lancet 1971; 1:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/177\">",
"      Liaw CC, Liaw SJ, Wang CH, et al. Transient hyperammonemia related to chemotherapy with continuous infusion of high-dose 5-fluorouracil. Anticancer Drugs 1993; 4:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/178\">",
"      Liaw CC, Wang HM, Wang CH, et al. Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. Anticancer Drugs 1999; 10:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/179\">",
"      Nott L, Price TJ, Pittman K, et al. Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. Leuk Lymphoma 2007; 48:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/180\">",
"      Kikuta S, Asakage T, Nakao K, et al. The aggravating factors of hyperammonemia related to 5-fluorouracil infusion--a report of two cases. Auris Nasus Larynx 2008; 35:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/181\">",
"      Delval L, Klastersky J. Optic neuropathy in cancer patients. Report of a case possibly related to 5 fluorouracil toxicity and review of the literature. J Neurooncol 2002; 60:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/182\">",
"      Bixenman WW, Nicholls JV, Warwick OH. Oculomotor disturbances associated with 5-fluorouracil chemotherapy. Am J Ophthalmol 1977; 83:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/183\">",
"      Brashear A, Siemers E. Focal dystonia after chemotherapy: a case series. J Neurooncol 1997; 34:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/184\">",
"      El Amrani M, Heinzlef O, Debroucker T, et al. Brain infarction following 5-fluorouracil and cisplatin therapy. Neurology 1998; 51:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/185\">",
"      Bergevin PR, Patwardhan VC, Weissman J, Lee SM. Letter: Neurotoxicity of 5-fluorouracil. Lancet 1975; 1:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/186\">",
"      Stein ME, Drumea K, Yarnitsky D, et al. A rare event of 5-fluorouracil-associated peripheral neuropathy: a report of two patients. Am J Clin Oncol 1998; 21:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/187\">",
"      Pirzada NA, Ali II, Dafer RM. Fluorouracil-induced neurotoxicity. Ann Pharmacother 2000; 34:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/188\">",
"      Takimoto CH, Lu ZH, Zhang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 1996; 2:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/189\">",
"      Heier MS, Foss&aring; SD. Neurological manifestations in a phase 2 study of 13 patients treated with doxyfluridine. Acta Neurol Scand 1985; 72:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/190\">",
"      Kuzuhara S, Ohkoshi N, Kanemaru K, et al. Subacute leucoencephalopathy induced by carmofur, a 5-fluorouracil derivative. J Neurol 1987; 234:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/191\">",
"      Ohara S, Hayashi R, Hata S, et al. Leukoencephalopathy induced by chemotherapy with tegafur, a 5-fluorouracil derivative. Acta Neuropathol 1998; 96:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/192\">",
"      Renouf D, Gill S. Capecitabine-induced cerebellar toxicity. Clin Colorectal Cancer 2006; 6:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/193\">",
"      Formica V, Leary A, Cunningham D, Chua YJ. 5-Fluorouracil can cross brain-blood barrier and cause encephalopathy: should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma. Cancer Chemother Pharmacol 2006; 58:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/194\">",
"      Videnovic A, Semenov I, Chua-Adajar R, et al. Capecitabine-induced multifocal leukoencephalopathy: a report of five cases. Neurology 2005; 65:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/195\">",
"      Meanwell CA, Blake AE, Kelly KA, et al. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986; 22:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/196\">",
"      David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol 2005; 28:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/197\">",
"      Rieger C, Fiegl M, Tischer J, et al. Incidence and severity of ifosfamide-induced encephalopathy. Anticancer Drugs 2004; 15:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/198\">",
"      Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007; 25:3144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/199\">",
"      Pratt CB, Goren MP, Meyer WH, et al. Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors. J Clin Oncol 1990; 8:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/200\">",
"      Durand JP, Gourmel B, Mir O, Goldwasser F. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. Ann Oncol 2007; 18:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/201\">",
"      Howell JE, Szabatura AH, Hatfield Seung A, Nesbit SA. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant. J Oncol Pharm Pract 2008; 14:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/202\">",
"      Yuen C. Aprepitant-associated ifosfamide neurotoxicity. J Oncol Pharm Pract 2010; 16:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/203\">",
"      Jarkowski A 3rd. Possible contribution of aprepitant to ifosfamide-induced neurotoxicity. Am J Health Syst Pharm 2008; 65:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/204\">",
"      K&uuml;pfer A, Aeschlimann C, Wermuth B, Cerny T. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 1994; 343:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/205\">",
"      Pelgrims J, De Vos F, Van den Brande J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000; 82:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/206\">",
"      Buesa JM, Garc&iacute;a-Teijido P, Losa R, Fra J. Treatment of ifosfamide encephalopathy with intravenous thiamin. Clin Cancer Res 2003; 9:4636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/207\">",
"      Bernard PA, McCabe T, Bayliff S, Hayes D Jr. Successful treatment of ifosfamide neurotoxicity with dexmedetomidine. J Oncol Pharm Pract 2010; 16:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/208\">",
"      Wengs WJ, Talwar D, Bernard J. Ifosfamide-induced nonconvulsive status epilepticus. Arch Neurol 1993; 50:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/209\">",
"      Primavera A, Audenino D, Cocito L. Ifosfamide encephalopathy and nonconvulsive status epilepticus. Can J Neurol Sci 2002; 29:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/210\">",
"      Patel SR, Forman AD, Benjamin RS. High-dose ifosfamide-induced exacerbation of peripheral neuropathy. J Natl Cancer Inst 1994; 86:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/211\">",
"      Anderson NR, Tandon DS. Ifosfamide extrapyramidal neurotoxicity. Cancer 1991; 68:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/212\">",
"      Ames B, Lewis LD, Chaffee S, et al. Ifosfamide-induced encephalopathy and movement disorder. Pediatr Blood Cancer 2010; 54:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/213\">",
"      Burger PC, Kamenar E, Schold SC, et al. Encephalomyelopathy following high-dose BCNU therapy. Cancer 1980; 48:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/214\">",
"      Shapiro WR, Green SB, Burger PC, et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992; 76:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/215\">",
"      Shapiro WR, Green SB. Reevaluating the efficacy of intra-arterial BCNU. J Neurosurg 1987; 66:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/216\">",
"      Hiesiger EM, Green SB, Shapiro WR, et al. Results of a randomized trial comparing intra-arterial cisplatin and intravenous PCNU for the treatment of primary brain tumors in adults: Brain Tumor Cooperative Group trial 8420A. J Neurooncol 1995; 25:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/217\">",
"      Rosenblum MK, Delattre JY, Walker RW, Shapiro WR. Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study. J Neurooncol 1989; 7:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/218\">",
"      Subach BR, Witham TF, Kondziolka D, et al. Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery 1999; 45:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/219\">",
"      Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used antineoplastic agents (second of two parts). N Engl J Med 1974; 291:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/220\">",
"      Postma TJ, van Groeningen CJ, Witjes RJ, et al. Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma. J Neurooncol 1998; 38:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/221\">",
"      Feinberg WM, Swenson MR. Cerebrovascular complications of L-asparaginase therapy. Neurology 1988; 38:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/222\">",
"      Barbui T, Rambaldi A, Parenzan L, et al. Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. Lancet 1992; 339:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/223\">",
"      Schachter S, Freeman R. Transient ischemic attack and adriamycin cardiomyopathy. Neurology 1982; 32:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/224\">",
"      Marcus RE, Goldman JM. Convulsions due to high-dose busulphan. Lancet 1984; 2:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/225\">",
"      Wyllie AR, Bayliff CD, Kovacs MJ. Myoclonus due to chlorambucil in two adults with lymphoma. Ann Pharmacother 1997; 31:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/226\">",
"      Salloum E, Khan KK, Cooper DL. Chlorambucil-induced seizures. Cancer 1997; 79:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/227\">",
"      Lubiniecki GM, Berlin JA, Weinstein RB, Vaughn DJ. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis. Cancer 2004; 101:2755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/228\">",
"      Dormann AJ, Gr&uuml;newald T, Wigginghaus B, Huchzermeyer H. Gemcitabine-associated autonomic neuropathy. Lancet 1998; 351:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/229\">",
"      Ardavanis AS, Ioannidis GN, Rigatos GA. Acute myopathy in a patient with lung adenocarcinoma treated with gemcitabine and docetaxel. Anticancer Res 2005; 25:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/230\">",
"      Friedlander PA, Bansal R, Schwartz L, et al. Gemcitabine-related radiation recall preferentially involves internal tissue and organs. Cancer 2004; 100:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/231\">",
"      Larsen FO, Hansen SW. Severe neurotoxicity caused by gemcitabine treatment. Acta Oncol 2004; 43:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/232\">",
"      Han CH, Findlay MP. Chemotherapy-induced reversible posterior leucoencephalopathy syndrome. Intern Med J 2010; 40:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/233\">",
"      Cunningham D, Glimelius B. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol 1999; 26:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/234\">",
"      Hamberg P, Donders RC, ten Bokkel Huinink D. Central nervous system toxicity induced by irinotecan. J Natl Cancer Inst 2006; 98:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/235\">",
"      Doll DC, Yarbro JW. Vascular toxicity associated with antineoplastic agents. Semin Oncol 1992; 19:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/236\">",
"      Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs: a review. J Clin Oncol 1994; 12:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/237\">",
"      Gonzalez H, Bolgert F, Camporo P, Leblond V. Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP). Hematol Cell Ther 1999; 41:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/238\">",
"      Warrell RP Jr, Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 1986; 4:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/239\">",
"      Selleri C, Pane F, Notaro R, et al. All-trans-retinoic acid (ATRA) responsive skin relapses of acute promyelocytic leukaemia followed by ATRA-induced pseudotumour cerebri. Br J Haematol 1996; 92:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/240\">",
"      Yamaji S, Kanamori H, Mishima A, et al. All-trans retinoic acid-induced multiple mononeuropathies. Am J Hematol 1999; 60:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/241\">",
"      Cairncross G, Swinnen L, Bayer R, et al. Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro Oncol 2000; 2:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/242\">",
"      Gutin PH, Levi JA, Wiernik PH, Walker MD. Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study. Cancer Treat Rep 1977; 61:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/243\">",
"      Arnaud L, Schartz NE, Bousquet G, et al. Transient sunitinib-induced coma in a patient with fibromyxoid sarcoma. J Clin Oncol 2008; 26:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/244\">",
"      Mannavola D, Coco P, Vannucchi G, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007; 92:3531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/245\">",
"      Lele AV, Clutter S, Price E, De Ruyter ML. Severe hypothyroidism presenting as myxedema coma in the postoperative period in a patient taking sunitinib: case report and review of literature. J Clin Anesth 2013; 25:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/246\">",
"      Mart&iacute;n G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 2007; 25:3559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/247\">",
"      Chen A, Agarwal N. Reversible posterior leucoencephalopathy syndrome associated with sunitinib. Intern Med J 2009; 39:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/248\">",
"      Padhy BM, Shanmugam SP, Gupta YK, Goyal A. Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy. Br J Clin Pharmacol 2011; 71:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/249\">",
"      Palma JA, Gomez-Iba&ntilde;ez A, Martin B, et al. Nonconvulsive status epilepticus related to posterior reversible leukoencephalopathy syndrome induced by cetuximab. Neurologist 2011; 17:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/250\">",
"      Khan KH, Fenton A, Murtagh E, et al. Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature. Tumori 2012; 98:139e.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/32/43530/abstract/251\">",
"      Klein O, Ribas A, Chmielowski B, et al. Facial Palsy As a Side Effect of Vemurafenib Treatment in Patients With Malignant Melanoma. J Clin Oncol 2013.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2836 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.65.114.212-BA2C6614F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_32_43530=[""].join("\n");
var outline_f42_32_43530=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H55\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      METHOTREXATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Aseptic meningitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Transverse myelopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Acute and subacute encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Leukoencephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dose and route of administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - High-dose systemic MTX",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - IT MTX",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Management of accidental overdose of IT MTX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TAXANES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Paclitaxel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Manifestations and incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Dose and schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Nab-paclitaxel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Docetaxel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H710933\">",
"      Cabazitaxel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment and prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OTHER MICROTUBULE BINDING AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Vincristine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other vinca alkaloids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Ixabepilone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30392699\">",
"      Eribulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      THALIDOMIDE AND LENALIDOMIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      BORTEZOMIB AND CARFILZOMIB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10517786\">",
"      Bortezomib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10517793\">",
"      Carfilzomib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      NELARABINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      OTHER AGENTS CAUSING NEUROTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Cytarabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Intrathecal cytarabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Intrathecal liposomal cytarabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Fluoropyrimidines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Fluorouracil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Capecitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Ifosfamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Nitrosoureas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Procarbazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Asparaginase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27907516\">",
"      Ipilimumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      RARE CAUSES OF NEUROTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Anthracyclines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Busulfan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Chlorambucil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Estramustine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Etoposide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Gemcitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Irinotecan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Mechlorethamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Mitomycin C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Purine analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Retinoic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Temozolomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Thioguanine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Thiotepa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Sunitinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68497967\">",
"      Vemurafenib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H127140612\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2836\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2836|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/9/35998\" title=\"table 1\">",
"      Neurologic complications CA Rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/34/35373\" title=\"table 2\">",
"      Neurotox cytotoxic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/35/11836\" title=\"table 3\">",
"      NCI CTCAE grading of neurotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/59/8123\" title=\"table 4\">",
"      Dose mod neurotox Velcade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/26/26029\" title=\"table 5\">",
"      Chemotherapy preparative regimens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42391?source=related_link\">",
"      Adjuvant chemotherapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/28/2506?source=related_link\">",
"      Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/3/15417?source=related_link\">",
"      Aseptic meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/10/17576?source=related_link\">",
"      Cerebrospinal fluid: Physiology and utility of an examination in disease states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6280?source=related_link\">",
"      Chemotherapy in castrate-resistant prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=related_link\">",
"      Clinical neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38437?source=related_link\">",
"      Complications of peripheral nerve irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/1/7190?source=related_link\">",
"      Complications of spinal cord irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=related_link\">",
"      Drug-induced thrombosis and vascular disease in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=related_link\">",
"      Enhanced elimination of poisons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=related_link\">",
"      Enterotoxicity of chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16934?source=related_link\">",
"      Epidemiology and classification of diabetic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19674?source=related_link\">",
"      Experimental treatment approaches for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=related_link\">",
"      Fludarabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/59/35770?source=related_link\">",
"      Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=related_link\">",
"      Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/1/28698?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18282?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43064?source=related_link\">",
"      Neurologic complications of cancer treatment with biologic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=related_link\">",
"      Neurologic complications of platinum-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/1/34842?source=related_link\">",
"      Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29528?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Single agent chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=related_link\">",
"      Therapeutic use and toxicity of high-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36856?source=related_link\">",
"      Third cranial nerve (oculomotor nerve) palsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37914?source=related_link\">",
"      Treatment and prognosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=related_link\">",
"      Treatment of leptomeningeal metastases (carcinomatous meningitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21753?source=related_link\">",
"      Treatment of relapsed or refractory acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_32_43531="Tension-type headache criteria";
var content_f42_32_43531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F79672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F79672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tension-type headache diagnostic criteria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        A. At least 10 episodes fulfilling criteria B through E. The number of days per month with such headache determines the subtype:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;1 day a month: infrequent episodic TTH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 to 14 days a month: frequent episodic TTH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;15 days a month: chronic TTH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        B. Headache lasting from 30 minutes to 7 days for episodic TTH; headache lasts hours or may be continuous for chronic TTH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        C. At least two of the following pain characteristics:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pressing/tightening (nonpulsating) quality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mild or moderate intensity (may inhibit but does not prohibit activities)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bilateral location",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No aggravation by walking stairs or similar routine physical activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        D. Both of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No nausea or vomiting (anorexia may occur)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Photophobia and phonophobia are absent, or one but not the other may be present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        E. Not attributed to another disorder",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TTH: tension-type headache.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Headache classification subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24(Suppl 1):9.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_32_43531=[""].join("\n");
var outline_f42_32_43531=null;
var title_f42_32_43532="TNM panc endo exo CA";
var content_f42_32_43532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging system for exocrine and endocrine tumors of the pancreas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td colspan=\"3\">",
"       Carcinoma in situ*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor limited to the pancreas, 2 cm or less in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor limited to the pancreas, more than 2 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor involves the celiac axis or the superior mesenteric artery (unresectable primary tumor)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage 0",
"      </td>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IA",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IB",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIA",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Stage IIB",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage III",
"      </td>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IV",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * This includes lesions classified as PanInIII classification.",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_32_43532=[""].join("\n");
var outline_f42_32_43532=null;
var title_f42_32_43533="CV risk before diabetes";
var content_f42_32_43533=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F55653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F55653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    HbA1c concentration as a predictor of mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 257px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of men ages 45 to 79, HbA1c, a marker of blood glucose concentration, was correlated with cardiovascular (red bars) and all cause (blue bars) mortality, even within the nondiabetic range.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Khaw, K-T, Wareham, N, Luben, R, et al. Glycated hemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001; 3221:15.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_32_43533=[""].join("\n");
var outline_f42_32_43533=null;
var title_f42_32_43534="Monteggia fracture";
var content_f42_32_43534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Monteggia fracture/dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 154px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 4-year-old boy fell off his bike. The ulna is fractured and angulated, and a line through the radius clearly does not pass through the center of the capitellum. (Courtesy of Dr. Andrew Capraro.)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baskin M. Trauma: Extremeties. In: Atlas of pediatric emergency medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_32_43534=[""].join("\n");
var outline_f42_32_43534=null;
var title_f42_32_43535="Typhlitis management";
var content_f42_32_43535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Recommended approach to the patient with suspected typhlitis (neutropenic enterocolitis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 662px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     G-CSF: granulocyte colony-stimulating factor.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Can J Surg 1999; 42(6):415. Copyright &copy; 1999 Canadian Medical Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_32_43535=[""].join("\n");
var outline_f42_32_43535=null;
